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SUMMARY 
 
 
Purpose: Atrial fibrillation (AF) is the most common heart arrhythmia and is 
associated with an increased risk of stroke. Stroke risk is commonly treated with oral 
anticoagulation (OAC) with a narrow therapeutic range (INR 2.0 to 3.0); which is 
poorly controlled in practice. Barriers to adherence include poor knowledge, and 
inaccurate perceptions surrounding illness and medications. Trial registration: 
ISRCTN93952605. 
 
Systematic review: Seven trials of educational, self-monitoring and decision aid 
interventions were included in a systematic review. Pooled analysis suggested 
education OR, 95% CI 7.89 (5.54-10.24) and self monitoring OR (95% CI) 5.47(2.55-
8.39) significantly improve TTR; whereas decision aids are no more effective in 
reducing decision conflict than usual care, OR (95% CI) -0.10 (-0.17 to -0.02).  
Intervention development: The intervention was theoretically-driven (utilising the 
common sense and beliefs about medication models) and developed with expert 
patient feedback. Described using behavioural change techniques, the one-off group 
session included an educational booklet, ‘expert-patient’ focussed DVD, and 
worksheet.  
 
Methods: Ninety seven warfarin-naïve AF patients were randomised to receive the 
intervention (n=43), or usual care (n=54). The primary endpoint was time within 
therapeutic range (TTR), secondary endpoints included knowledge, quality of life 
(AF-QoL-18), beliefs about medication (BMQ), illness perceptions (IPQ-B), and 
anxiety and depression (HADS). 
 
Results: Intervention group had significantly higher TTR than usual care (78.5% vs. 
66.7%; p=0.01). Knowledge changed significantly across time (F (3, 47) = 6.4; 
p<0.01), but not between groups (F (1, 47) = 3.3; p = 0.07). At six months knowledge 
predicted TTR (r=0.245; p=0.04). Illness concern negatively correlated with TTR (r= -
0.199; p=0.05). General Harm scores at one month predicted TTR (F (1, 72) = 4.08; 
p=0.048). There were significant differences in emotional representations (F (3, 49) = 
3.3 (3, 49); p= 0.03), anxiety (F (3, 46) = 25.2; p<0.01) and depression (F (3, 46) = 
37.7; p<0.01) across time.  
 
Conclusion: A theory-driven educational intervention can improve TTR in AF 
patients and potentially reduce the risk of adverse clinical outcomes. Improving 
education provision for AF patients is essential to ensure efficacious treatment. 
 
Key words: Atrial Fibrillation; Health Intervention; Illness Perceptions; Beliefs about 
Medication; Oral Anticoagulation.  
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1 Introduction 
 
This chapter aims to introduce both the patient group and the need for a theory 
driven health intervention. As such it will discuss patient barriers to adherence in 
general, before focussing on the particular group of study, atrial fibrillation (AF) 
patients. The epidemiological background of both the patient group and their 
prescribed treatment is particularly relevant for intervention design. Oral 
anticoagulation (OAC) is a treatment carrying significant risks. As such any factors 
which may influence why patients may or may not adhere to recommendations are 
particularly important. Furthermore, any factors that may be useful for intervention 
design are also discussed, including patients’ decision making, knowledge, physical 
and psychological prognosis following diagnosis. 
 
1.1 Adherence 
 
Medical research has provided efficacious treatments for numerous chronic illnesses, 
many of which are self administered. However, the effectiveness of these treatments 
is often undermined by low levels of adherence (Sabate, 2003; Sackett & Snow, 
1979). Research suggests that patients substantially over estimate their actual 
adherence rates. One study comparing self-reported adherence to electronic 
monitors found patients over-reported their adherence to cardiac medications 78.8% 
of the time; self-report correlated poorly with objective monitoring of electronic pillbox 
recordings (regression coefficients <0.1) (Zeller, Ramseier, Teagtmeyer, & Battegay, 
2008). Treatment discontinuation rates have also been found to increase over time in 
patients with chronic conditions such as hypertension and diabetes (Bloom, 1998; 
Lerman, 2005). Patients’ overestimation of adherence and their discontinuation of 
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treatment could be a result of numerous factors including a poor understanding of the 
treatment regimen, memory deficits, and in some cases demand characteristics (i.e. 
wanting to please the physician). It is important for health care practitioners to 
consider factors that impact upon adherence, particularly as both intentional and 
unintentional non-adherence can result in treatments being in-effective or even 
harmful. Furthermore, cumulative non-adherence represents a costly waste of 
resources (Horne, Weinman, Barber, Elliot, & Morgan, 2005). 
 
Psychological theory suggests that patients develop beliefs about medications in 
general and the medications they are prescribed for their individual health concern, 
which may influence their interpretation of information and in turn affect their levels of 
adherence (Horne, Weinmann, & Hankins, 1999). Beliefs about medication have 
been found to predict intentional and non-intentional adherence in patients starting 
medication for a range of chronic illnesses (Clifford, Barber, & Horne, 2008).  
 
Patient’s perceptions of their illness (for an extended discussion see section 3.1.2) 
have been also been related to medication adherence in hypertension (Meyer, 
Leventhal, & Gutmann, 1985), and diabetes (Gonder-Frederick & Cox, 1991). Illness 
perceptions may be inaccurate, representing a barrier to patient adherence. One 
study found illness representations during convalescence predicted adherence to 
recommendations to attend cardiac rehabilitation classes following a first myocardial 
infarction (MI) (Petrie, Weinman, Sharpe, & Buckley, 1993). Where patients have a 
coherent understanding of their illness and its cause, timeframe and consequences, 
they may be more likely to understand the necessity of adherence to medication. 
Thus, theories surrounding patients’ perception of both their medications and their 
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illness can allow for a greater understanding of the barriers to adherence, and 
further, can aid the development of theory-based interventions. 
 
A huge amount of attention has been devoted to improving adherence in numerous 
patient groups, by targeting psychological barriers. The common sense model (CSM; 
for an extended discussion see section 3.1.2) focuses on patients’ illness 
representations. The model suggests that when diagnosed with a chronic illness we 
form a representation of that illness, including an understanding of the cause, 
consequences and timeline, illness coherence and emotional representation of the 
illness. The CSM has been used to design effective interventions for serious 
illnesses, for example two studies found that training women with breast cancer in 
emotional regulation skills can confer benefits (Antoni, 2003; Cunningham, Edmonds, 
Hampson, Hanson, Havonec, & Jenkins, 1991). Further interventions with MI 
patients, targeting problem-focussed self-regulation, found significant positive 
changes in patients’ views of their MI; patients felt more prepared for leaving hospital 
(p<0.05) and subsequently returned to work at a significantly faster rate than the 
control group (p <0.05). At the 3-month follow-up, patients in the intervention group 
reported a significantly lower rate of angina symptoms than control subjects (14.3% 
vs. 39.3%, p <0.03) (Petrie, Cameron, Ellis, Buick, & Weinman, 2002).  
 
Another intervention targeted problem-focussed self-regulation in patients 
undergoing gastrointestinal endoscopy using an educational brochure. They found 
those patients receiving the education experienced less anxiety before and after the 
gastroscopy, and they also reported greater satisfaction with preparation for the 
procedure (Van Zuuren, Grypdonck, Crevits, Walle, & Defloor, 2006). These 
interventions have targeted a range of psychological barriers to adherence, and have 
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succeeded in improving symptom control, return to work rates and patient 
satisfaction. It is important that the methods utilised for intervention design have 
established effectiveness, thus research must trial various interventions before 
adopting techniques as a ‘usual care’ procedure.  
 
In practice very few interventions have been rigorously tested and few have 
considered psychological barriers in their design and evaluation. One Cochrane 
review examined interventions that have targeted adherence for a range of 
conditions and prescribed medications (Haynes, Yao, Degani, Kripalani, Garg, & 
McDonald, 2006). They found that of the 25 studies (evaluating 29 interventions) 
which met the review criteria, nine interventions were associated with significant 
improvements in at least one adherence measure at six to twelve months. Several 
methods of increasing adherence have been highlighted, using both long term and 
short term strategies (see Table 1.1); but few have a theoretical-basis. 
 
One theory-driven trial used an education and counselling intervention to improve 
adherence to HIV medication (Pradier, Bentz, Spire, Tourette-Turgis, Morin, & 
Souville, 2003). This intervention was founded on the principles of motivational 
psychology, using client-centred, empathic therapy to enhance participants’ self 
efficacy. The intervention focused on cognitive, emotional, social and behavioural 
determinants affecting adherence and consisted of three individually delivered 
sessions by nurses lasting 45-60 minutes. Both self-reported adherence (available 
for 83% of patients) and mean difference in HIV ribonucleic acid between baseline 
and six months (for all patients) were significantly improved in the intervention group, 
versus control (Pradier, et al., 2003). However, the trial was criticised for basing 
measurements of adherence on self-report.  
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Problems with studying the phenomenon of adherence usually stem from a lack of 
objective measurement tools, often relying on subjective self-report, where patients 
may overestimate their adherence (Zeller, Ramseier, Teagtmeyer, & Battegay, 
2008). Practical ways of overcoming this include checking those patients who appear 
not to respond to treatment increments or those who fail to attend appointments. 
However, most objective measures rely on biological assays where available (i.e. 
blood, saliva, and urine samples), which are susceptible to dosage and timing issues 
(Haynes, McDonald, & Garg, 2002).  
 
The medical research council published a framework for the development and 
evaluation of randomised control trials (RCTs) for complex interventions to improve 
health (MRC, 2000), including a step-by-step guide for implementation. The initial 
stage of the process includes exploring the relevant theory to ensure the best choice 
of intervention, for which several trials fail to do so, perhaps due to the absence of 
formal guidance on how to incorporate theory. Many interventions do attempt to 
incorporate strategies to improve adherence (see Table 1.1), often with success in 
both the short- (e.g. reminder packaging, written instructions) and long-term (e.g. 
instructions, simplifying drug regime and counselling).  However, most rely on 
pragmatic decision-making when choosing intervention components, rather than an 
established development technique. 
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Table 1.1: Successful strategies for improving adherence to medications based on a 
review by Haynes et al (Haynes, Yao, Degani, Kripalani, Garg, & McDonald, 2006). 
 
Increasing adherence with short 
term strategies# 
Increasing adherence with long term 
strategies (interventions involving ≥1 
strategy)* 
 
 Counselling about the 
importance of adherence  
 
 Instructions and instruction 
manuals 
 
 Written instructions about taking 
medicines 
 
 Simplifying the regimen 
 
 Reminder packaging (e.g. 
dosettes, calendar packs) 
 
 Counselling about the regimen 
  Support group sessions 
  
 Reminders for medications and 
appointments 
  
 Cuing medications to daily events 
  
 Reinforcement and rewards 
(explicitly acknowledging patients 
efforts to adhere) 
  
 Self monitoring with regular 
physician review 
  
 Involving family members and 
significant others 
# based on studies by (McDonald, Garg, & Haynes, 2002; Sharpe & Mikeal, 1974; 
Linkewich, Catalano, & Flack, 1974; Dickey, Mattar, & Chudzik, 1975) *based on 
reviews by (McDonald, Garg, & Haynes, 2002; Haynes, 1979). 
 
More recently health psychologists have published a list of validated ‘behavioural 
taxonomies’ for the development of behaviour change interventions (Abraham & 
Michie, 2006). This taxonomy represents a practical and accessible guide, whereby 
researchers can use applicable theory-based behaviour change techniques within 
their interventions. With the use of validated domains, we are able to operationalise 
our intervention descriptions and replicate successful interventions in practice. 
Provision of instruction, reminders, memory aids/cues, opportunities for social 
support and self monitoring, are examples of these taxonomies, which directly link 
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into numerous psychological theories (Abraham & Michie, 2006), many of which are 
also highlighted as successful strategies within the review by Haynes and colleagues 
(Haynes, et al., 2006). However, the decision as to which strategies should be 
included in the intervention remains with the researcher or practitioner, and there is 
little guidance on the most appropriate evaluation strategy. 
 
One patient group, with a high risk of stroke, who have received little attention 
regarding theory-based intervention development are patients with atrial fibrillation 
(AF). Patients with AF are prescribed oral anticoagulation (OAC), to reduce their risk 
of stroke, and their adherence to treatment and recommendations can be objectively 
monitored over time (Rosendaal, Cannegieter, van der Meer, & Briet, 1993) (refer to 
Section 4.3.1). Furthermore, this group is particularly suited to a theoretically-driven 
intervention as evidence suggests they have little knowledge of their condition or 
treatment (Lane, Ponsford, Shelley, Sirpal, & Lip, 2006; Nadar, Begum, Kaur, 
Sandhu, & Lip, 2003; Coelho-Dantas, Thompson, Manson, Tracy, & Upshur, 2004), 
poor adherence (Connolly, et al., 2008; Morgan, McEwan, Tukiendorf, Robinson, 
Clemens, & Plumb, 2009), high levels of anxiety and depression (Thrall, Lip, Carroll, 
& Lane, 2007; Lane, Langman, Lip, & Nouwen, 2009) and inaccurate illness 
representations (McCabe, Barnason, & Houfek, 2011). 
 
1.2 Atrial Fibrillation  
 
1.2.1 Etiology and prevalence 
 
AF is defined as an atrial tachyarrhythmia (commonly known as an irregular heart 
beat); characterised by uncoordinated atrial activation and consequently by the 
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deterioration of atrial mechanical function (ESC, 2010). Patients can be both 
symptomatic and asymptomatic, and symptoms vary in frequency and duration 
including: palpitations, chest pain, fatigue, dizziness and exercise intolerance (ESC, 
2010). Acute clinical management includes the assessment of these symptoms and 
is based on the European Heart Rhythm Association (EHRA) score (see Table 1.2) 
(Lip, et al., 2011). 
 
Table 1.2: Classification of AF-related symptoms 
EHRA Class Explanation 
EHRA I ‘No symptoms’ 
EHRA II ‘Mild symptoms’, normal daily life not 
affected. 
EHRA III ‘Severe symptoms’, normal daily life 
affected 
EHRA IV ‘Disabling symptoms’, normal daily life 
discontinued. 
EHRA: European Heart Rhythm Association (Lip, et al., 2011). 
 
The pattern of this arrhythmia varies from patient to patient and can change over 
time. For clinical purposes there are five types of AF based on presentation and 
duration (ESC, 2010):  
 
1. Newly diagnosed AF: every patient fits into this category initially irrespective of 
the severity of symptoms or duration of the arrhythmia.  
2. Paroxysmal AF: usually episodes terminate spontaneously (usually in less than 
48 hours), although episodes may last for up to seven days. 
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3. Persistent AF: characterised by an episode lasting more than seven days, but 
less than one year duration, requiring termination via cardioversion. 
4. Long standing persistent AF: permanent AF whereby a rhythm control strategy is 
adopted. 
5. Permanent AF: continuous for more than one year and accepted by the patient 
and the physician (hence no rhythm control adopted) (ESC, 2010). 
 
The five categories are not mutually exclusive. For example, patients with 
paroxysmal AF can have periods of persistent AF and the reverse may also occur. A 
further factor to consider is the term ‘silent AF’, whereby patients are asymptomatic 
and only diagnosed via electrocardiogram (ECG) or following an AF complication. 
Silent AF can occur with any of the above types of AF (ESC, 2010). Patients can 
experience a number of symptoms including dizziness, palpitations, breathlessness 
and exercise intolerance; however, the majority of AF patients are asymptomatic 
(ESC, 2010). 
 
AF is the most common arrhythmia in clinical practice (Fuster, Ryden, Cannom, 
Crijins, Curtis, & Ellenbogen, 2006; Lloyd-Jones, et al., 2004; Heeringa, et al., 2006), 
and the incidence and prevalence is rising. One US population-based study (n=4618) 
found the age/sex-adjusted incidence of AF per 1000 person-years was 3.04 (95% CI 
2.78-3.31) in 1980, increasing to 3.68 (3.42-3.95) in 2000; amounting to a relative 
increase of 12.6% (Miyasaka, Barnes, & Gersh, 2006). Similar findings in the 
European Rotterdam Study (n= 6806) found the overall prevelance of AF was 5.5% 
to 6.0% in men and 5.1% in women (Heeringa, et al., 2006). In Iceland the 
prevalence in 2008 was 2.0%, and is projected to increase to 3.5-4.8% in 2050 
(Stenfansdottir, Aspelund, Gudnason, & Arnar, 2011). Projected incidence of AF in 
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the US assuming a continued increase in age-adjusted incidence [as evidenced by 
1980-2000 data] would suggest that by 2050 16 million people will be treated for AF 
(Miyasaka, Barnes, & Gersh, 2006). As AF may remain undiagnosed, particularly 
when asymptomatic (’silent AF’), the true prevalence of the condition may be higher. 
A UK population-based study found that 534 000 people (281 000 men and 253 000 
women) were being treated for AF in the UK in 1995, this equated to 0.9% of the 
whole population and 5% of those over 65 years. Based on this population they 
calculated that including hospital admissions, treatment costs and long-term nursing 
home care, AF accounts for 0.62% of total health care expenditure, with a projected 
cost of 0.82% of total expenditure in 2000 (Stewart, Murphy, Walker, McGuire, & 
McMurray, 2004).  
 
The prevalence of AF dramatically increases with age, from 0.5% at 40–50 years, 
rising to 5–15% at 80 years (see Figure 1.1) (Stewart, Hart, & Hole, 2001; Go, Hylek, 
Borowsky, Phillips, Selby, & Singer, 1999; Miyasaka, Barnes, & Gersh, 2006; 
Heeringa, et al., 2006; Naccareli, Varker, Lin, & Schulman, 2009; Lloyd-Jones, et al., 
2004), with the prevalence being slightly higher in men than in women (Lloyd-Jones, 
et al., 2004). However, these figures can only be applied to certain populations as AF 
in non-White populations is less well studied (ESC, 2010). Data from the 
Framingham Heart Study suggests that at age 40 both men and women have a one 
in four lifetime risk of developing AF (Lloyd-Jones, et al., 2004).  
 
1.2.2 Risk factors for atrial fibrillation 
 
Numerous risk factors have been identified as contributing to the development of AF. 
These factors can have an additive or cumulative effect by increasing the patient’s 
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risk of developing the condition (Benjamin, et al., 2009). Where no predisposing 
factor can be identified, patients are classified as ‘lone AF’ (atrial fibrillation in the 
absence of overt cardiovascular disease or precipitating illness) (Kopecky, et al., 
1987). Whilst the prevalence of lone AF appears to be small, a longitudinal study with 
over 30-years follow-up found the prevalence was 2.7% (n=97) (Kopecky, et al., 
1987). A more recent review suggests the true prevalence of lone AF could range 
anywhere between 1.6% and 30% (Potpara & Lip, 2011), depending on patients age 
and study criteria.  Further, evidence is often criticised for the inclusion of 
hypertensive and diabetic patients to the lone AF category.  
 
AF appears to be progressive in both frequency and duration; evidence suggests it 
can progress from paroxysmal to permanent arrhythmia (Wijffels, Kirchhof, Dorland, 
& Allessie, 1995). EHRA recently published a comprehensive review of risk factors 
and markers for AF (Kirchhof, et al., 2011). Established and validated risk factors 
leading to the development of AF include age (see Section 1.2.2 for extended 
discussion), male gender, hypertension, valvular heart disease, heart failure, 
coronary artery disease, diabetes (Benjamin, Levy, & Vaziri, 1994; Gami, et al., 2007; 
Furberg, Psaty, Manolio, Gardin, Smith, & Rautaharju, 1994; Krahn, Manfreda, Tate, 
Mathewson, & Cuddy, 1995; Schnabel, et al., 2009), and genetic factors (Amar, et 
al., 2006; Fox, et al., 2004). Indeed, many of these risk factors, once identified form 
part of the patients risk stratification for stroke (see Section 1.2.3.2) and early 
intervention can help to prevent disease progression (Kirchhof, et al., 2011). 
 
Hypertension is often considered one of the most important factors; the higher the 
blood pressure, the greater risk of AF (Conen, Tedrow, Koplan, Glynn, Buring, & 
Albert, 2009; Thomas, et al., 2008). In one large cohort study hypertension was 
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found in 49.3% of AF patients (Go, et al., 2001). The underlying pathophysiological 
link, as with other conditions such as heart failure, appears to be atrial pressure 
and/or overload (Benjamin, et al., 1994; Furberg, et al., 1994). Whilst male gender 
has an established link with the incidence of AF, it should be mentioned that fewer 
females are included in clinical trials. This also contrasts with female gender being a 
key additional risk factor for stroke in AF patients (ESC, 2010), a contradiction that 
has yet to be explained within the literature. 
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Figure 1.1: The increase in cumalative risk for AF at selected ages for men and women (Lloyd-Jones, et al., 2004; pg. 1044). 
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1.2.2.1 Less well established risk factors for AF 
 
Some less established factors, such as obesity may provide further insight into AF 
and its progression (Krahn, Manfreda, Tate, Mathewson, & Cuddy, 1995). Evidence 
suggests that one in four AF patients are obese (Nabauer, et al., 2009). In one 
German AF registry survey the mean body mass index was 27.5 kg/m2 (equivalent to 
moderately obese; Nabauer, et al., 2009). Blood/pulse pressure (Conen, Tedrow, 
Koplan, Glynn, Buring, & Albert, 2009; Psaty, et al., 1997), height (Psaty, et al., 
1997), sleep apnea syndrome (Gami, et al., 2007), subclinical hyperthyroidism 
(Sawin, et al., 1994), alcohol consumption (Conen, Tedrow, Cook, Moorthy, Buring, & 
Albert, 2008), chronic kidney disease (Iguchi, et al., 2008), competitive or athlete-
level endurance sports (Mont, et al., 2008), chronic obstructive pulmonary disease 
(de Vos, et al., 2010), smoking (Furberg, et al., 1994; Krahn, et al., 1995; Benjamin, 
Levy, & Vaziri, 1994) and coffee consumption (Conen, Chiuve, Everett, Zhang, 
Buring, & Albert, 2010; Mattioli, Bonatti, Zennaro, Melotti, & Mattioli, 2008) are also 
less established risk factors.  
 
Psychological determinants have also been highlighted as risk factors for AF. One 
study examined prevalence of acute psychological stress in patients with first 
presentation AF compared to an age- and sex-matched control group. Recent stress 
was associated with a greater risk of AF, alongside a high intake of coffee and 
obesity. Acute stress appeared to induce an increase in coffee consumption and 
changes in patient’s lifestyle (Mattioli, Bonatti, Zennaro, Melotti, & Mattioli, 2008). The 
Framingham Offspring Study, following 3873 participants (‘off-spring’ of AF patients) 
found trait-anger (RR=1.1; 95% CI, 1.0 to 1.4; P=0.04), symptoms of anger (RR=1.2; 
95% CI, 1.0 to 1.4; P=0.008), and hostility (RR=1.3; 95% CI, 1.1 to 1.5; P=0.003) 
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were predictive of 10-year incidence of AF in men (Eaker, Sullivan, Kelly-Hayes, 
D'Agostino, & Benjamin, 2004). Anger has also been found to trigger arrhythmias 
(OR, 1.8; 95% CI, 1.0 to 3.2) in patients with implantable cardioverter-defibrillators 
(Lampert, Joska, Burg, Batsford, McPherson, & Jain, 2002). Previous studies have 
only suggested a tentative relationship between emotion and arrhythmia, thus more 
evidence is needed to explain this relationship further. 
 
1.2.3 AF prognosis 
 
1.2.3.1  Morbidity and mortality 
 
AF is associated with various clinical events, prevention of which is the main 
therapeutic goal. Stroke is the most common and feared complication, and strokes 
which occur in association with AF are often more severe, resulting in long-term 
disability or death, greater morbidity, poorer functional outcome, and longer hospital 
stays (Marini, De Santis, & Sacco, 2005; Steger, Pratter, & Martinek-Bregel, 2004; 
Savelieva, Bajpai, & Camm, 2007). AF is an independent risk factor for stroke, 
conferring a five-fold excess risk in AF patients compared to those in sinus rhythm 
and accounts for almost 10-15% of all ischemic strokes and approximately one in 
four strokes in those aged over 80 years (Lip & Edwards, 2006). Furthermore, 
undiagnosed ‘silent AF’ is a likely cause of some unexplained strokes (Kirchhof, et 
al., 2007; Knecht, et al., 2008).  
 
The risk of stroke and thromboembolism is comparable whether AF is paroxysmal, 
persistent or permanent, symptomatic or asymptomatic (Flaker, Belew, & Beckman, 
2005); and varies according to the number of risk factors present (Hughes & Lip, 
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2007). These factors include age (64-75 or ≥75 are at greater risk), presence of 
diabetes mellitus and hypertension, previous history of stroke or transient ischemic 
attack (TIA) and poor cardiac function (stroke risk stratification is discussed in more 
detail in Section 1.2.3.2).  
 
Quality of life and exercise capacity are often impaired in AF patients when 
compared to healthy controls, patients with coronary heart disease or the general 
population (Thrall, Lane, Carroll, & Lip, 2006). However, as Thrall and colleagues 
discuss in their review, most of these studies were highly selective and focused on 
symptomatic patients receiving an intervention to improve quality of life, and as such 
may not relate to all AF patients. As patient’s quality of life is often dependent on 
symptom control (symptomatic patients exhibit poorer quality of life outcomes), 
assessment of symptoms now forms part of the recommendations for physicians 
(ESC, 2010; for an extended discussion of AF related quality of life see Section 
1.5.2). 
 
Other factors which contribute to high levels of morbidity in this patient group include 
impaired left ventricular hypertrophy (LVH), caused by an irregular, fast ventricular 
rate (ESC, 2010). LV impairment represents an additional cardiovascular risk factor; 
the rate of fatal and non-fatal hospitalizations, cardiovascular events and all cause 
death is markedly greater in these patients (four-fold to five-fold) compared to 
patients without LVH, even when adjusting for other variables such as blood pressure 
(Bombelli, et al., 2009).  
 
Cognitive dysfunction may also relate to AF; observational studies suggest that 
asymptomatic embolic events may contribute to long term cognitive impairment 
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(Knecht, et al., 2008). However, research also suggests that antiplatelet treatment 
may contribute to cerebral microbleeds, affecting a large percentage of older patients 
prescribed aspirin to reduce cardiovascular risk (adjusted odds ratio compared with 
non-users, OR, 1.71, 95% CI, 1.21-2.41) (Vernooij, et al., 2009). This was further 
supported by a pooled analysis of trial data suggesting that microbleeds increased 
the risk of transient ischemic attack (TIA) and intracerebral hemorrhage, the excess 
increased from 2.8 (odds ratio; range, 2.3–3.5) in non-antithrombotic users to 5.7 
(range, 3.4 –9.7) in antiplatelet users and 8.0 (range, 3.5–17.8) in warfarin users (P 
difference=0.01) (Lovelock, Cordonnier, Naka, Al-shahi Salman, Sudlow, & Group, 
2010). Thus the link between AF and cognitive decline may be linked to treatment 
history (use of anti-platelet drugs) rather than an inherent causal link. Hospitalizations 
are more frequent in patients with AF (than other arrhythmias) for various reasons 
including aggravation of heart failure, thromboembolic complications, and acute 
arrhythmia management (ESC, 2010).  
 
1.2.3.2 Risk stratification 
 
The risk of stroke in AF patients varies markedly between patients and is dependent 
upon the presence or absence of risk factors. The clinical management of AF 
involves stratification of individual stroke risk profiles to ensure each patient is treated 
appropriately. A recent review of stratification schemes found 12 schemes varying in 
complexity (Stroke Risk in Atrial Fibrillation Working Group, 2008). Among the twelve 
risk schemas, the most frequently employed variables for predicting stroke risk were 
previous stroke or TIA (100%), age (83%), hypertension (83%), and diabetes (83%). 
Other factors included were heart failure (50%), left ventricular systolic dysfunction 
(50%), systolic blood pressure (42%), coronary artery disease (CAD; 33%) and 
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female sex (25%). Schemes also varied in their definition of the age threshold (>65 
or >75 years) and whether variables were continuous or ordered. Unsurprisingly, the 
fraction of patients categorised as being low or high risk varies substantially and this 
can greatly affect whether or not they are prescribed appropriate antithrombotic 
treatments (Stroke risk in atrial fibrillation working group, 2007). 
 
The National Institute for Clinical Excellence (NICE, 2006) proposed a stroke risk 
algorithm for physicians to use when deciding upon appropriate antithrombotic 
treatment (warfarin, aspirin, or no antithrombotic therapy). Patients are categorised 
as low (aged <65 with no moderate or high risk factors), moderate (aged ≥65 with no 
high risk factors or aged <75 with hypertension, diabetes or vascular disease) or high 
risk (previous stroke/TIA/ thromboembolic event, aged ≥75 with hypertension, 
diabetes or vascular disease, clinical evidence of valve disease, heart failure, or 
impaired left ventricular function). The recommended antithrombotic therapy for low 
risk patients is aspirin, while moderate risk patients can be treated with either aspirin 
or warfarin (physician decision). High risk patients are recommended for warfarin, 
unless contraindicated (NICE, 2006).  
 
Since the development of the NICE stratification schema, it has become evident that 
stroke risk algorithms need to be simple and consider other risk factors that are 
evident within the literature. Furthermore, the strict categorisation into low, moderate 
and high risk categories may under or overestimate individual risk. Of particular 
concern is the intermediate risk category, where either aspirin or warfarin may be 
prescribed. This can leave physicians with a degree of uncertainty, and may explain 
why OAC is under-prescribed (Nieuwlaat, et al., 2006). 
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An alternative stroke risk stratification scheme, which is commonly used is the 
CHADS2 index (see Table 1.3) which assigns one point for the presence of 
congestive heart failure, hypertension, age ≥75 years, and diabetes mellitus, and two 
points for previous stroke or TIA (Gage, Waterman, & Shannon, 2001). However, the 
CHADS2 index has been criticised for underestimating patients’ stroke risk. For 
example, a patient with previous stroke or TIA only, would have a risk score of two, 
which puts the patient in the moderate risk category, when they are high risk patients 
(Lip & Lim, 2007). However, both CHADS2 and the National Institute for Health and 
Clinical Excellence (NICE, 2006) risk stratification schemes have similar value in 
predicting stroke and vascular events (Lip & Lim, 2007).  
 
Previous risk stratification schemes have overlooked many potential risk factors, 
perhaps because many of these additional factors have not been systematically 
documented clinical trials (Lip, Nieuwlaat, Pisters, Lane, & Crijins, 2010). One 
systematic review carried out by the stroke working group found that in addition to 
the four major clinical predictors of stroke (prior stroke and/or TIA, advancing age, 
diabetes, and hypertension), there were also several factors with modest predictive 
value (Stroke risk in atrial fibrillation working group, 2007).  For example, the Euro 
Heart survey data suggests female gender increases thromboembolic risk (Lane & 
Lip, 2009), as well as other vascular diseases such as myocardial infarction, 
peripheral vascular disease and aortic plaque (Schmitt, Duray, Gersh, & Hohnloser, 
2009). Further, the BAFTA trial results suggest stroke risk increases in patients aged 
>65, thus patients risk score needs to be reassessed with increasing age (Lip & Lim, 
2007; Mant, et al., 2007).  
 
  
35 
 
More recently the CHADS2 scheme has been refined to include ‘clinically relevant 
non-major’ risk factors. These factors include vascular disease (defined as coronary 
artery disease, peripheral vascular disease, or previous thromboembolism other than 
stroke/TIA), age 65-74 years, and sex category (female sex). The updated schema, 
known by its acronym, CHA2DS2-VASc, allocates two points for patients that are 75 
years and over and for those patients with a previous stroke/TIA/thromboembolism, 
highlighting the importance of age as a risk factor for stroke in AF.  In addition to 
congestive heart failure, hypertension, and diabetes mellitus, CHA2DS2-VASc also 
allocates one point to the presence of vascular disease, age 65-74 years, and female 
gender (see Table 1.3). The Euro Heart survey group compared current risk 
stratification schemes and found the Birmingham 2009 schema (classified as 
CHA2DS2-VASC) proved the best predictor of thromboembolism (Lip, Nieuwlaat, 
Pisters, Lane, & Crijins, 2010). This approach of comprehensive risk factor 
assessment has been incorporated into the recent ESC guidelines for the 
management of AF patients.  The management cascade shown in Figure 1.2, 
demonstrates how this risk factor approach to antithrombotic therapy is 
operationalised (ESC, 2010). 
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Figure 1.2: The management cascade for patients with AF taken from ESC 
guidelines (ESC, 2010, p. 12). 
 
Presentation  
EHRA score 
Associated disease 
Initial assessment 
Atrial Fibrillation 
Anticoagulation 
issues 
Rate and rhythm 
control 
Underlying 
disease – 
‘upstream 
therapy’ 
Record 12-lead ECG 
Assess TE risk 
AF type symptoms 
Consider referral 
Oral anticoagulant  
Aspirin 
None 
Rate control 
± Rhythm control 
Antiarrhythmic drugs 
Ablation 
ACEIs/ARBs 
Statins/PUFAs 
Others 
 
* ACEI = Angiotensin-converting enzyme inhibitor; ARB = Angiotensin receptor 
blocker, PUFA = polyunsaturated fatty acid, EHRA = European Heart Rhythm 
Association. 
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The ESC guidelines recommend that patients with a CHA2DS2-VASc score of zero 
can be treated with no therapy or aspirin with a preference for no antithrombotic 
therapy.  Those with a CHA2DS2-VASc score of ≥1 should receive oral 
anticoagulation, unless contraindicated. 
 
Table 1.3: CHA2DS2-VASc score risk factor-based approach based on the ESC 
guidelines (ESC, 2010). 
 
CHADS2 Score Risk factor CHA2DS2-VASc Score 
1 Congestive heart failure/LV* 
dysfunction 
1 
1 Hypertension 1 
1 Age ≥75 2 
1 Diabetes mellitus 1 
2 Stroke/TIA*/thromboembolism 2 
0 Vascular disease 1 
0 Age 65-74 1 
0 Sex category (i.e. female sex) 1 
6 Maximum score 9 
*TIA= transient ischemic attack; LV=Left ventricular 
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1.3  Antithrombotic therapy in AF 
 
1.3.1 Warfarin versus placebo 
 
Evidence from numerous RCTs supports the use of OAC for thromboprophylaxis in 
AF patients, demonstrating highly significant reductions in the incidence of stroke. A 
meta-analysis of the six RCTs (n=2900; five primary and one secondary prevention), 
comparing dose-adjusted warfarin (target International Normalised Ratio (INR) 2.0-
3.0) with placebo demonstrated a 64% (95% CI 49%-74%)  relative risk reduction in 
stroke with warfarin over placebo (Hart, Pearce, & Aguillar, 2007). Furthermore, the 
absolute risk reduction was greater for secondary stroke prevention (8.4%, number 
needed to treat (NNT) for 1 year to prevent a stroke was 12 vs. 2.7%, NNT 37, 
respectively), although only one secondary prevention study was included (Hart, 
Pearce, & Aguillar, 2007). The review suggested that the benefits of warfarin may in 
fact be underestimated, as many of the strokes that occurred in these studies 
occurred when patients were not taking anticoagulants or when the dose was sub-
therapeutic (Hart, Pearce, & Aguillar, 2007). The risk reduction for ischemic strokes 
was particularly high (RRR 67%, 95% CI, 54% -77%).  
 
1.3.2 Warfarin versus antiplatelets 
 
A meta-analysis conducted by Hart and colleagues (Hart, et al., 2007) also 
demonstrated the effectiveness of dose-adjusted warfarin in reducing the risk of 
ischemic stroke or embolism (RRR 39%, 95% CI 22-52%) compared to antiplatelet 
therapy (11 trials) (Hart, et al., 2007). However, findings suggest that whilst the 
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increase in absolute risk of bleeding was small (0.2% per year), the risk of 
intracranial haemorrhage was doubled with adjusted dose warfarin compared with 
aspirin (RRR 128%, 95% CI -399% to -4%) (Hart, et al., 2007). However, the small 
number of strokes in this trial may limit the estimates of bleeding with warfarin versus 
antiplatelet therapy. 
 
Since the meta-analysis of the earlier trials on antithrombotic therapy, the 
Birmingham Atrial Fibrillation Treatment of the Aged (BAFTA) study assessed 
whether warfarin, managed in primary care, reduced the primary endpoint of major 
stroke, arterial embolism or intracranial haemorrhage, compared with aspirin in 973 
elderly (aged ≥75 years) patients. AF patients were followed up for an average of 2.7 
years (Mant, et al., 2007). There were more adverse events among the aspirin 
patients (44 strokes, three systemic embolisms, one other intracranial haemorrhage), 
at a rate of 3.8% compared to 1.8% in warfarin patients (21 strokes, one systemic 
embolism, two other intracranial haemorrhage). Warfarin was associated with a 48% 
risk reduction (95% CI 0.28-0.80; p=0.003) for total number of events, while the risk 
of major haemorrhage (including intracranial and haemorrhagic stroke) was similar 
with warfarin and aspirin (Risk per year 1.9% vs. 2.0% respectively; RR 0.96, CI 
95%, 0.53-1.75, p= 0.90). The BAFTA trial suggests that warfarin was more 
efficacious than aspirin in elderly AF patients, with a similar safety profile. The 
BAFTA trial also suggests that warfarin is still more efficacious than aspirin in 
patients >85 years old (RR 0.50, 95% CI, 0.17-1.31) and that there were no 
significant differences in risk reduction between age groups (age brackets included 
75-79, 80-84, >85) (Mant, et al., 2007). 
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The anticoagulation and risk factors in atrial fibrillation (ATRIA) study, with a large 
retrospective cohort (n=13,559) of non-valvular AF patients, recently documented the 
net clinical benefit of risk (thromboembolism and bleeding) based recommendations 
for anticoagulation.  The authors quantified net clinical benefit including estimated 
reduction in rate of thromboembolism, ischemic stroke, minus 1.5 times the 
estimated increased rate of intracranial haemorrhage attributable to warfarin therapy. 
The overall adjusted net clinical benefit with warfarin was 0.68% per year (95% CI, 
0.34% to 0.87%). Adjusted net clinical benefit was greatest for patients with a history 
of ischemic stroke (2.48% per year [CI, 0.75% to 4.22%] and for those patients who 
were 85 years or older [2.34% per year [CI, 1.29% to 3.30%]) (Singer, et al., 2009).  
 
 
1.3.3  Novel oral anticoagulants versus traditional antithrombotic therapy 
 
The inherent difficulties associated with warfarin, such as regular blood monitoring, 
dietary and alcohol restrictions and interactions with other medications (see Section 
1.4.3.2 for a full discussion), have led to the development of novel oral anticoagulant 
drugs which have sought to overcome these difficulties by reducing thromboembolic 
risk without substantially increasing the risk of major bleeding.  Several new oral 
anticoagulant drugs have been tested in clinical trials, some of which have been 
completed (Granger, et al., 2011; Connolly, et al., 2011; Connolly, et al., 2009; Patel, 
et al., 2011) while others (Ruff, et al., 2010) are still ongoing. Table 1.4 illustrates that 
whilst many of the novel anticoagulants are non-inferior to warfarin in reducing 
incidence of stroke and mortality, some carry additional risks including increases in 
gastrointestinal bleeds. However, Apixaban appears to be both non-inferior and has 
a reduced risk of bleeding, with fewer treatment discontinuations (Granger, et al., 
2011). In the future interventions targeting patients with atrial fibrillation may need to 
be adapted and/or relevant for novel OAC. 
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Table 1.4: Trials comparing new anticoagulants to warfarin in atrial fibrillation 
 
Trial Type of anticoagulant Key findings 
RE-LY Dabigatran etexilate 150 
 
Non-inferiority stroke 
Reduction in hemorrhagic & ischemic stroke 
Reduction in mortality 
Increased gastro intestinal bleeds 
Increased myocardial infarction 
Dabigatran etexilate 110 Non-inferiority stroke 
Reduction in hemorrhagic & ischemic stroke 
Reduction in major bleeding 
Increased myocardial infarction 
ARISTOTLE Apixaban Non-inferiority stroke 
Reduction in hemorrhagic & ischemic stroke 
Reduction in mortality 
Reduction in major bleeding 
Fewer treatment discontinuations 
ROCKET-AF Rivaroxaban Non-inferiority stroke 
Reduction in hemorrhagic & ischemic stroke 
Increased gastrointestinal bleeds 
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1.3.4 Bleeding epidemiology 
 
Whilst the evidence discussed clearly highlights the net benefit of OAC for AF 
patients at risk of stroke, major bleeding events can be devastating if they do occur. 
Unfortunately, vitamin K antagonists, of which warfarin is the most commonly used, 
have a very narrow therapeutic range, and the INR needs to be maintained in the 
therapeutic range of 2.0–3.0 (Singer, et al., 2009). The risk of ischemic stroke 
increases when INR levels are below 2.0, and when they exceed 3.0, the risk of 
bleeding is increased (Singer, et al., 2009; Lip, et al., 2011). Hence, INR monitoring 
is necessary on a regular basis and dose adjustments may be required to reduce the 
risk of adverse bleeding.  When deciding upon anticoagulant therapy, the risks of the 
treatment (i.e., bleeding risk) need to be assessed in conjunction with the risk of 
stroke (Lip, et al., 2011). 
 
Anticoagulation intensity can be influenced by multiple drug and food interactions, as 
well as by alcohol consumption (Holbrook, et al., 2005). Furthermore, OAC is most 
often prescribed to elderly patients with multiple co-morbidities. The consequences of 
bleeding complications arising as the result of falls and overdosing, due to cognitive 
impairment, can be devastating.  Ninety percent of the deaths associated with 
warfarin-related haemorrhage in AF patients are intra-cranial (Fang, Go, & Chang, 
2007). A review carried out for the National Institute for Health and Clinical 
Excellence found several risk factors for anticoagulation-related bleeding, these 
include a history of myocardial infarction, diabetes, other bleeding and polypharmacy 
(particularly with aspirin and non steroidal anti-inflammatory drugs) (Hughes & Lip, 
2007). 
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Patients are at greater risk of bleeding upon initiation of warfarin therapy, with the 
first 90 days of treatment appearing to be the most crucial period.  In addition, elderly 
patients (those aged over 80 years), with supra-therapeutic INR (INR of ≥ 4.0), and 
high stroke risk (CHADS2 score of 3 or more) are at greatest risk of major bleeding 
(Hylek, Evans-Molina, Shea, Henault, & Regan, 2007). However, for those with a 
high stroke risk, the benefits of anticoagulation often outweigh the risks. Hence, the 
risks of bleeding should reinforce the need for appropriate management and 
monitoring of treatment and INR, rather than to deter the use of OAC treatment all 
together.  
 
In the same way that stroke risk stratification was developed, it is evident that 
bleeding risk may need a similar process. Previous bleeding risk stratification 
schemes are not AF specific and are validated with small samples (e.g. Beyth, Quin, 
& Landefeld, 2000; Kuijer, Hutten, & Prins, 1999). Four different stratification 
schemes have been published (Tay, Lane, & Lip, 2008). However, whilst age is 
accounted for in all schemes, female gender is only accounted for in two schema 
(Shireman, Mahnken, & Howard, 2006; Gage, Yan, & Milligan, 2006) anaemia in 
three (Gage, Yan, & Milligan, 2006; Shireman, Mahnken, & Howard, 2006) and 
recent myocardial infarction in one (Beyth, Quinn, & Landefeld, 1998). All schemas 
also take into account a range of varying factors, with limited predictive validity and 
clinical applicability (Tay, Lane, & Lip, 2008) 
 
As alluded to earlier, treatment decisions regarding the most appropriate 
antithrombotic therapy for AF patients needs to consider both the risk of stroke and 
the risk of bleeding.  However, the available schemas to assess bleeding risk have a 
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number of limitations as highlighted in the previous paragraph.  Consequently, a new 
bleeding risk score was developed using data from the Euro Heart Study.  This new 
bleeding clinical prediction rule is known by the acronym HAS-BLED (hypertension, 
abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR, 
elderly (>65), drugs/alcohol concomitantly; see Table 1.5). Results from the 
validation of HAS-BLED in the Euro Heart Survey cohort demonstrates that the risk 
of major bleeding rises sharply once the HAS-BLED score is ≥3 (Pisters, Lane, 
Nieuwlaat, de Vos, Crijns, & Lip, 2010), suggesting that such patients require close 
monitoring of their INR and assessment of associated risk factors to try to prevent 
treatment-associated bleeding complications. 
 
HAS-BLED has been validated in the SPORTIF III (Stroke Prevention Using an ORal 
Thrombin Inhibitor in Atrial Fibrillation) and IV trials and compared against the other 
published bleeding risk tools (Lip, Frison, Halperin, & Lane, 2011). HAS-BLED score 
performed best in predicting bleeding events (p<0.0001). The c statistic (a measure 
of predictive accuracy) for bleeding was 0.65 (95% CI, 0.61 - 0.68) in the overall 
cohort and 0.66 (95% CI, 0.55-0.74) among patients naive to warfarin at baseline (n 
= 769). A further study compared the use of HAS-BLED with an older prediction 
scheme HEMORR2HAGES in a cohort of ‘real world’ AF patients (Olesen, et al., 
2011). Using HAS-BLED (n = 44 771), 34.8% were categorized as ‘low bleeding risk’ 
and 47.3% using HEMORR2HAGES. C-statistics for the two schemes were 0.795 
(0.759–0.829) and 0.771 (0.733–0.806) respectively (Olesen, et al., 2011). Thus 
whilst the two schemes were comparable in predictive ability, HAS-BLED was 
deemed easier to use in clinical practice. This tool can be used to highlight high risk 
patients and decide whether they require extra monitoring or treatment review (ESC, 
2010). 
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New bleeding risk stratification schemes such as the ATRIA bleeding risk score 
(Fang, et al., 2011), also have good predictive ability, the c-index for the continuous 
risk score for this scheme was 0.74 and 0.69 for  the 3-category score (low- 
intermediate- and high-risk). Thus the predictive ability of this scheme is also good. 
The ESC guidelines have also endorsed formal assessment of bleeding risk when 
initiating antithrombotic therapy and suggest using a bleeding risk tool (ESC, 2010). 
 
Table 1.4: Clinical characteristics comprising the HAS-BLED bleeding risk score (Lip, 
et al., 2011). 
 
Letter Clinical characteristic* Points awarded 
H Hypertension 1 
A Abnormal renal and liver function (1 point 
each) 
1 or 2 
S Stroke 1 
B Bleeding 1 
L Labile INRs 1 
E Elderly (age >65) 1 
D Drugs or alcohol (1 point each) 1 or 2 
  Maximum 9 points 
*‘Hypertension’ is defined as systolic blood pressure >160mmHG; ‘Abnormal renal 
function’ is defined as the presence of chronic dialysis or renal transplantation; 
‘Abnormal liver functions’ is defined as chronic hepatic disease (cirrhosis) or 
biochemical evidence of significant hepatic derangement; ‘Bleeding’ refers to 
previous history of bleeding or predisposition to bleeding; ‘Labile INRs’ refers to 
unstable or high INRs and limited time within therapeutic range (<60%); 
‘Drugs/alcohol’ refers to concomitant use of drugs such as antiplatelets, non-steroidal 
anti-inflammatory drugs and alcohol abuse. 
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1.3.5 Time within therapeutic range (TTR) 
 
One of the most important goals of anticoagulation is to ensure that the international 
normalised ration (INR) is maintained within the target therapeutic range (TTR) of 2.0 
to 3.0, where warfarin treatment offers the best benefit/risk ratio (Fuster, Ryden, 
Cannom, Crijins, Curtis, & Ellenbogen, 2006). Rosendaal (Rosendaal, Cannegieter, 
van der Meer, & Briet, 1993) first described a method for assessing the variability of 
INR target levels i.e. TTR (for details of its calculation see Section 4.3.1). This 
involves setting a study time-frame over which the cohort is observed, and gathering 
dates of all prothrombin time assessments; the INR is treated as gradually increasing 
or decreasing over the interval time frame (Rosendaal, Cannegieter, van der Meer, & 
Briet, 1993). 
 
The ACTIVE-W trial explored the variation in INR control between centres and 
countries and observed how this variation impacted on the effectiveness of OAC 
therapy in patients with AF. The mean TTR of all patients in the trial varied by both 
centre and country (46 -78%) despite the parameters set by a clinical trial (such as 
the protocol-mandated target INR of 2.0-3.0 and minimum monthly measurements) 
(Connolly, et al., 2008).  The findings suggested that where TTR values ≤ 58%, one 
cannot expect any net benefit from being on OAC, and a TTR >65% is critical to 
achieve clinical benefit (Connolly, et al., 2008).  
 
Another study, using record-linkage data from hospitalised inpatients in Wales, 
sought to determine what proportion of TTR may be defined as good control in terms 
of reduced stroke and mortality for AF patients (Morgan, McEwan, Tukiendorf, 
Robinson, Clemens, & Plumb, 2009). This study found that 51% (n=248) of patients 
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with a CHADS2 score ≥2 were outside the therapeutic range for 50% or more of the 
time for the duration of their warfarin treatment. The outcomes of this study suggest 
that warfarin treatment offers no or limited clinical benefit [reduced stroke and 
mortality] unless a patient can maintain their therapeutic range for more than 71% of 
the time (see Figure 1.3). Furthermore, there was a non-significant trend towards 
worse outcomes with TTR control lower than 30% for mortality and lower than 40% 
for stroke (Morgan, et al., 2009). 
 
  
Figure 1.3: Cox proportional hazards model for 
stroke, for patients at moderate or high risk of stroke CHADS2 
control (Morgan, et al., 2009)
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major haemorrhage per 100 patient-years, and a 12% improvement in TTR would 
lead to a reduction of one thromboembolic event per 100 patient-years (Wan, et al., 
2008). 
 
More recently the RE-LY trial examined TTR in patients taking a novel OAC, 
dabigatran (110mg or 150 mg) versus warfarin. Patients were followed-up over a 
period of two years (n=18113). An increasing TTR in the warfarin group resulted in 
fewer strokes and systemic embolisms (at TTR <55.1% event rate per 100 person-
years was 1.92, at >72.6% TTR event rates dropped to 1.34), but not fewer 
occurrences of intracranial bleeding. They also found no significant interactions 
between centre TTR control and total stroke with either dose of dabigatran 
(Wallentin, et al., 2010). There were however, lower rates of non-hemorrhagic stroke 
at higher quartiles of TTR in the dabigatran groups (in dabigatran 150 dose TTR 
>72.6% resulted in an event rate of 0.30 person-years, compared to 0.77 in the 
warfarin group), suggesting novel anticoagulants may be superior in reducing the 
incidence of bleeding, when patients remain within therapeutic range (Wallentin, et 
al., 2010). 
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Figure 1.4: TTR versus adverse events (weighted by sample size) for all studies (Wan, et al., 2008). 
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1.4 Barriers to Anticoagulation 
 
Whilst it is clear that patients need to be assessed using appropriate risk stratification 
schemes and they need to remain within therapeutic range of their prescribed OAC 
treatment, there are many factors that influence whether patients are prescribed 
anticoagulation and indeed whether they adhere to recommendations. Barriers may 
be at the level of the health-care provider, the physician, or the patient themselves.  
 
1.4.1 Health-care barriers 
 
Achieving a good quality of OAC care can be problematic, particularly as the most 
cost effective method for monitoring patients requires them to travel to their nearest 
hospital or community clinic. Thus, the inconvenience of travelling and frequent 
venipunctures could impact upon adherence. However, anticoagulation control also 
varies extensively depending on the group, setting, drug types and type of 
management (i.e. self management; van Walraven, Jennings, Oake, Fergusson, & 
Forster, 2006). One systematic review and meta-analysis of warfarin therapy, found 
that studies set in the community, and those that did not use self-monitoring of INR, 
had the lowest percentage of TTR (van Walraven, et al., 2006). Unfortunately, this 
describes the majority of patients taking warfarin in both the UK and the US. The 
difference in TTR between community practices and anticoagulation clinics was 
significant in a meta-analysis (-8.3%; 95% CI, -4.4 to -12.1), with better INR control 
seen in anticoagulation clinics, however, there was no significant difference between 
anticoagulation clinics and randomised trials (van Walraven, et al, 2006). Thus 
patients taking part in trials and those receiving hospital care follow-up are more 
likely to achieve a better TTR and therefore, less warfarin-associated complications 
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Self-monitoring trials appear to achieve better TTR than traditional methods such as 
anticoagulation clinics (71.5% vs. 63.1% respectively) (van Walraven, et al., 2006). 
These patients are trained to self manage their treatment, and are also likely to 
demonstrate greater knowledge of the factors affecting TTR, taking more 
responsibility for their health outcomes. However, self-management is costly, few 
patients are suitable for this type of intervention, and self management trials often 
have high levels of attrition, perhaps due to a patients’ lack of confidence in 
performing these tests.  
 
1.4.2 Physician barriers 
 
Despite the documented benefits of anticoagulation for AF patients, the Euro Heart 
Survey found that warfarin was prescribed in only 67% of eligible patients (Nieuwlaat, 
et al., 2006). Antithrombotic treatment needs to be tailored according to patients’ 
individual risk profiles. However, in the Euro Heart Survey a similar proportion of 
patients received OAC therapy (40-50%) regardless of their stroke risk (see Figure 
1.5). Evidence suggests that a high proportion of low risk (CHADS2=0) patients (40-
50%) are being prescribed warfarin, leaving them exposed to an avoidable bleeding 
hazard. Furthermore, some of the key risk factors such as prior stroke or TIA and age 
>75 were not associated with anticoagulant prescription (Nieuwlaat, et al., 2006). 
Factors that were associated with OAC prescription included valvular heart disease 
(OR 5.67, 95% CI, 3.83 – 8.38, p<0.001), AF type (paroxysmal, persistent, and 
permanent; p<0.001), diabetes (OR 1.47, 95% CI, 1.17 – 1.85), reason for hospital 
admission (i.e. AF only or another reason; p<0.001), lack of an OAC monitoring clinic 
(OR 0.75, 95% CI, 0.62-0.91, p=0.003), and type of heart rhythm control strategy 
(p<0.001) (Nieuwlaat, et al., 2006). Some of these non-traditional factors associated 
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provide cause for concern; for example, paroxysmal AF patients are less likely to be 
prescribed treatment, which could link to an inaccurate assumption that a low AF 
burden also confers a low risk of stroke (Nieuwlaat, et al., 2006).  
 
Evidently there are numerous factors that physicians consider, alongside traditional 
risk stratification factors for stroke. From the physician's perspective, there is 
reluctance to use warfarin, partly due to overestimation of bleeding risks (Marini, De 
Santis, & Sacco, 2005; Hart, Pearce, & Rothbart, 2000; Flaker, Belew, & Beckman, 
2005; Choudry & Lip, 2004; Goldman, Pearce, & Hart, 1999). One study noted 
substantial differences between the amount of excess bleeding risk physicians and 
patients were willing to accept to reduce the potential risk of future stroke 
(Devereaux, Anderson, Gardner, Putnam, & Flowerdew, 2001). Participants were 
given descriptions of major and minor stroke and bleeding and completed four clinical 
scenarios to determine their thresholds for the minimum reduction in risk of stroke 
necessary to justify treatment [two warfarin and two aspirin scenarios]. Participants 
decided whether they would prescribe or agree to take warfarin in the given scenario. 
The stroke thresholds for warfarin were very different; 74% [n=45] of patients were 
willing to take warfarin if it prevented one stroke in 100 patients, whereas 38% [n=24] 
of physicians were willing to recommend warfarin for the same reduction in stroke.  
 
Thus there was a significant difference between patient and physician threshold (P= 
0.009).Thirty-five (57%) patients were willing to accept 22 more episodes of bleeding 
in 100 patients over a two year period; this is significantly different from physicians 
(p<0.001) (Devereaux, et al., 2001). Thus, the variability of physicians’ bleeding 
thresholds may explain some of the under prescribing of OAC treatments. Physicians 
may not recommend warfarin if they think that the bleeding risks outweigh the 
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benefits. Thus it also follows that physicians are less likely to prescribe warfarin in 
scenarios where they perceive there to be a high risk of bleeding. One survey 
(Gattellari, Worthington, Zwar, & Middleton, 2007) utilising clinical vignettes to elicit 
OAC prescribing decisions, found that physicians prescribed warfarin less in 
scenarios where this risk of bleeding appeared high, e.g. due to a history of falls, 
recent bleeding and previous intracranial haemorrhage, despite a high risk of stroke.  
 
Physicians’ experiences of prescribing warfarin may also have an influence; as one 
survey also found that Australian family physicians felt more responsible for a stroke 
occurring whilst not on warfarin than a haemorrhage occurring whilst on warfarin. 
Approximately one fifth (17.6%) anticipated feeling most responsible for an 
intracranial haemorrhage on anticoagulation, whereas 31.5% anticipated feeling most 
responsible for an ischemic stroke in a patient without anticoagulation. Physicians 
who anticipated feeling most responsible for an intracranial haemorrhage were more 
likely to have previously experienced this outcome compared with physicians who 
anticipated feeling most responsible for a stroke (Gattellari, et al., 2007).  
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Figure 1.5: Antithrombotic drug prescription per risk category according to ACC/AHA/ESC guidelines (A) ACCP guidelines (B), CHADS2 score 
(C), Framingham score (D) from an article by Nieuwlaat and colleagues (Nieuwlaat, et al., 2006). 
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Knowledge also plays an important role in physicians’ confidence in treating AF 
(Murray, Lazure, Pullen, Maltais, & Dorian, 2011).  One Canadian study found 
physicians lacked the confidence to provide optimal care for AF patients, 
predominantly because their knowledge was lacking. There was a lack of consensus 
over whether AF was a disease itself or a manifestation of another disease or 
condition. There was also a lack of confidence in identifying underlying factors of AF 
and detection of paroxysmal AF, as well as a lack of up-to-date knowledge 
surrounding appropriate treatment and the clinical decision making process. The 
study also identified contextual and communication barriers such as lack of access to 
specialists and incomplete referrals processes (Murray, et al., 2011). Evidently there 
are education gaps across the continuum of care that need to be addressed to 
ensure optimum treatment is provided for patients. 
 
Whilst risk stratification models are improving in terms of clinical application, 
physicians may be less likely to adhere to the guidelines if their knowledge of them is 
poor (Lane & Lip, 2007). One qualitative study also highlighted this barrier and found 
senior physicians were often uncertain when prescribing OAC, ‘certainty’ in 
prescribing was expressed by <20% of physicians in any one vignette (Anderson, 
Fuller, & Dudley, 2007). Furthermore, physicians discussed a lack of availability of 
risk information, and their lack of AF-specific knowledge, leading to many of their 
decisions about patient treatment being influenced by experiential views (Anderson, 
Fuller, & Dudley, 2007). 
 
More recent risk stratification schemes such as CHADS2 (Gage, Waterman, & 
Shannon, 2001), and CHA2DS2-VASc (Lip et al, 2010), and HAS-BLED (Pisters, 
Lane, Nieuwlaat, de Vos, Crijns, & Lip, 2010), have led the way in proposing 
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standardised, easy-to-use schemes to help facilitate appropriate, and wider-ranging 
prescription of antithrombotic therapy among AF patients. Inadequate physician 
knowledge and appreciation of relevant data from clinical trials (Deplanque, Leys, & 
Parnetti, 2004), may also reflect a need for better dissemination of these guidelines 
(Lip & Lim, 2007).  
 
1.4.3 Patient Barriers 
 
Patient barriers to optimal OAC treatment are complex. There are several reasons 
why patients may choose not to take OAC or why they may not adhere to medication 
and lifestyle recommendations. The literature has focussed on patients’ perceptions 
of the risks associated with treatment, the impact of the warfarin regime on quality of 
life, the decision making process itself and their knowledge and understanding 
surrounding AF and treatment choice.  
 
1.4.3.1  Perception of risk 
 
Risk index guidelines do not account for individual management of patients’ 
complexities, co-morbidities and concerns. Patient related factors have been 
identified as barriers to anticoagulation and perception of risk is perhaps the most 
important consideration in deciding whether or not to start taking OAC.  
 
It is presumed that we make rational decisions regarding treatment choice, opting for 
whichever plan of action results in the greatest benefit or usefulness to the individual. 
However, risk communication can also impact upon this process, particularly the 
‘framing’ of the message. The way in which the risks and benefits are presented to 
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an individual in a consultation and how they are perceived will evidently affect their 
treatment choice (Dudley, 2001). Some physicians may communicate this 
information in a positive way by focussing on positive aspects of treatment and 
omitting negative aspects (positive framing), whilst others may focus on particular 
limitations or negative aspects of treatment, i.e. age, mobility or lifestyle changes 
(negative framing). This suggests that the physicians own opinions and perceptions 
of risk may also play an important role in determining patient risk perception (Dudley, 
2001).  
 
Qualitative evidence suggests that the majority of patients with atrial fibrillation are 
unaware that they are at risk of stroke (61% 34/56) (Howitt & Armstrong, 1999). 
Furthermore, of those patients that were aware, only two (2/56) felt able to estimate 
the level of risk (Howitt & Armstrong, 1999). These findings were also reflected in a 
local Birmingham-based study that found only half of the patients considered AF a 
serious condition, and only 9% considered it a ‘very serious’ condition. Furthermore, 
only 54% were aware that AF could predispose them to blood clots or stroke (Lane, 
Ponsford, Shelley, Sirpal, & Lip, 2006). One qualitative study suggests whilst patients 
may be aware of the name of their treatment, they are less likely to know the reason 
why they are taking it (Bajorek, Krass, Ogle, Duguid, & Shenfield, 2006). Without the 
knowledge to facilitate the link between their illness and the necessity for treatment, 
many patients may not view their condition as risky and indeed may underestimate 
the necessity of their medication. 
 
Patients appear to have little knowledge of the risk associated with warfarin use or 
their potential risk of stroke, and the importance of their perception of risk has been 
highlighted in previous studies (Howitt & Armstrong, 1999). Patients’ judgement of 
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the minimal level of benefit for which they would take warfarin (versus aspirin) 
predicted those patients who were going to start warfarin, with a mean minimal 
clinically important difference (between warfarin and aspirin) at the first interview of 
2.56% and 4.86% for those not starting warfarin (t test 2.93, p<0.05) (Howitt & 
Armstrong, 1999). Clearly patients are managing risk based on the evidence 
acquired, or alternatively their perception of risk. 
 
An example of the decision making process was highlighted in a decision aid study 
by Fuller and colleagues. They examined treatment choices of older patients when 
given information about the cumulative benefits of warfarin on stroke risks over a 10 
year period (Fuller, Dudley, & Blacktop, 2004). Pictograms were used to illustrate the 
risks and benefits, both visually and numerically. Patients aged ≥ 65 were asked to 
choose a treatment option from treatment P (placebo) and treatment J (warfarin) for a 
patient with AF who has had a recent ischemic stroke. Pictograms illustrated the 
number of strokes suffered in both treatment arms at 10 years, participants were 
asked which treatment they would choose, all participants chose treatment J (n=81). 
As additional information was given regarding the risk of intracerebral haemorrhage, 
increasing from 0.1% risk (1 person in 10 years) to 4% (34 people after 10 years), the 
percentage of participants opting for treatment J was reduced from 99% (with 
0.1%/year risk) to 49% (with 4%/year risk). However, even with the maximum 
bleeding risks nearly half of the participants were opting for treatment with warfarin 
suggesting that patients fear the risk of stroke more than the risk of bleeding on OAC 
(Fuller, Dudley, & Blacktop, 2004).  
 
Patients’ perception of risk plays an important role in their decision to start 
anticoagulation therapy, and information on the risk of bleeding significantly 
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attenuates the number of patients willing to take OAC, suggesting that patients 
‘trade-off’ the risk of stroke with the risk of bleeding, to arrive at a decision about 
OAC therapy. Qualitative evidence suggests that patients who decide not to take 
warfarin do not perceive themselves at high risk of stroke (Howitt & Armstrong, 
1999), thus they may place greater emphasis on the ‘unnecessary’ risks of bleeding. 
 
However, not all patients feel able to make a judgement regarding the minimum 
clinically important difference between stroke and bleeding risk (Fuller, Dudley, & 
Blacktop, 2004). Thus for many patients it may be difficult to understand the risk 
information presented to them. In practice these patients would most probably seek 
the advice of the physician or social networks. Hence it is important when developing 
educational materials that they are piloted with patient groups to ensure 
understanding, as misunderstanding could attenuate the effects of the intervention. 
Further, physicians need to ensure that they are not framing the communication of 
risk in a way that may present a barrier to patient uptake. 
 
1.4.3.2  Warfarin regimen 
 
The warfarin regime requires several changes to a patients’ lifestyle. Regular INR 
monitoring is achieved via blood testing, which often takes place at a community GP 
surgery or hospital outpatient clinic. Furthermore, patients are given lifestyle 
recommendations based on the numerous factors that can influence warfarin 
metabolism. Despite the burden of the treatment regimen the Boston Area 
Anticoagulation Trial for Atrial Fibrillation found that patients decided to take warfarin 
93% of the time (Gottlieb & Salem-Schatz, 1994). However, 26% of patients (aged 80 
years and over) in another study stopped taking warfarin within the first year. For 
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over 80% of these patients, physicians stopped their treatment due to concerns 
about safety (Hylek, Evans-Molina, Shea, Henault, & Regan, 2007). This may explain 
why surveys of prescribing physicians have found they may withhold warfarin based 
on the belief that patients would be non-adherent (Kutner, Nixon, & Silverstone, 
1991). Whilst patients are prepared to take OAC based on recommendations, they 
may be reticent about doing so, influencing their decision to discontinue their 
treatment or perhaps not adhere to recommendations. 
 
The impact of the warfarin regime varies, whilst the vast majority of patients in one 
qualitative study reported no warfarin complications, others report minor 
inconveniences (Coelho-Dantas, Thompson, Manson, Tracy, & Upshur, 2004). 
Those patients who regarded warfarin as having a significant impact on their day-to-
day lives were more likely to have multiple co-morbid illnesses, multiple treatment 
plans, and struggle with the addition of the warfarin regime (Coelho-Dantas, et al., 
2004). Therefore, it is important to find out which elements of the regime patients find 
difficult to integrate into their lifestyle. 
 
One study by Fuller and colleagues (Fuller, et al., 2004) examined decision-making 
when faced with the additional information about warfarin (i.e. the need for blood 
tests, necessity of tablets and the risks of bleeding). INR (blood) checks did not 
substantially reduce the number of participants opting for warfarin from 12-weekly 
blood check (99%) to 2-weekly (84%), but 15% of participants were choosing not to 
take warfarin because of the inconvenience of the tests. Furthermore, whilst 98% of 
patients still opted for warfarin with the limitation of two units of alcohol per day, 11% 
of patients chose not to opt for this treatment if they were not able to drink alcohol at 
all (Fuller, et al., 2004).  
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A large scale European cross-sectional study (n=711) also suggested that patients 
felt that OAC treatment impacted on them in numerous ways. For 67% of the cohort 
the impact included diet, socialising, career, independence, and the impact was more 
prevalent in patients that were younger (74%) (Lip, Agnelli, Thach, Knight, Rost, & 
Tangelder, 2007). Therefore the burden of INR tests and lifestyles changes can 
present a challenge for patients; for some these changes may influence their 
decision to adhere to guidelines. 
 
Evidently whilst patients are willing to start treatment to reduce the risk of stroke, they 
may not adhere to associated lifestyle recommendations. One qualitative study 
interviewing anticoagulation nurses suggested patients were unperturbed by the risk 
of bleeding, even to the point of ignoring safety measures (Bajorek, Krass, Ogle, 
Duguid, & Shenfield, 2006). When provided with the risks of bleeding, and lifestyle 
recommendations, many patients still choose not to adhere to treatment guidelines 
(i.e. ‘informed dissent’). This could result from other influencing factors, for example, 
several studies highlight the lack of patient knowledge surrounding treatment and AF 
(Bajorek, Krass, Ogle, Duguid, & Shenfield, 2006; Lane, Ponsford, Shelley, Sirpal, & 
Lip, 2006; Bajorek, Ogle, Duguid, Shenfield, & Krass, 2007; Coelho-Dantas, 
Thompson, Manson, Tracy, & Upshur, 2004), therefore, perhaps patients are not 
aware of the extent of the risks associated with non-adherence, thus are less willing 
to make changes to their lifestyle.  
 
1.4.3.3 Decision making 
 
The decision to take warfarin can be a difficult one for patients, who may need to 
consider the associated risks and required lifestyle changes. One qualitative study of 
  
63 
 
patients taking warfarin (n=21) found several themes within patient narratives 
regarding perspectives on taking warfarin (Coelho-Dantas, Thompson, Manson, 
Tracy, & Upshur, 2004). Patients report that the decision to initiate warfarin therapy 
had been made by the doctors; typically there was no patient involvement in the 
decision-making process (Coelho-Dantas, et al., 2004). This lack of involvement in 
the decision-making process often coincided with a high level of trust in medical 
expertise, as illustrated by the commonly-used phrase “doctor knows best”.   
 
The decision of whether or not to take OAC is an important one, particularly as it may 
impact on a patient’s morbidity and mortality. Several studies have designed patient 
decision aids to ascertain a patients’ ability to make decisions about their 
antithrombotic therapy (Man-Son-Hing, et al., 1999; Thomson, Robinson, 
Greenaway, & Lowe, 2002; Holbrook, Labris, Goldsmith, Ota, Harb, & Sebaldt, 2007; 
McAlister, et al., 2005).  One RCT used a booklet, personal worksheet and audiotape 
to guide the trial group through the decision making process (Man-Son-Hing, et al., 
1999). The materials highlighted the risk of stroke and haemorrhage for patients 
taking aspirin or warfarin using pictograms and descriptive examples. The results 
suggest patients in the intervention group were less likely to take warfarin than those 
patients not receiving the decision aid, despite the benefits of anticoagulation (n=12 
[8%] in trial group, n=17 [11%] in control group, p=.02). However, using the decision 
aid did not improve patient satisfaction when compared to the control group even 
though trial patients believed they were more informed (-0.21 units; 95% CI, -0.34 to -
0.08). Evidently, improving patient knowledge may reduce the number of patients 
prepared to take warfarin, and encouraging shared decision making may have a 
negative impact on patient satisfaction surrounding their consultation. 
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Another trial examined differences in patient outcomes/preferences based on (i) the 
format (decision board, decision booklet with audio tape or computer decision aid), 
(ii) the graphical presentation of risk data, and (iii) the names of the treatments 
(Holbrook, Labris, Goldsmith, Ota, Harb, & Sebaldt, 2007). The authors found 
knowledge improved significantly after the decision aid (p < 0.01), as indicated by an 
increase in the mean comprehension score (from 4.6, standard deviation [SD] 2.2) to 
7.7 (SD 1.8), regardless of type of graphical presentation.  
 
Interestingly more patients chose treatment with warfarin when blinded to treatment 
names; 39 participants chose treatment A (warfarin), 41 chose treatment B (aspirin), 
and 18 selected treatment C (no treatment). When told the treatment name the 
number of participants selecting warfarin decreased to 27 (p = 0.023), the number 
choosing no treatment decreased to 5 (p < 0.001), and the number selecting aspirin 
increased to 66 (p < 0.001) (Holbrook, Labris, Goldsmith, Ota, Harb, & Sebaldt, 
2007). It is important to consider whether patients’ decisions are influenced by 
preconceived ideas or beliefs about the available treatments. Evidently patients are 
not only influenced by the risks associated with the treatment, but also by their 
perceptions of it, which may derived from personal information-seeking through 
social networks or the media (for a discussion of beliefs about medication refer to 
Section 3.1.1).  However, patients in this trial were not diagnosed with AF, the trial 
was examining pseudo-decision making, thus cannot be applied to ‘real-life’ decision 
making. 
 
The DAAFI (Decision Aid in Atrial Fibrillation Investigators) trial examined the impact 
of a decision aid on the appropriateness of treatment (McAlister, et al., 2005). The 
patient decision aid was a self-administered booklet and audio-tape versus usual 
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care. This trial highlights the potential benefits of using a decision aid, as in the 
intervention group, the number of patients receiving therapy appropriate to their 
stroke risk increased by 9% (32% [69/219] at baseline vs. 41% [89/219] at 3 months). 
However, the proportion of patients whose therapy met the ACCP (American College 
of Chest Physicians) treatment recommendations did not differ between study arms 
at baseline (p = 0.11) or 3 months (p = 0.44). Thus decision aids maybe one step 
towards improving this decision making process. Furthermore, there were 
significantly more patients in the intervention group able to make accurate estimates 
of the stroke risk (p<0.001), signifying an increase in knowledge. Therefore, even a 
cohort with longstanding AF (such as in the DAAFI trial) can increase their 
knowledge regarding treatment choice and stroke risk. The potential impact an 
intervention may have on a warfarin-naive or newly diagnosed cohort maybe greater.  
 
The results of these trials signify the importance of shared decision making between 
the patient and clinician. The benefits of improving patient knowledge and 
understanding of treatment risk could include more patients taking warfarin and 
adhering to recommendations. Equally improving knowledge of risk could also have a 
negative impact on patient anxiety and treatment uptake. More evidence is needed to 
evaluate the impact of decision aids of newly diagnosed AF patients.  
 
1.4.3.4  Treatment knowledge  
 
The importance of a patient’s knowledge surrounding their illness and medication has 
been consistently highlighted in the literature. Patient knowledge surrounding 
treatment varies with age. Elderly patients (>75) demonstrate poorer knowledge, with 
less than half of one patient sample able to name even one specific benefit, risk or 
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lifestyle change associated with warfarin (Coelho-Dantas, Thompson, Manson, 
Tracy, & Upshur, 2004). In several cases spouses were more knowledgeable than 
patients and appeared to play a vital role in monitoring their treatment regime 
(Coelho-Dantas, et al, 2004). Furthermore, this study sample was from a patient 
population of an academic primary-care practice that is both well educated and of 
medium-high socio-economic status, thus a more heterogeneous sample may 
demonstrate even less treatment related knowledge. Indeed a pan European patient 
survey (n=711) found that only 7% of patients knew that OAC was taken to prevent 
stroke (Lip, Agnelli, Thach, Knight, Rost, & Tangelder, 2007). Perhaps this explains 
why 21% of patients admitted missing clinic appointments (Lip,et al., 2007). 
 
One survey collected data from hospital emergency rooms in Finland (Koponen, 
Rekola, Ruotsalainen, Lehto, Leino-Kilpi, & Voipio-Pulkki, 2008). Patients only had 
moderate levels of knowledge about atrial fibrillation, which improved slightly three 
months after the visit. Patients exhibited the highest accuracy on questions about AF 
symptoms and its effects on everyday life. Fewer patients were knowledgeable about 
the disease, treatment, detection of symptoms and when to seek treatment. 
Knowledge level varied between participants, and factors associated with better 
knowledge included male gender and previous atrial fibrillation diagnosis (Koponen, 
et al., 2008).  
 
Local studies (based in Birmingham) also found poor knowledge surrounding OAC 
(Lane, Ponsford, Shelley, Sirpal, & Lip, 2006; Lip, Kamath, Jafri, Mohammed, & 
Bareford, 2002; Nadar, Begum, Kaur, Sandhu, & Lip, 2003). One study examined 
whether knowledge and perceptions of OAC differed between ethnic groups (Nadar, 
et al.,  2003). Knowledge scores were high for many of the questions i.e. drug name 
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(90%), type of drug (94%), name one or less side effects (91%). However, few 
patients were able to name two or more side effects (9%), or name the condition for 
which warfarin was being taken (54%). Furthermore, there was a significant 
difference between ethnic groups knowledge, Indo-Asian patients were less likely to 
know the name of the drug (p<0.001) or their target INR (p=0.01), Afro-Caribbean’s 
were less likely to know which condition warfarin was for (p=0.04). Further, 45% of 
Indo-Asians, compared with 18% of white Europeans and 19% of Afro-Caribbean’s, 
felt they had difficulty understanding their anticoagulant management (p=0.04). 
Whilst this study is cross-sectional and applied to multiple indications for warfarin, it 
does highlight the inconsistencies in patient knowledge surrounding OAC, particularly 
between ethnic groups (Nadar, et al., 2003).  
 
A similar study examined ethnic differences in AF-related knowledge (Lip, Kamath, 
Jafri, Mohammed, Bareford, & McAlister, 2002), finding only 63% of patients were 
aware of their cardiac condition, with significantly less awareness in ethnic minority 
groups (p<0.001). Furthermore, the majority of patients did not perceive AF as a 
serious condition (61%), only 33% perceived AF as serious and 6% as very serious. 
The findings highlight the lack of patient knowledge surrounding their condition, as 
only 63% were aware of AF predisposing to ‘blood clots’ and 53% were aware of it 
predisposing to stroke (Lip, et al., 2002). Patients will understandably have 
inaccurate perceptions of the risk where their knowledge surrounding their illness is 
poor. This lack of knowledge and potential inaccurate illness perceptions may also 
impact on their ability to adhere to required regimens.  
 
A prospective study of Chinese patients attending an anticoagulation clinic evaluated 
patients’ treatment related knowledge and its relationship to anticoagulation control 
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(Tang, Lai, Lee, Wong, Cheng, & Chan, 2003). The knowledge of a random sample 
of patients (n=122) was moderate with an overall score of 0.48±0.18 (maximum 
score = 1.0), which did not differ for men and women. Tang and colleagues found an 
inverse relationship between age and knowledge score of the patient (r -0.43; 
p<0.001) and a positive association between duration of warfarin treatment and 
knowledge (r 0.18; p=0.044). Most importantly the proportion of patients with INR 
values within target range declined with age (r -0.30; p<0.01), and there was a 
positive correlation between patients’ knowledge of warfarin treatment and the 
number of INR values within range (r 0.20; p=0.024). Thus more knowledgeable 
patients were more likely to be within therapeutic range (Tang, et al, 2003). This 
suggests that warfarin-experienced patients often lack knowledge surrounding their 
treatment, and whilst this study lacks the rigour of an RCT and had limited follow-up, 
it does suggest that increasing patient knowledge, may also increase time spent 
within therapeutic INR range.  
 
A brief educational intervention (Lane, Ponsford, Shelley, Sirpal, & Lip, 2006) has 
successfully increased knowledge. These patients were predominantly White 
Europeans (95.7%), presenting at baseline with poor knowledge. Only half of the 
patients were aware that their cardiac condition was known as ‘atrial fibrillation’ 
(49%), 57% were aware that anticoagulation prevents blood clots and 19% were 
aware that OAC prevents stroke. A particular concern was patients’ lack of 
awareness of the factors that may affect their INR levels, only 37% of patients at 
baseline were aware of these factors. A brief educational booklet significantly 
improved patients’ knowledge of their target INR (p=0.001) and factors affecting INR 
levels (p=0.014), but not patients’ awareness of AF related factors (Lane, et al., 
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2006). Thus there is potential to improve knowledge and even improve INR control, 
with the use of appropriate interventions. 
 
Where patients lack knowledge surrounding their condition, it is likely that they rely 
on other (possibly misleading) sources of information, potentially formulating 
inaccurate perceptions of AF. More importantly patients’ lack of knowledge 
surrounding their treatment carries significant risks. Without sufficient knowledge of 
the factors affecting target INR patients cannot adhere to recommendations. 
Evidently even a brief intervention can improve patients’ levels of knowledge, 
therefore theory-driven intensive interventions may have a significant impact with this 
group. 
 
1.5  Psychological prognosis 
 
In addition to the established cardiac prognosis, psychological factors have been 
implicated in the aetiology of AF and the potential prognosis for AF patients. Few 
studies have examined the significance of depression and anxiety among AF (Thrall, 
Lane, Carroll, & Lip, 2006; Lane, Langman, Lip, & Nouwen, 2009), those that have 
predominantly focus on quality of life (QoL) in symptomatic AF patients undergoing 
surgical or pharmacological interventions (Thrall, et al., 2006). 
 
1.5.1 Depression and anxiety 
 
Depression and anxiety in AF appears to be highly co-morbid, with 71% of patients 
reporting Beck’s Depression Index (BDI) scores ≥10, and also exhibiting high levels 
of anxiety. Furthermore, symptoms of depression and anxiety also seem to persist in 
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follow-up studies (Thrall, et al., 2007).  Thrall and colleagues compared the 
psychological wellbeing of AF patients (n=101) to a hypertensive “disease control” 
group (n=97) in sinus rhythm. AF and hypertensive patients displayed similar levels 
of depression and quality of life (QoL) at baseline. However, the AF group exhibited 
higher levels of trait anxiety (p<0.02) and percentage of scores (≥40 on STAI, 
p=0.03). Therefore, it is evident that the psychological prognosis for AF patients is 
similar to that of other cardiac disorders, with significantly higher anxiety levels than 
the disease control (Thrall, et al., 2007).  
 
Lane and colleagues carried out a study examining anxiety, depression and QoL in 
‘lone’ AF patients (Lane, Langman, Lip, & Nouwen, 2009). The study found few 
depressive symptoms at any of the time points. However, state anxiety (STAI-S ≥40) 
symptoms were elevated at all time points (38.5%, 30.9% and 35.7%, at baseline, six 
and twelve months respectively), with no significant differences over time. One 
influential factor determining a patient’s psychological prognosis was age. Those 
patients with elevated anxiety levels were found to be significantly younger than non-
anxious patients (p=0.02). However, anxiety and depression levels in patients with 
‘lone’ AF were not significantly different to age-matched general population norms, in 
contrast with the findings from Thrall’s study.  The differences between the findings 
for ‘lone AF’ patients and a mixed AF patient group suggest that co-morbidities may 
also play an important role, as lone AF patients with no other co-morbidities suffer 
from fewer symptoms of depression and anxiety (Lane, et al., 2009). 
 
In other comparable cardiac conditions such as coronary heart disease, post-
myocardial infarction, angina, CHF, depression further predicts clinical prognosis 
(Frasure-Smith & Lesperance, 2006; Lett, et al., 2004). Depression is a suggested 
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risk factor for stroke (Larson, Owens, Ford, & Eaton, 2001) and sudden death 
(Whang, et al., 2005). The AF-CHF trial data suggests that elevated BDI-II 
depression scores significantly predicted cardiovascular death (Hazard Ratio 1.30, 
95% CI 1.16-1.46, p<0.001), arrhythmic death (HR 1.36, 95% CI 1.15-1.60, p=0.001) 
and all-cause mortality (HR 1.23, 95% CI 1.11-1.37, p<0.001) in both study groups 
(Frasure-Smith, et al., 2009). Thus, where AF patients exhibit elevated depression 
scores, there may be an increased risk of stroke and mortality. 
 
1.5.2  Quality of life  
 
AF can be a highly symptomatic condition, with patients reporting palpitations, 
dizziness, breathlessness, exercise intolerance and fatigue (ESC, 2010). Thus, it is 
unsurprising that patients report a reduction in QoL when compared to the age- and 
sex-matched general population in sinus rhythm (Howes, Reid, Brandt, Ruo, Yerkey, 
& Prasad, 2001; van den Berg, Hassink, & Tuinenburg, 2001; Dorian, Jung, & 
Newman, 2000; Thrall, Lip, Carroll, & Lane, 2007).  Given that AF is a chronic 
condition which places patients at increased risk of mortality and morbidity, and often 
requires life-long treatment, including long-term oral anticoagulation, QoL is therefore 
an important treatment outcome when measuring a patient’s physical, emotional and 
social functioning, as well as their perceived health (Smith, Lip, & Lane, 2010).   
 
Thrall’s review (2006) suggests AF patients score poorest on general health, vitality, 
physical, social and emotional role functions, however, QoL does improve with 
symptom alleviation (Thrall, Lane, Carroll, & Lip, 2006). The predictability of a 
patient’s ventricular rate is an important determinant of QoL (Thrall, Lane, Carroll, & 
Lip, 2006).  Of the five randomised controlled trials that compared pharmacological 
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rate-control versus rhythm-control, four reported QoL as an outcome (Carlsson, 
Miketic, Windeler, Cuneo, Haun, & Micus, 2003; Gronefield, Lilienthal, Kuck, & 
Hohnloser, 2003; Hagens, Ranchor, Van Sonderen, Bosker, Kamp, & Tijssen, 2004; 
Jenkins, Brodsky, Schron, Chung, Rocco Jr, & Lader, 2005). All four trials 
demonstrated improvements in QoL following intervention, three reported greater 
improvements in patients among those receiving rate-control strategies (Carlsson, 
Miketic, Windeler, Cuneo, Haun, & Micus, 2003; Gronefield, Lilienthal, Kuck, & 
Hohnloser, 2003; Hagens, Ranchor, Van Sonderen, Bosker, Kamp, & Tijssen, 2004) 
and the AFFIRM trial demonstrated similar improvements for both rate and rhythm-
control treatment (Jenkins, Brodsky, Schron, Chung, Rocco Jr, & Lader, 2005). 
Physical QoL outcomes were more frequently improved, specifically domains such as 
general health, physical functioning, physical role and bodily pain. However, 
significant improvements to psychological domains such as mental health and social 
functioning were also reported (Thrall, et al., 2006). Patients undergoing invasive 
procedures are often highly symptomatic and the relief of these symptoms appears to 
lead to significant improvements in QoL. 
 
Symptomatic relief may affect the patient in numerous ways (Smith, Lip, & Lane, 
2010).  First, some suggest that treatment may have a placebo affect whereby 
patients report fewer symptoms because they believe their treatment is successful 
(Berkowitsch, Neumann, Kurzidim, Reiner, Kuniss, & Siemon, 2003). Second, 
perhaps simply being informed that their heart rate is beating in a ‘normal’ rhythm 
may reduce patient anxiety and increase psychological wellbeing.  Indeed one study 
(Pappone, Rosanio, Augello, Gallus, Vicedomini, & Mazzone, 2003) compared QoL 
in patients undergoing radiofrequency isolation of the pulmonary vein or 
pharmacological rhythm-control.  At baseline both groups were clinically comparable 
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and both physical and mental functioning scores showed similar changes over time. 
However, a significant time trend (p=0.007) was found only in ablated patients 
(p=0.004), where QoL levels at six months were similar to those of healthy-matched 
controls, with no further improvements at 12 months. For both patient groups the 
maintenance of sinus rhythm was associated with a reduced risk of death (ablation: 
hazard ratio (HR), 0.66, 95% confidence interval (CI), 0.09 to 0.48; pharmacological: 
0.46 (0.12 to 0.32)) and adverse event rates (ablation: 0.61 (0.16 to 0.68); 
pharmacological: 0.45 (0.08 to 0.21); 13).  Therefore, whilst QoL outcomes could be 
attributed to many factors including placebo or expectancy effects of an invasive 
procedure, it is likely that the improvement in QoL was again related to a reduction in 
AF burden (Smith, Lip, & Lane, 2010).  
 
If control of the ventricular rate improves QoL, patients with paroxysmal AF, 
particularly symptomatic paroxysms are likely to report lower QoL when compared to 
patients with permanent or persistent AF (Smith, Lip, & Lane, 2010). PAF patients 
experience intermittent periods of AF interspersed with episodes of normal sinus 
rhythm, normally lasting <7 days (Levy, Novella, Ricard, & Paganelli, 1995). PAF 
comprises from 25 to 62% of AF cases seen by physicians and GPs (Kannel, Wolf, & 
Benjamin, 1998; Takahashi, Seki, Imataka, & Fujii, 1981), and the prevalence of PAF 
varies due to differences in definition. When compared to patients with permanent 
sustained AF, PAF patients tend to be younger, have less hypertension and 
congestive heart disease and are more symptomatic (Flaker, Belew, & Beckman, 
2005).  However, as symptoms are often infrequent, unpredictable and hard to 
document, the subsequent clinical course is not as clear as persistent AF patients 
who may have relatively more ‘stable’ heart rates and fewer treatment options. 
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Hence QoL is often poorer among PAF patients (Thrall, et al., 2006) due in part to 
the uncertainity of their AF prognosis and treament options and outcomes.  
 
Evidently the prognosis for patients with AF is poor, they are at risk of psychological 
and physical morbidity. Furthermore, OAC represents a burdensome treatment 
regime with additional risks, and patients appear to exhibit poor knowledge 
surrounding their treatment and are often subsequently non-adherent. This presents 
problems in clinical practice as non-adherence is costly, both for the patient and the 
health care system. It is therefore important that interventions are developed to 
improve patient knowledge surrounding their treatment with the aim of subsequently 
improving adherence. Finally, in order to design successful interventions it is 
important that we consider both the barriers patients face and the motivation to 
change, as well as the intervention components that have proven successful in 
previous studies.  
 
This study aims to develop an intervention that will improve patient adherence to their 
medication and treatment regimen. This includes restricting vitamin K intake, alcohol 
consumption and monitoring other drugs or herbal remedies that may interfere with 
warfarin’s metabolism, as well as ensuring they remember to take their tablets. The 
literature has highlighted several reasons why patients may not adhere, including 
poor knowledge of their treatment and illness, poor communication of risk by the 
health care professional, a lack of shared decision making and patients anxiety 
following diagnosis of AF.  Chapter 2 aims to review previous randomised trials of 
educational and behavioural interventions for patients with atrial fibrillation taking 
warfarin. By gaining an understanding which interventions have been trialled 
previously, and whether they proved successful in increasing adherence, we are 
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more able to choose an effective intervention strategy. Chapter 3 aims to document 
the design of the theory-driven behavioural intervention, explaining how the 
intervention components attempt to targets patients’ barriers to adherence, such as 
their beliefs about medications and their illness representations. Chapter 5 aims to 
evaluate the effectiveness of the intervention, examining differences between the 
group receiving the intervention and the group that received usual care. It further 
attempts to explain why these differences exist.  
 
1.6 Objectives 
 
To increase patients’ adherence to their medication and lifestyle recommendations, 
as measured by their subsequent time spent in therapeutic INR range. 
 
To improve patients’ knowledge and understanding of their treatment regimen and 
their condition. 
 
To reduce inaccurate beliefs about medication and illness perceptions and 
subsequently reduce potential barriers to adherence. 
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2  Systematic review 
 
2.1 Importance of the review 
 
Patients need sufficient information to make informed choices and actively participate 
in the management of their own treatment (Thrall, Lane, Carroll, & Lip, 2006). Patient 
education aims to influence patient behaviour and improve knowledge, attitudes and 
practices that are necessary to improve health outcomes (Wofford, Wells, & Singh, 
2008). Techniques used in delivering patient education cover a wide spectrum, 
including the use of booklets and videos as media to transmit additional information, 
alone or in addition to other self management interventions (such as INR self 
monitoring) and interventions which used decision aids. Behavioural interventions 
include those which attempt to modify patients’ behaviour towards treatment and 
symptoms such as cognitive behavioural therapy (CBT), motivational interviewing 
and heart rate variability bio-feedback. This review, for which the protocol has 
previously been published (Smith, Borg Xuereb, Pattison, Lip, & Lane, 2010), 
evaluates the value of educational and behavioural interventions for patients with AF, 
currently prescribed warfarin; including the impact on the time spent within the 
therapeutic INR range (TTR) and secondary outcomes such as patient knowledge 
and quality of life. 
 
2.2 Objective 
 
The aim of the review was to assess the effects of educational and behavioural 
interventions for OAC in patients with atrial fibrillation and whether the interventions 
increased time spent within therapeutic range. 
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2.3  Methods 
 
2.3.1 Criteria for considering studies for this review 
 
2.3.1.1  Types of studies 
 
Randomised controlled trials (RCTs) of any type of intervention with any length of 
follow-up and in any language were included. 
 
2.3.1.2  Types of participants 
 
Adults (aged 18 years or older) with AF categorised according to the 
ESC guidelines (ESC, 2010) including; (1)   First diagnosed AF, (2)   Paroxysmal AF, 
(3)   Persistent AF, (4)   Long standing persistent AF and (5)   Permanent AF. AF will 
have been diagnosed and documented by electrocardiogram (12-lead or holter 
monitoring). Patients who are eligible for or currently receiving OAC were considered 
eligible for inclusion in this review. Studies which included AF patients with other 
medical conditions, were also included in this review where the studies were RCTs 
comparing at least one intervention with a control group, and including patients with 
atrial fibrillation as either the study population or a subgroup. Studies were only 
included where patients are grouped per indication i.e. patients taking oral 
anticoagulants for AF, DVT/PE, valve replacements etc, and only AF patients data 
were included within the analysis. 
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2.3.1.3 Types of interventions 
 
All types of educational and behavioural interventions given to AF patients who were 
taking OAC were considered for this systematic review. Educational interventions 
included those giving patient information, such as using booklets and videos as 
media to transmit additional information, alone or in addition to other self 
management interventions (such as INR self monitoring), interventions which used 
decision aids, and talking interventions. Behavioural interventions included 
interventions that attempt to modify patients’ behaviour towards treatment and 
symptoms such as cognitive behavioural therapy (CBT), self monitoring and/or 
management, motivational interviewing and heart-rate variability bio-feedback. 
Interventions could be targeted at adults on the individual level or as a group 
intervention. The intervention may have taken place in an emergency department, 
hospital, home or in the community. The intervention could have been delivered by a 
nurse, pharmacist, educator, health or medical practitioner, or a multidisciplinary 
team associated with the hospital or referred to by the hospital. The intervention 
could be undertaken at any time point from diagnosis of AF or initiation of OAC (i.e. 
not only newly diagnosed AF patients or those newly referred for OAC). Trials were 
only considered where the comparison groups were; usual care, no intervention, or 
intervention in combination with other self management techniques. Usual care was 
defined as standard anticoagulation clinic practice, where patients attend routine INR 
checks (defined as usual care by the author). Any length of follow-up was included. 
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2.3.2  Types of outcome measures 
 
2.3.2.1  Primary outcomes 
 
The primary outcome measure was the percentage of time spent within the 
therapeutic range (TTR) of INR (2.0 to 3.0). 
 
2.3.2.2 Secondary outcomes 
 
The secondary outcomes were: major bleeding (defined as bleeds that result in 
death, are life threatening, cause chronic sequel or consume major health care 
resources) and minor bleeding (Schulman & Kearon, 2005); stroke and 
thromboembolic events; increased knowledge with regards to AF and anticoagulation 
therapy; patient satisfaction; acceptability of the anticoagulant therapy; quality of life; 
psychological well being; changes in perception towards AF and INR control; 
changes in the patients’ illness beliefs and illness representations; self reported 
adherence to treatment and a change in the patients’ beliefs about medications; 
economic costs of the intervention (cost-effectiveness); and decision conflict. 
Decision conflict was included as a secondary outcome in the final analysis. Whilst 
not specified as an outcome of interest in the original protocol, it was highlighted as a 
common secondary outcome measure in three of the studies included in the final 
review. For this reason the authors decided to include this data within the results. All 
outcomes could have been quantified using validated or non-validated 
questionnaires, ratings or scales. 
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2.3.3 Search methods for identification of studies 
 
2.3.3.1  Electronic searches 
 
The Cochrane Central Register of Controlled Trials (CENTRAL) and the Database of 
Abstracts of Reviews of Effects (DARE) on The Cochrane Library (Issue 2, 2010), 
MEDLINE OVID (1950 to June, week 2, 2010), EMBASE OVID (1980 to 2010 week 
23), EMBASE OVID classic (1947 to 1979) PsycINFO OVID (1806 to June 2010 
week 3) and CINAHL plus with full text were searched. All searches took place from 
18th to the 21st June 2010 (See appendix for search strategies).  
 
2.3.3.2  Searching other resources 
 
Abstract books from national and international cardiology, psychology and psychiatry 
conferences were hand-searched, including: 
• Society for Behavioural Medicine and the Division of Health Psychology 
Conference 
• European Health Psychology Conference 
• Royal College of Psychiatrists Annual Meeting 
• Dissertation abstracts (UMI ProQuest Digital Dissertations)  
 
Reference lists of all relevant papers were searched to identify other potentially 
relevant articles.  
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2.4 Data collection and analysis 
 
2.4.1 Selection of studies 
 
Two reviewers scrutinised the titles found from the search and decided on inclusion 
or exclusion. From the included titles these two reviewers (DEC and supervisor DAL) 
then selected the abstracts and papers for inclusion and exclusion. Where 
disagreements arose on which papers to include the reviewers discussed the article 
and agreed on a consensus. 
 
2.4.2 Data extraction and management 
 
Two reviewers independently extracted the data. For each trial, the following data 
was extracted using a specially designed data extraction form: participants (sample 
size, age, sex, ethnicity, marital status, type of AF); type of anticoagulation therapy 
(warfarin, other); type and duration of the interventions (intervention versus usual 
care or no intervention; other combinations); primary and secondary outcomes; 
length of follow-up; statistical methods employed; the effect size and its precision. 
 
2.4.3 Assessment of risk of bias in included studies 
 
Two reviewers independently assessed the methodological quality of each trial in 
accordance with guidelines in the Cochrane handbook for systematic reviews of 
interventions (Higgins & Green, 2009). Each study was assessed on several areas of 
bias (sequence generation, allocation concealment, degree of blinding, patient 
attrition rate, selective reporting bias). The risk of bias was determined using the 
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Collaboration's risk of bias tool. The domains listed below were considered when 
reviewing each study. There were three possible responses: yes, no, or unclear. Yes 
indicates a low risk of bias and no indicates a high risk of bias. If insufficient detail 
was reported the judgement on risk of bias will be unclear.  
 
2.4.3.1 Sequence generation 
 
Yes, if the allocation sequence was generated using techniques such as a random 
number table; a computer random number generator; coin tossing; shuffling cards or 
envelopes; or throwing dice. No, if the allocation sequence was generated using 
techniques such as odd or even date of birth; date (or day) of admission; hospital or 
clinic record number. Unclear, if there was insufficient information about the 
sequence generation process to permit judgement. 
 
2.4.3.2 Allocation concealment 
 
Yes, if the allocation concealment used methods such as central allocation (including 
telephone, web-based, and pharmacy-controlled randomisation); sequentially 
numbered drug containers of identical appearance; sequentially numbered opaque, 
sealed envelopes. No, if the participants or investigators enrolling participants could 
possibly foresee assignments and thus introduce selection bias such as allocation 
based on using an open random allocation schedule (e.g. a list of random numbers); 
assignment envelopes used without appropriate safeguards (e.g. if envelopes were 
unsealed or non-opaque, or not sequentially numbered); alternation or rotation; date 
of birth; case record number. Unclear, if there was insufficient information to permit 
judgement of Yes or No, if the method of concealment was not described or not 
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described in sufficient detail to allow a definite judgement (e.g. if the use of 
assignment envelopes was described but it remained unclear whether envelopes 
were sequentially numbered, opaque and sealed). Where the method of allocation is 
unclear, we contacted study authors to provide further details. 
 
2.4.3.3 Blinding 
 
Yes, if there was no blinding but the review authors judged that the outcome and the 
outcome measurement were likely to be influenced by lack of blinding; if blinding of 
participants and key study personnel was ensured and it was unlikely that the 
blinding could have been broken; if either participants or some key study personnel 
were not blinded but outcome assessment was blinded and the non-blinding of 
others was unlikely to introduce bias. No, if there was no blinding or incomplete 
blinding and the outcome or outcome measurement was likely to be influenced by 
lack of blinding; if blinding of key study participants and personnel was attempted but 
it was likely that the blinding could have been broken; if either participants or some 
key study personnel were not blinded and the non-blinding of others was likely to 
introduce bias. Unclear, if there was insufficient information to permit judgement of 
yes or no or the study did not address this outcome (e.g. where the blinding was 
described only as double-blind without any other details). 
 
2.4.3.4 Incomplete data assessment  
 
Yes, if there were no missing outcome data; reasons for missing outcome data were 
unlikely to be related to the true outcome; missing outcome data were balanced in 
numbers across intervention groups with similar reasons for missing data across 
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groups; for dichotomous outcome data, the proportion of missing outcomes 
compared with observed event risk was not enough to have a clinically relevant 
impact on the intervention effect estimate; for continuous outcome data, plausible 
effect size (difference in means or standardised difference in means) among missing 
outcomes was not enough to have a clinically relevant impact on observed effect 
size; missing data were imputed using appropriate methods. No, if the reasons for 
missing outcome data were likely to be related to the true outcome, with either 
imbalance in numbers or reasons for missing data across intervention groups. For 
dichotomous outcome data, the proportion of missing outcomes compared with 
observed event risk was enough to introduce clinically relevant bias in the 
intervention effect estimate; for continuous outcome data, plausible effect size 
(difference in means or standardised difference in means) among missing outcomes 
was enough to introduce clinically relevant bias in observed effect size; ‘as-treated’ 
analysis done with substantial departure of the intervention received from that 
assigned at randomisation; potentially inappropriate application of simple imputation. 
Unclear, if there was insufficient reporting of attrition or exclusions to permit 
judgement of yes or no (e.g. numbers randomised were not stated, no reasons for 
missing data were provided); or the study did not address this. 
 
2.4.3.5 Selective outcome reporting 
 
Yes, if the study protocol was available and all of the study’s pre-specified (primary 
and secondary) outcomes that were of interest in the review were reported in the pre-
specified way; the study protocol was not available but it was clear that the published 
reports included all expected outcomes, including those that were pre-specified. No, 
if not all of the study’s pre-specified primary outcomes were reported; one or more 
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primary outcomes were reported using measurements, analysis methods or subsets 
of the data (e.g. sub scales) that were not pre-specified; one or more reported 
primary outcomes were not pre-specified (unless clear justification for their reporting 
was provided, such as an unexpected adverse effect); one or more outcomes of 
interest in the review were reported incompletely so that they could not be entered in 
a meta-analysis; the study report failed to include results for a key outcome that 
would be expected to have been reported for such a study. Unclear, if there was 
insufficient information to permit judgement of Yes or No. 
 
2.4.3.6 Other sources of bias 
 
Yes, if the study appeared to be free of other sources of bias. No, if there was at 
least one important risk of bias (e.g. the study had a potential source of bias related 
to the specific study design used; stopped early due to some data-dependent 
process (including a formal-stopping rule); had extreme baseline imbalance; had 
been claimed to be fraudulent; had some other problem). Unclear, if there was either 
insufficient information to assess whether an important risk of bias existed or if there 
was insufficient rationale or evidence that an identified problem would introduce bias. 
 
2.4.4 Measures of treatment effect 
 
Statistical analyses were undertaken as follows: for continuous variables the 
weighted mean difference was used. As a summary measure of effectiveness, odds 
ratios with 95% confidence intervals were calculated for dichotomous variables. 
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2.4.5 Dealing with missing data 
 
Authors were contacted for studies with incomplete information in published articles 
and for data clarifications. 
 
2.4.6 Assessment of reporting biases 
 
Publication bias was not assessed in this review as studies either included a protocol 
paper listing outcomes that corresponded with those reported, or they address each 
of the outcomes listed in their methods. 
 
2.4.7 Data synthesis 
 
Results of individual studies are initially combined within a narrative review. This 
takes into account methodological quality of the study. Where possible, meta-
analysis was used to statistically combine results. If insufficient data are present to 
conduct a meta-analysis, we reported effect sizes and confidence intervals (CIs) of 
the included studies using a standard method of presentation. TTR data was only 
included if directly reported, or where available from personal communication with the 
authors. 
 
2.4.8 Subgroup analysis and investigation of heterogeneity 
 
Subgroup analyses were carried out looking at the type of intervention (educational 
alone, behavioural alone, and a combination of education and behavioural vs. usual 
care). However, due to insufficient number of trials it was not possible to examine the 
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effects of frequency (one session vs. multiple sessions) and duration (e.g. < 6 
months vs. > 6 months) of the intervention, length of time on OAC, men vs. women, 
individual vs. group interventions and age of participant groups. 
 
2.5 Results 
 
2.5.1  Results of the search 
 
The search retrieved 815 articles from all sources. Of these, 749 were excluded by 
assessing titles and abstracts. Sixty three full text articles were obtained for 
consideration. Fifty three articles were excluded based on the review of the full text 
article. Ten articles reporting on seven studies were included in this review (Khan, 
Kamali, Kesteven, Avery, & Wynne, 2004; Christensen, Magaard, Sorensen, 
Hjortdal, & Hasenkam, 2006; McAlister, et al., 2005; Man-Son-Hing, et al., 1999; 
Beyth, Quinn, & Landefeld, 2000; Thomson, et al., 2007). Features of the 
interventions are included in the ‘characteristics of included studies’ table (Table 2.1); 
see PRISMA flow chart for inclusion process (see Figure 2.1). 
 
2.5.1.1 Methods 
 
All seven included studies were randomised controlled trials. Four of the studies 
specifically recruited AF patients (Khan, Kamali, Kesteven, Avery, & Wynne, 2004; 
McAlister, et al., 2005; Man-Son-Hing, et al., 1999; Thomson, et al., 2007), a further 
three trials recruited patients with a range of indications (e.g. AF, venous 
thromboembolism, cardiovascular disease, heart valve prosthesis, peripheral 
vascular disease, myocardial infarction) and  provided unpublished data on AF 
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patients (Beyth, Quinn, & Landefeld, 2000; Gadisseur, Kaptein, Breukink-Engbers, 
van Der Meer, & Rosendaal, 2004; Christensen, Magaard, Sorensen, Hjortdal, & 
Hasenkam, 2006). 
 
2.5.1.2  Included studies 
 
Figure 2.1: PRISMA flow chart for inclusion of studies within the systematic review. 
 
 815 records identified through 
database searching 
3 additional records identified 
through conference abstract searches 
4 duplicates removed 
814 records screened 749 records excluded on the basis of 
title and abstract 
65 full text articles assessed for 
eligibility 
54 full text articles excluded for the 
following reasons: 
• Ongoing trials 
• No AF patients mentioned as 
a subgroup of the cohort 
• Authors did not provide AF 
specific data 
• Data was unavailable 
• Study was not a randomised 
trial 
• Paper was a protocol 
• None of the outcomes 
specified in the review were 
reported 
11 articles of 7 studies were included 
in the final review 
5 studies were included in the 
quantitative synthesis 
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Table 2.1: Characteristics of included studies 
 
Study 
Year 
Country 
N of AF 
ppts 
Age of AF patients; n± 
SD/ n(range) 
Study 
design 
Length of 
follow-up 
Type Duration Facilitator 
Setting 
 
Beyth 
2000 
USA 
 
 
n=54 
 
74.6±6.8 intervention 
versus 75.5± 6.2 UC 
 
RCT, 
parallel 
groups 
design 
 
 
6 months 
 
Education and 
SM vs. UC 
 
30-60 
minutes (one-
off) 
 
Lay educator 
Hospital 
Christensen 
2007 
Denmark 
n=20 59±18 intervention versus 
51 ±12 UC 
RCT, cross-
over design 
6 months 
pre- and 
post- 
intervention 
 
Education and 
SM vs. UC 
# # 
Hospital 
Gadisseur 
2003 
Netherlands 
 
n=58 # Multi-centre 
RCT (4 trial 
arms) 
6 months (A) Self-
testing vs. (B) 
SM. (C) 
educated UC 
vs. (D) UC 
 
90-120 minutes 
(3 sessions) 
Physician or 
Health care 
professional 
Khan 
2004 
UK 
n=125 71 (65-91) self-monitoring 
versus 75 (65-87) education 
versus 73 (65-93) UC 
RCT (3 trial 
arms) 
6 months SM vs. 
education vs. 
UC 
2 hour  
education 
session (one-
off) 
 
Physician or 
Health care 
professional 
Hospital 
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Man-Son-Hing 
1999 
USA 
 
n=287 
 
65 (#) for both groups 
 
RCT 
 
6 months 
 
DA,  PTOT vs. 
UC 
 
# 
 
Computerised/ 
audio tool 
Hospital 
 
McAlister 
2005 
Canada 
n=434 73±9 intervention versus 71
±10 UC 
Cluster RCT 1 year DA, PTOT vs. 
UC 
# Physician or 
Health care 
professional 
GP Practice 
 
Thomson 2007 
UK 
n=136 73.1±6.7 decision aid 
versus 73.7±6.2 guidelines 
RCT 12 months Computerised 
DA vs. 
guideline 
evidence 
30-60 minutes 
(one-off 
session) 
Computerised/ 
audio tool 
Research clinic 
# Not reported; PTOT = probability trade-off tool; RCT = randomised control trial; DA = decision aid; DC= decision conflict; SM=self-
management; UC=usual care; n=number.
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2.5.1.3 Participants 
 
The total sample size of AF patients including published and unpublished data varied 
from 24 (Christensen unpublished) to 434 (McAlister, et al., 2005) participants. The 
mean age of the trial participants was 59 (±18 Standard deviations; Christensen 
unpublished) to 75 with a small range (65-87). One trial did not provide any 
demographical information for AF patients (Gadisseur, Kaptein, Breukink-Engbers, 
van Der Meer, & Rosendaal, 2004). 
 
2.5.1.4 Type of studies 
 
Of the seven studies that were identified, two compared education with usual care  
(Khan, Kamali, Kesteven, Avery, & Wynne, 2004; Gadisseur, Kaptein, Breukink-
Engbers, van Der Meer, & Rosendaal, 2004), four compared self monitoring with 
usual care (Beyth, Quinn, & Landefeld, 2000; Khan, Kamali, Kesteven, Avery, & 
Wynne, 2004; Gadisseur, et al., 2004; Christensen, Magaard, Sorensen, Hjortdal, & 
Hasenkam, 2006), one also included a self-management group (Gadisseur, et al., 
2004). A further three trials focused on the use of a decision support aid versus usual 
care (McAlister, et al., 2005; Man-Son-Hing, et al., 1999) or a comparison group 
(Thomson, et al., 2007). 
 
2.5.1.5 Types of interventions 
 
Interventions were either one to one (Beyth, Quin, & Landefeld, 2000; McAlister, et 
al., 2005) or group training session(s) (Gadisseur, Kaptein, Breukink-Engbers, van 
Der Meer, & Rosendaal, 2004; Khan, Kamali, Kesteven, Avery, & Wynne, 2004). 
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Three of the trials did not explicitly specify group or individual intervention type 
(Christensen, Magaard, Sorensen, Hjortdal, & Hasenkam, 2006; Man-Son-Hing, et 
al., 1999; Thomson, et al., 2007). 
 
All of the interventions included an educational element, usually consisting of a 
description of the consequences of minor/major stroke and major haemorrhage, the 
blood monitoring required for warfarin and the probability of stroke and major 
haemorrhage for patients taking warfarin (for intervention components see Table 
2.2). Most interventions also included information regarding the lifestyle factors 
influencing warfarin control. Self monitoring interventions included training on the use 
of INR monitoring devices (Khan, Kamali, Kesteven, Avery, & Wynne, 2004; 
Gadisseur, et al., 2004; Beyth, Quinn, & Landefeld, 2000; Christensen, et al., 2006). 
Decision aid interventions offered more detailed information on the risks of bleeding 
and thromboembolism (Man-Son-Hing, et al., 1999; McAlister, et al., 2005; Thomson, 
et al., 2007). All three trials using a decision support aid employed pictograms, 
depicting the risk of stroke and bleeding on either placebo, aspirin or warfarin; two 
utilised paper based charts (Man-Son-Hing, et al., 1999; McAlister, et al., 2005) and 
the third (Thomson, et al., 2007), employed a computerised version. The decision aid 
was presented and patients were asked to select which treatment they would prefer 
on the basis of the risk information (probability trade-off). 
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2.5.1.6 Duration of intervention 
 
The duration of the educational training element of interventions varied: trials 
reported a one-off consultation of 30-60 minutes (Beyth, et al., 2007), a two hour 
session (Khan, et al., 2004) or three sessions each lasting 90-120 minutes 
(Gadisseur, et al., 2004). The other three trials did not specify how long the 
intervention lasted or the number of sessions (Christensen, et al., 2006; Man-Son-
Hing, et al., 1999; McAlister, et al., 2005). 
 
2.5.1.7 Intervention facilitator 
 
One study did not specify type of facilitator (Christensen, et al., 2006). Of those that 
did, facilitators included a lay educator (Beyth, et al., 2000), a physician or health 
care professional (Gadisseur, et al., 2004; Khan, et al., 2004; McAlister, et al., 2005) 
and a computerised/audio tool (Man-Son-Hing, et al., 1999; Thomson, et al., 2007). 
 
2.5.1.8 Country 
 
The geographical settings of the studies were based in Europe, USA or Canada, but 
varied considerably; Denmark (Christensen, et al., 2006), The Netherlands 
(Gadisseur, et al., 2004), USA (Beyth, et al., 2000; Man-Son-Hing, et al., 1999), 
Canada (McAlister, et al., 2005), UK (Khan, et al., 2004; Thomson, et al., 2007). 
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2.5.1.9 Setting for intervention 
 
Most of the interventions were conducted in a hospital/anticoagulation clinic setting 
(Beyth, et al., 2000; Man-Son-Hing, et al., 1999; Khan, et al., 2004; Christensen,et 
al., 2006; Gadisseur, et al., 2004). One of the trials took place in a GP practice 
(McAlister, et al., 2005), another in a research clinic within a GP practice (Thomson, 
et al., 2007). 
 
2.5.1.10 Follow-up 
 
Assessment of the impact of the intervention on outcomes over time ranged from 
three (Thomson, et al., 2007; McAlister, et al., 2005) to six months (Khan, et al., 
2004; Beyth, et al., 2000; Gadisseur, et al., 2004; Christensen, et al., 2006; Man-
Son-Hing, et al., 1999). 
 
2.5.1.11 Funding 
 
Two of the trials declared some funding input by drug companies (Gadisseur, et al., 
2004; Man-Son-Hing, et al., 1999). 
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2.5.2 Outcome measures 
 
 
Table 2.2: Intervention components and review outcomes included in each study. 
 
Study Intervention components Primary review 
outcomes 
included 
Secondary review 
outcomes included 
Beyth 2000 Patient education - one to one teaching by a lay educator. 
Self-monitoring training - patients were taught to self-monitor prothrombin 
time. Patients instructed to use monitor three times in 1st week and once weekly 
after that. 
Consultation - assessed each patient’s indication for therapy and potential risks 
for warfarin related bleeding, including specific recommendations about 
modifiable risk factors, such as use of non-steroidal anti-inflammatory drugs. 
Coaching- aimed to increase patient’s participation in their care and improve 
information seeking-skills. 
Workbook - to teach them about warfarin, indications for its use, drug and food 
interactions, and the signs and symptoms of bleeding. 
TTR Major bleeding, stroke 
and thromboembolic 
events 
Mortality 
Christensen 
2007 
Patient education - not explained in detail. 
Self-monitoring training - included patient practicing analysis of blood 
specimens. The patient gradually assumed management of OAC. 
Examination - after 27 weeks patients took an exam, if passed patient went onto 
self-manage. 
TTR 
Complication 
outcome 
# 
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Gadisseur 
2003 
Patient education - information about the study, the blood coagulation system, 
OAC, and the effects of some substances (e.g. Alcohol, certain medications and 
foods rich in vitamin k). 
Self-monitoring training – included being taught how to use monitoring device, 
and instructions on oral self-dosing of OAC. This also contained theoretical and 
practical self-dosing training.  
Written information - on all the topics discussed. 
Telephone support - to confirm whether they could adhere to their proposed 
dosing schedule or if they needed to adjust it (self management only). 
TTR Patient satisfaction 
QoL 
Khan 2004 Patient education - patients were told about atrial fibrillation and the clinical 
benefits and risks of OAC.  
Self-monitoring training - in capillary INR testing. 
Written information - covering the issues raised. 
Telephone dosing support - based on the patients INR value, gave appropriate 
advice about warfarin daily dosage for the next seven days. 
TTR QoL 
Man-Son-
Hing 1999 
Decision aid – included a 29-page booklet, personal worksheet (complete pre-
intervention), and a 20-minute audiotape that guided the patient. 
Patient education - included a description of the consequences of minor/major 
stroke and major haemorrhage, the blood monitoring required for warfarin and 
the two-year probability of stroke and major haemorrhage for patients taking 
aspirin/warfarin using pictograms. 
# Patient knowledge 
Patient satisfaction 
Decision conflict 
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McAlister 
2005 
Decision aid – included a 30-page decision aid booklet, personal worksheet, 50-
minute audiotape to guide participants through the booklet, and worksheet. Four 
versions of the decision aid were available depending on patient’s baseline 
stroke risk. 
Patient education – provided background information about AF, the potential 
consequences of stroke and major haemorrhage, relative efficacy/bleeding risks 
with warfarin, and aspirin therapy. 
Worksheet - was completed by the patient after reviewing the booklet to clarify 
their personal values regarding desired outcomes, the therapy they are inclined 
to take, their preferred role in the decision process, and any questions they have 
for their physician. 
Percentage of 
INR's in range 
Patient 
knowledge 
Patient satisfaction 
Decision conflict 
Thomson 
2007 
Decision aid - included risk/benefit presentation “implicit tool” [computerized 
decision aid]. 
Patient education – included benefits and harms of warfarin treatment, 
advantages/disadvantages, and personalized risk assessment [using the 
Framingham equation]. The presentation used graphical and numerical media. 
# Patient knowledge 
Decision conflict 
Anxiety 
# Not included in published article; QoL = quality of life; TTR = time in therapeutic range; INR= international normalised ratio. 
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2.5.2.1 Primary outcome 
 
The percentage of time spent within the therapeutic range (TTR) of INR (2.0 to 3.0) 
was reported by four trials (Khan, et al., 2004; Gadisseur, et al., 2004; Beyth, et al., 
2000; Christensen, et al., 2006). Two trials reported other indicators of INR control; 
percentage of in-range INRs (McAlister, et al., 2005) and combined INR and 
complication outcomes (Christensen, et al., 2006). Of those studies reporting TTR, all 
were self monitoring interventions but only one published AF specific data (Khan, et 
al., 2004). Thus, the remaining trial authors were contacted for AF-specific data, this 
was provided by three of the authors (Gadisseur, et al., 2004; Christensen, et al., 
2006; Beyth, et al., 2000). AF specific data was not requested for outcomes that were 
not comparable, i.e. combined INR and complication outcomes (Christensen, et al., 
2006). 
 
2.5.2.2 Secondary outcomes 
 
One study reported major bleeding, stroke and thromboembolic events (Beyth, Quin, 
& Landefeld, 2000). None of the studies reported minor bleeding. Three trials 
reported on patient knowledge (Thomson, et al., 2007; McAlister, et al., 2005; Man-
Son-Hing, et al., 1999). Two trials assessed knowledge before and after the 
intervention (Thomson, et al., 2007; Man-Son-Hing, et al., 1999), one only tested 
after the intervention, thus cannot be included as a measure of the effect of the 
intervention. Three trials included patient satisfaction as a specified outcome 
(Gadisseur, et al., 2004; McAlister, et al., 2005; Man-Son-Hing, et al., 1999), one trial 
did not report on this outcome (McAlister, et al., 2005) thus data is not included. 
None of the studies reported on patients’ acceptability of anticoagulant therapy. Two 
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studies reported QoL as an outcome (Gadisseur, et al., 2004; Khan, et al., 2004), 
using the SF-36 (Khan, Kamali, Kesteven, Avery, & Wynne, 2004) and a 
questionnaire originally validated by Sawicki and colleagues (Gadisseur, et al., 
2004). The QoL data could not be pooled. Further, one of the trials did not publish AF 
specific data (Gadisseur, et al., 2004). The other trial (Khan, et al., 2004), only 
reported QoL data for those receiving education alone and education plus self-
monitoring; QoL in the usual care arm is not reported. None of the studies reported 
changes in patients’ illness beliefs, illness perceptions, self-reported adherence to 
treatment, beliefs about medication, or the economic costs of the intervention. Three 
studies reported decision conflict (McAlister, et al., 2005; Man-Son-Hing, et al., 1999; 
Thomson, et al., 2007). However, one of the studies did not have a usual care arm 
(Thomson, et al., 2007), thus was not included in the pooled data analysis. One study 
reported patient anxiety (Thomson, et al., 2007). One study reported on mortality 
(Beyth, et al., 2000), but do not state whether they have measured all cause or 
cardiac specific mortality outcomes. 
 
2.5.3 Excluded studies 
 
Fifty one papers on 47 studies were excluded for the following reasons: 
 
Fifteen studies were excluded because they did not include AF patients (Baker, 
Roberts, Newcombe, & Fox, 1991; Bump & Campbell, 1977; Claes, et al., 2005; 
Claes, et al., 2006; Cromheecke, Levi, & Colly, 2001; Cordasco, et al., 2009; 
Cromheecke, et al., 2000; Fitzmaurice, et al., 2005; Holbrook, Labiris, Goldsmith, 
Ota, Harb, & Sebalt, 2007; Landefeld & Anderson, 1992; Mazor, Baril, Dugan, 
  
100 
 
Spencer, Burgwinkle, & Gurwitz, 2007; Pernod, et al., 2008; Vadher, Patterson, & 
Leaning, 1997; Vadher, Patterson, & Leaning, 1996; Waterman A, et al., 2001). 
 
Ten studies were eligible for inclusion but the data presentation was inadequate and 
attempts to obtain the specific data from the authors, was unsuccessful. For nine of 
these trials/studies the authors could not be contacted (Stone, Holden, Knapic, & 
Ansell, 1989; Sawicki, 1999; Watzke, Forberg, & Svolba, 2000), or did not respond to 
e-mail/written requests for unpublished data (Barcellona, Contu, & Marongiu, 2006; 
Mendez-Jandula, Souto, & Oliver, 2005; Ryan, Byrne, & OShea, 2009; Siebenhofer, 
Rakovac, Kleepies, Piso, & Didjurgeit, 2007; Chan, Wong, Lau, Chan, Cheng, & You, 
2006; Gardiner, Williams, Longair, Mackie, Machin, & Cohen, 2006). For one study 
(Machtinger, Wang, Chen, Rodriguez, Wu, & Schilinger, 2007) the author was 
successfully contacted but the data was unavailable. 
 
Fifteen studies were not randomised controlled trials (Bajorek, Krass, Ogle, Duguid, 
& Shenfield, 2005; Blaise, et al., 2009; Burns, 2009; Corbella, et al., 2009; Davis, 
Billett, Cohen, & Arnsten, 2005; Leger, et al., 2004; Megden, Heidgen, & Vetter, 
1999; Nedaz, 2002; Polzien, 2007; Satger, et al., 2009; Sawicki, et al., 2003; Taylor, 
Gray, Cohen, Gaminara, & Ramsay, 1997; Witt, Sadler, Shanahan, Mazzoli, & 
Tillman, 2005; Wurster & Doran, 2006; Woodend, 2005). 
 
Four commentaries or protocol papers on three studies were identified (Fitzmaurice, 
Hobbs, Murray, Holder, Allan, & Rose, 2000; Fitzmaurice, et al., 2005; Mendez-
Jandula , et al., 2005). 
 
  
101 
 
Seven studies did not fulfil our predefined inclusion criteria. Three did not include an 
educational or behavioural intervention (Fitzmaurice, Hobbs, Murray, Bradley, & 
Holder, 1996; Matchar, et al., 2005; Fitzmaurice, Hobbs, Murray, Holder, Allan, & 
Rose, 2000; Waterman, Miligan, Banet, Gatchel, & Gage, 2001). None of the studies 
were excluded for including participants >18 years. Three studies did not report any 
of the pre-specified outcomes (Batty, Oborne, Hooper, & Jackson, 2001; Jackson, 
Peterson, & Vial, 2004; Lees, et al., 2003). 
 
2.5.4 Risk of bias  
 
Risk of bias was assessed independently by two reviewers (DEC and supervisor 
DAL) in accordance with the Cochrane Handbook for Systematic Reviews of 
Interventions, Version 5 (Higgins & Green, 2009). 
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Figure 2.2: Risk of bias for each of the included studies 
  
(+) suggests authors have considered methods to reduce type of bias, (-) suggests 
measures were not taken thus there is a risk of bias, (?) indicates not enough 
information was given to determine whether there was a risk of bias.  
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2.5.4.1 Allocation (selection bias) 
 
Six of the included trials provided information about adequate sequence generation. 
For the majority this consisted of randomisation to intervention or usual care, 
according to a computer-generated sequence using block randomisation (Thomson, 
et al., 2007; McAlister, et al., 2005; Man-Son-Hing, et al., 1999; Christensen, 
Magaard, Sorensen, Hjortdal, & Hasenkam, 2006), a random numbers table (Khan, 
et al., 2004) or a two step partial-zelen design (Gadisseur, et al., 2004). The other 
trial provided information regarding patient stratification, but not specifically about 
sequence generation (Beyth, et al., 2000). 
 
2.5.4.2 Blinding (performance bias and detection bias) 
 
Blinding patients to which arm of the intervention they were receiving was not 
possible in this type of intervention, nor was it possible to blind the intervention 
facilitator to which arm the patients were receiving and this inevitably raises the risk 
of bias. However, blinding the data analyst or researcher to which intervention arm 
the patient was assigned to is possible in principle, and was undertaken in four trials 
(McAlister, et al., 2005; Christensen, et al., 2006; Gadisseur, et al., 2004; Beyth, et 
al., 2000). Three trials do not state whether their data analyst was blinded to which 
group the patients were randomised to (Thomson, et al., 2007; Khan, et al., 2004; 
Man-Son-Hing, et al., 1999) or indeed whether the individual delivering the 
intervention also carried out the analysis. 
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2.5.4.3 Incomplete outcome data (attrition bias) 
 
The percentage of patients completing the final follow-up ranged from 72% 
(Thomson, et al., 2007) to 97% (McAlister, et al., 2005). Thus, all of the trials had low 
levels of attrition. 
 
2.5.4.4 Selective reporting (reporting bias) 
 
One of the studies published a protocol paper (McAlister, et al., 2005) and reported 
on all but one of the pre-specified outcomes (patient satisfaction). A further six 
studies did not publish protocol papers (Christensen, et al., 2006; Gadisseur, et al., 
2004; Beyth, Quin, & Landefeld, 2000; Khan, et al., 2004; Man-Son-Hing, et al., 
1999; Thomson, et al., 2007) but reported on all the outcomes specified within their 
method section. 
 
2.5.4.5 Inclusion bias 
 
All of the studies reported the number of eligible participants. However, for the mixed 
cohort trials, it was difficult to retrospectively assess which of the screened patients 
had AF. Of those trials specifically recruiting AF patients, the percentage of eligible 
patients randomised ranged from 30% (Thomson, et al., 2007) to 79% (Khan, et al., 
2004). In the mixed indication cohort trials this percentage ranged from 18% 
(Gadisseur, et al., 2004) to 95% (Christensen, et al., 2006).Thus some of the trials 
are more representative than others and trials that randomised a low percentage of 
eligible patients may be at risk of inclusion bias. 
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2.6 Effects of interventions 
 
Various methods of measuring outcomes were employed and this was the main 
obstacle when comparing study findings. This was further complicated by the 
different time points at which measurements were taken, depending on the length of 
the trial. Further, the included studies differed in type (behavioural and decision aids) 
and in their comparator group.  Where data was comparable, i.e. using the same 
measurement tool and type of intervention, AF-specific data was requested.  
 
2.6.1 Education  
 
2.6.1.1  Time within therapeutic range 
 
Two of the trials included a comparison between education only groups and usual 
care (Khan, et al., 2004; Gadisseur, et al., 2004). Khan et al found TTR in the 
education only group increased from a mean 61.1 ±15.1 during the 6 months prior, to 
70.4 ±24.5 during the 6 months after the study began (mean difference 8.8, 95% CI: -
0.2-7.8, p=0.054). However the difference between groups is not significant 
(intervention groups 0.25±0.30 vs. control 0.16± 0.30, p=0.12). Gadisseur and 
colleagues studied a mixed indication cohort taking OAC and provided additional 
unpublished data on the AF patients. TTR in the education group was 75% (95% CI: 
66.19-83.80) compared with 67.1% (95% CI: 59.18-74.98) in the usual care alone 
group and 70.32% (95% CI: 55.33-85.31) in the self-monitoring plus education group. 
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Table 2.3: Results of systematic review table 
 
 
Author, year, 
country 
Study population 
No. participants, mean 
(SD/Range) age, years 
Study design, 
length of follow-up. 
Type of 
intervention 
Outcomes for AF patient data 
Man-Son-Hing 
1999, USA  
N=287; control 67(#), 
intervention 65 (#). 
RCT; 6 months. DA,  PTOT vs. UC • Proportion choosing warfarin greater in 
control group 
• PTOT    ability to make decision choice. 
• DA group significantly greater knowledge 
of treatment related information than usual 
care (p<0.001). 
• DA did not significantly affect patient 
satisfaction. 
• No significant differences between groups 
on DC (p=.14). 
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Thomson 2007, UK N=136; guidelines 
73.7(6.2), decision aid 
73.1(6.7). 
RCT, 12 months. Computerised DA 
vs. guideline 
evidence. 
• Computerised decision aid led to 
significantly fewer patients choosing 
warfarin. 
• NS differences between knowledge 
scores of 2 groups. 
• DC fell in both groups post-intervention 
with significant difference between groups 
(p=0.036), DA group reported less 
conflict. 
• Anxiety fell in both groups, but there was 
no significant difference between groups 
(p=0.98). 
McAlister 2005, 
Canada 
N=434; control 71(10), 
intervention 73(9). 
Cluster randomised 
trial. 
DA, PTOT vs. UC • PTOT    patient ability to choose 
‘appropriate’ antithrombotic therapy in 
short term only. 
• INR control     over time in UC arm,     
over time in SM arm. 
• DA group scored lower on DC than UC 
group (p=0.05). 
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Christensen 2007, 
Denmark 
N=92; control 46.3(13.4), 
intervention 51.5(14.4). 
RCT, cross-over 
design; 6 months 
pre- and post-
randomisation. 
Education and SM 
vs. UC 
•    % TTR in SM vs. UC (77% vs. 71.5%), 
differences NS. 
Khan 2004, UK N=125; control 73(56-93), 
self-monitoring 71 (65-91), 
education 75(65-87). 
RCT (3 trial arms); 6 
months. 
SM vs. education 
vs. UC 
•    TTR in education group (p=0.054),   
TTR in self-monitoring group (p<0.001), 
NS differences between groups. 
• NS differences in QoL (SF-36) between 
groups, except on emotional role limitation 
(p=0.04). 
Beyth 2000, USA N=294; control 74.5 (6.6), 
intervention 74.9 (6.9). 
RCT, parallel groups 
design; 6 months. 
Education and SM 
vs. UC 
• No differences in major bleeding, stroke 
and thromboembolic events between 
groups. 
Gaddiseur 2003, 
Netherlands 
N=161; (A) 54.8(25-74), 
(B) 53.9(24-75), (C) 56(21-
73), (D) 62(32-75). 
Multi-centre RCT (4 
trial arms); mean=24 
weeks. 
(A) Self-testing vs. 
(B) SM. (C) 
educated UC vs. 
(D) UC 
•    % TTR in SM vs. UC (70.32% vs. 
67.08%), differences NS. 
• DA did not significantly impact on patient 
satisfaction. 
# Not reported; PTOT = probability trade-off tool; RCT = randomised control trial; TTR = time in therapeutic range; DA = decision aid; DC= 
decision conflict; NS= non significant; SM=self-management; UC=usual care; QoL=quality of life,  = increase,   = decrease  
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Pooled analysis of the two studies reporting TTR (Gadisseur, et al, 2004; Khan, et 
al., 2004) demonstrated that education significantly improves TTR compared with 
usual care OR, 95% CI 7.89 (5.54-10.24). 
 
2.6.1.2  Quality of life  
 
Only one study reported QoL (Khan, et al., 2004), assessed using the SF-36. No 
significant difference in QoL scores on any of the SF-36 sub scales, other than 
emotional role limitation (difference 13.33, 95% CI 0.85 to 25.81, p=0.04) were 
evident between education alone and education plus self monitoring groups. 
 
2.6.1.3  Patient satisfaction 
 
One educational intervention trial reported patient satisfaction (Gadisseur, et al., 
2004). Patients who were assigned to the self monitoring group showed a significant 
increase in their general treatment satisfaction (P < 0.01). There was no change from 
baseline to follow-up with the addition of the educational intervention (p=0.21).  
 
2.6.2 Self monitoring plus education 
 
2.6.2.1  Time within therapeutic range 
 
Four trials examined the impact of self monitoring plus education (Beyth, et al., 2000; 
Christensen, et al., 2006; Gadisseur, et al., 2004; Khan, et al., 2004). In the self 
monitoring plus education group, Khan found that TTR increased from 57.0±17.0 to 
71.1±14.5 (mean difference 14.1, 95% CI: 6.7-21.5, p<0.001). In the usual care 
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group there was no significant differences in TTR between the six months prior 
(60.0±18.8) to the six months after the study began (63.2±25.9) (mean difference: 
3.2, 95% CI: -7.3-13.7, p>0.5). Khan and colleagues found no significant differences 
between self monitoring plus education, education only and usual care groups 
(intervention groups 0.25±0.30 vs. control 0.16± 0.30, p=0.12) (Khan, et al., 2004). 
Christensen (Christensen, et al., 2006) recruited patients with multiple indications for 
OAC, with only 20 AF patients: 11 receiving self management plus education and 9 
in the usual care group. The findings suggest greater INR control in the intervention 
group (mean (SD) 77.3 (2.2) % vs. 71.5 (5) %, respectively).  
 
Gadisseur (Gadisseur, et al., 2004) provided data on AF patients but numbers were 
also small in the self monitoring plus education (n=6) and usual care (n=43) groups. 
However, the mean % TTR was greater in the self monitoring plus education group 
than usual care (70.32%, SD=7.495 vs. 67.08%, SD=7.04 respectively). 
 
Beyth et al (Beyth, et al., 2000) did not provide AF specific data on TTR outcomes 
and thus could not be included in these analyses. 
 
The pooled analysis of the three studies reporting TTR (Gadisseur, et al., 2004; 
Khan, et al., 2004; Christensen, et al., 2006) demonstrated that self monitoring 
significantly improves TTR compared to usual care, OR (95% CI) 5.47(2.55-8.39). 
 
2.6.2.2  Major bleeding, stroke and thromboembolic events 
 
One study found the number of cases of major bleeding (cases n=1(1.8% of total AF 
cohort) intervention group, n=2(3.7% of total AF cohort) usual care), and stroke and 
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thromboembolic events (cases n=1 (1.8% of total AF cohort) intervention group, 
n=2 (3.7% of total AF cohort) usual care) were minimal in both groups (Beyth, et al., 
2000). 
 
2.6.3 Education versus self monitoring 
 
Two trials compared self monitoring plus education with education only groups 
(Khan, et al., 2004; Gadisseur, et al., 2004). Khan and colleagues found that TTR 
increased from 57.0±17.0 to 71.1±14.5 (mean difference 14.1, 95% CI: 6.7-21.5, 
p<0.001) in the self monitoring plus education group. TTR in the education only 
group also increased from a mean 61.1 ±15.1 during the 6 months prior, to 70.4 
±24.5 during the 6 months after the study began (mean difference 8.8, 95% CI: -0.2-
7.8, p=0.054). Khan and colleagues found no significant differences between self 
monitoring plus education, education only and usual care groups (intervention groups 
0.25±0.30 vs. control 0.16± 0.30, p=0.12) (Khan, et al., 2004). Gadisseur (Gadisseur, 
et al., 2004) provided data on AF patients but numbers were small in the self 
monitoring plus education (n=6) and education only (n=17) groups. TTR in the self 
monitoring plus education group (70.32%, SD=7.495) compared to 75% (95% CI: 
66.19-83.80) in the education only. The data from these trials was pooled and the 
analysis did not favour education or self monitoring plus education OR (95% CI) -
2.79 [-7.91 to 2.33]. 
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2.6.4 Decision aids 
 
2.6.4.1  Percentage of INRs in range 
 
McAlister (McAlister, et al., 2005) found that INR control deteriorated in the usual-
care arm over time (INRs were between 2.0 and 3.0 on 66% of the days at 3 months 
vs. 70% of the days at baseline) while INR control improved in the intervention arm 
(INRs were between 2 and 3 72% of the days at 3 months vs. 65% at baseline) over 
time. The between group difference was statistically significant (p=0.02). By 12 
months care in both arms had regressed back to baseline levels. 
 
2.6.4.2  Patient knowledge 
 
Two trials reported on patient knowledge (Thomson, et al., 2007; Man-Son-Hing, et 
al., 1999). Thomson used an extension of the decision conflict scale and found that 
although knowledge scores after the intervention had improved slightly, by the three 
month follow-up they had returned to pre-intervention levels (Thomson, et al., 2007). 
There were no significant differences between decision aid and guidelines groups at 
any point. 
 
The second trial used an un- validated scale, and demonstrated that patients in the 
decision aid group had significantly greater knowledge of treatment related 
information [difference (95% CI) aspirin-related, 15.9 (4.6-27.2) p<.001; warfarin-
related, 14.9 (4.6-25.2) p<.001, in favour of decision aid group] than those in the 
usual care group (Man-Son-Hing, et al., 1999). 
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2.6.4.3  Patient satisfaction 
 
One decision aid trial reported patient satisfaction as an outcome (Man-Son-Hing, et 
al., 1999).They found that use of the decision aid did not significantly affect patients’ 
satisfaction with their physician consultation.  
 
2.6.4.4  Decision conflict 
 
Three studies (McAlister, et al., 2005; Man-Son-Hing, et al., 1999; Thomson, et al., 
2007) reported decision conflict, all of which used the decision conflict 
scale (O'Connor, 1995). 
 
Two of the trials reported patients’ level of decision conflict post-intervention (Man-
Son-Hing, et al., 1999; McAlister, et al., 2005). Man-Son-Hing and colleagues (Man-
Son-Hing, et al., 1999) found no statistically significant differences in overall decision 
conflict between the decision aid group and the control group (p=.14). McAlister and 
colleagues (McAlister, et al., 2005) found that there was a small but statistically 
significant difference in the decision conflict between the decision aid and the usual 
care group, the decision aid group scored lower on decision conflict (m=1.6, SD 0.5) 
than the usual care group (m=1.7, SD 0.5, p=0.05). 
 
The third trial reported levels of decision conflict at pre-clinic, post-clinic and three 
month follow-up (Thomson, et al., 2007). Thomson found that decision conflict fell in 
both groups post-intervention and the between group difference was significant 
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(r=2.12, df=107, p=0.036), with those in the decision aid group reporting less 
decision conflict, but this difference was not sustained at  the three month follow-up. 
 
Although three studies reported decision conflict as an outcome (Thomson, et al., 
2007; Man-Son-Hing, et al., 1999; McAlister, et al., 2005), only two compared 
differences between usual care and decision aid groups (Man-Son-Hing, et al., 1999; 
McAlister, et al., 2005). Data from these two trials were pooled, and analyses 
favoured neither usual care nor the decision aid in terms of reducing decision conflict, 
OR (95% CI) -0.10 (-0.17 to -0.02). 
 
2.6.4.5  Anxiety 
 
Only one trial reported anxiety as an outcome (Thomson, et al., 2007).  Anxiety fell 
significantly in both groups pre- to post-clinic, mean change -4.57 (95% CI) -6.30 to -
2.84), but there was no evidence of a significant difference in anxiety between the 
two groups (F (1, 95) = 0.001; p=0.98). 
 
2.7 Discussion 
 
2.7.1  Summary of main results 
 
This review found seven RCTs (Khan, Kamali, Kesteven, Avery, & Wynne, 2004; 
Christensen, et al., 2006; Man-Son-Hing, et al., 1999; Thomson, et al., 2007; Beyth, 
et al., 2000; Gadisseur, et al., 2004; McAlister, et al., 2005) of behavioural and 
educational interventions for anticoagulant therapy in patients with AF. Two trials 
compared education with usual care (Gadisseur, Kaptein, Breukink-Engbers, van Der 
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Meer, & Rosendaal, 2004; Khan, Kamali, Kesteven, Avery, & Wynne, 2004), four 
compared self monitoring plus education with usual care (Beyth, et al., 2000; Khan, 
et al., 2004; Christensen, et al., 2006; Gadisseur, et al., 2004) and one trial also 
compared a self management (consisting of self testing and self dosing) group 
(Gadisseur, et al., 2004). Three trials focused on the use of a decision support aid 
versus usual care (Man-Son-Hing, et al., 1999; McAlister, et al., 2005) or a 
comparison group (Thomson, et al., 2007). 
 
Two trials reported TTR data for educational interventions versus usual care 
(Gadisseur, et al., 2004; Khan, et al., 2004). Pooled analysis of the two studies 
reporting TTR (Gadisseur, et al. 2004; Khan, et al., 2004) demonstrated that 
education significantly improves TTR compared to usual care OR, 95% CI 7.89 
(5.54-10.24). This supports non-trial evidence from Tang and colleagues (Tang, et 
al., 2003), suggesting a link between treatment-related knowledge and INR control. 
Three self monitoring plus education trials also reported TTR (Christensen, et al., 
2006; Khan, et al., 2004; Gadisseur, et al., 2004). Pooled data for the AF patients 
demonstrated that self monitoring significantly improves TTR compared to usual 
care, OR (95% CI) 5.47(2.55-8.39). This evidence supports a previous Cochrane 
review into self monitoring trials for mixed indication patients taking OAC. In their 
review, pooled estimates showed significant reductions in both thromboembolic 
events (RR 0.50, 95% CI 0.36 to 0.69) and all-cause mortality (RR 0.64, 95% CI 0.46 
to 0.89) (Garcia-Alamino, et al., 2010). Evidently, self-monitoring plus education can 
significantly improve TTR and clinical outcomes. However, the pooled TTR analysis 
from our review was largely driven by Christensen’s study, which had a small AF 
sample (lacking statistical power); (Christensen, et al., 2006), with exclusively male 
participants in their intervention group. 
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Two trials compared self monitoring plus education with education only groups 
(Khan, et al., 2004; Gadisseur, et al., 2004). The data from these trials was pooled 
and the analysis favours neither education nor self monitoring (plus education) OR 
(95% CI) -2.79 (-7.91 to 2.33).  
 
Findings suggest that education may be the key factor influencing whether patients 
spend more time in therapeutic range. As many of the trials (decision aid and self 
monitoring plus education) did not clearly specify the content of their intervention and 
all of the self monitoring groups also received education, it is difficult to decipher 
which component is contributing to patients improved TTR. Furthermore, the 
evidence is based on a small number of trials with small sample sizes, thus should 
be interpreted with caution. Studies included are heterogeneous, with varying sample 
sizes, intervention content and mixed indication cohorts. 
 
Decision aid trials appear not to favour either the intervention or usual care group in 
minimising decision conflict (Thomson, et al., 2007; Man-Son-Hing, et al., 1999; 
McAlister, et al., 2005). Data from these two trials (Man-Son-Hing, et al., 1999; 
McAlister, et al., 2005) was pooled, and analysis favoured neither usual care nor 
decision aid in terms of reducing decision conflict, OR (95% CI) -0.10 (-0.17 to -0.02). 
However, the two trials with pooled data did not measure decision conflict prior to the 
intervention and therefore it is not possible to ascertain whether the intervention 
directly affected decisional conflict or not. The use of a decision aid did not have a 
significant impact on AF patients anxiety levels (Thomson, et al., 2007) or patient 
satisfaction (Man-Son-Hing, et al., 1999). 
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2.7.2 Overall completeness and applicability of evidence 
 
Three of the included trials had mixed indication cohorts (Beyth, et al., 2000; 
Gadisseur, et al., 2004; Christensen, et al., 2006), and ten further trials were 
excluded as they did not provide AF specific data (Barcellona, Contu, & Marongiu, 
2006; Mendez-Jandula, Souto, & Oliver, 2005; Ryan, Byrne, & OShea, 2009; 
Siebenhofer, Rakovac, Kleepies, Piso, & Didjurgeit, 2007; Chan, Wong, Lau, Chan, 
Cheng, & You, 2006; Gardiner, Williams, Longair, Mackie, Machin, & Cohen, 2006; 
Stone, Holden, Knapic, & Ansell, 1989; Sawicki, et al., 2003; Watzke, Forberg, & 
Svolba, 2000). Recruiting patients with mixed indications for warfarin can be 
problematic. Patients often have different INR ranges (e.g. with valve replacements) 
and each patient group is unique in their lifestyle and treatment recommendations. 
AF patients are often older (Kannel, Wolf, & Benjamin, 1998), prescribed treatment 
on a long-term basis (NICE, 2006) and susceptible to inaccurate illness 
representations (McCabe, Barnason, & Houfek, 2011), due to their symptoms being 
irregular and often unrecognised (Fuster, Ryden, Cannom, Crijins, Curtis, & 
Ellenbogen, 2006). Thus it is essential that interventions are disease specific, 
targeting the particular concerns of the target population. 
 
Six of the trials recruited patients that had previously taken OAC (Christensen, et al., 
2006; McAlister, et al., 2005; Gadisseur, et al., 2004; Khan, et al., 2004; Thomson, et 
al., 2007) and one recruited patients receiving anti-platelet treatment (Man-Son-Hing, 
et al., 1999). Most of the patients had been receiving antithrombotic treatment long 
term, for up to 5.5 years (Christensen, et al., 2006) prior to receiving the intervention. 
Whilst some trials included warfarin-naive patients (Thomson, et al., 2007) or in-
patients starting OAC (Beyth, et al., 2000) none of the trial cohorts were exclusively 
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warfarin-naive. Patients TTR tends to improve in the months following their 
diagnosis, and their knowledge also increases (Tang, et al., 2003). Therefore, 
previous experience of taking warfarin may influence patients TTR treatment control. 
Further evidence suggests that previous warfarin experience also influences patients’ 
treatment choice (Holbrook, Labris, Goldsmith, Ota, Harb, & Sebaldt, 2007; Lip, et 
al., 2011). Therefore, the results of these trials may not be representative of the 
effect of a behavioural or educational intervention may have on a sample of warfarin-
naive patients and we cannot draw conclusions on the use of interventions for newly 
referred patients, who are at greatest risk of complications. 
 
Prior treatment with warfarin may also influence patients’ decision making. Patients 
may have had prior education pertaining to OAC, stroke and the risk of major and 
minor bleeding.  Further, they may have developed specific beliefs about their 
medications that influence the decision making process, such as the inconvenience 
of regular blood tests, and reductions/abstinence of alcohol and dietary restrictions 
(Lane, et al., 2006; Lip, et al., 2002; Coelho-Dantas, et al., 2004). Patients may also 
feel a level of protection from harm (Lip, et al., 2011), thus increasing their likelihood 
of adopting a certain treatment. One of the trials in this review (Man-Son-Hing, et al., 
1999) recruited patients that had previously taken part in the SPAF trial (Man-Son-
Hing, et al., 1999). All of these patients had previously taken either anti-platelet (60% 
of decision aid group vs. 60% of the usual care group) or OAC (37% of the decision 
aid group vs. 38% of the usual care group). The patients within this trial are unlikely 
to be representative of patients that are making treatment decisions for the first time. 
Firstly, as they are ex-trial patients, thus are likely to have prior treatment related 
education and secondly, as they have had first-hand experience of one or both 
treatments. One study found that more patients chose warfarin in a decision aid trial 
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when the drug name was blinded, than when unblinded (Holbrook, et al., 2007).  
Thus their decisional conflict will be influenced by their prior knowledge of this 
treatment, and perhaps any adverse events they may have suffered from. Moreover, 
research suggests that patients are more likely to choose their current treatment over 
and above another, it has been suggested that this act prevents cognitive dissonance 
(i.e. the stress of choosing a preferred treatment over actual treatment choice) 
(Holbrook, et al., 2007; Howitt & Armstrong, 1999; Protheroe, Fahey, Montgomery, & 
Peters, 2000; Fuller, et al., 2004). 
 
2.7.3 Quality of the evidence 
 
The risk of bias was low in the majority of trials. Two types of bias were most 
prevalent within the studies. Firstly, blinding of patients to the intervention received 
was not possible, nor was it possible to blind the intervention facilitator, inevitably 
raising the risk of bias. However, blinding the data analyst or researcher to which 
intervention arm the patient was assigned to was undertaken in four trials (McAlister, 
et al., 2005; Christensen, et al., 2006; Gadisseur, et al., 2004; Beyth, et al., 2000). 
Trials must be explicit when reporting their methods and procedure to ensure 
accurate assessment of blinding bias and enable comparison of trials. 
 
Inclusion bias was also evident in many studies where the trial patients may not have 
been representative of the number of eligible participants. The percentage of eligible 
patients randomised was as little as 18% (Gadisseur, et al., 2004) in one of the 
mixed cohort trials. Perhaps the reluctance of individuals to participate may relate to 
the extensive training required, particularly for self-monitoring trials. Furthermore, 
many patients may refuse consent due to physical limitations, time commitment 
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associated with multiple training sessions, or psychological barriers to performing self 
monitoring.  AF patients in particular are mostly elderly (Kannel, Wolf, & Benjamin, 
1998) and often highly symptomatic (Lip, et al., 2011), thus trial participation may be 
a particular burden. 
 
The quality of care in the control groups may vary, affecting the benefit and control of 
standard anticoagulation monitoring. The educational element of the intervention may 
be one of the key factors improving TTR. However, trials vary in the intensity, 
duration and number of education sessions, thus we cannot draw conclusions about 
the influence of the educational components of these interventions. 
 
Three studies did not record patients level of education (Gadisseur, et al., 2004; 
Christensen, et al., 2006; Thomson, et al., 2007), a factor which may impact on 
knowledge uptake and treatment control. Research suggests that patients with 
greater knowledge of their treatment spend more time in therapeutic range (Tang, et 
al., 2003). Thus the results of the trials which do not indicate education level may be 
influenced by individual differences in educational achievement between trial groups. 
 
Interventions included within the review were largely self monitoring and decision aid 
trials that included some element of educational training. However, 
only two trials included an education only group (Khan, et al., 2004; Gadisseur, et al., 
2004). To establish whether the differences in TTR control were a result of self 
monitoring (i.e. an increased level of responsibility for their therapeutic outcomes) or 
the education itself (improved knowledge), it is essential to specify the educational 
components included in both the self monitoring and education only intervention 
groups. Without this information we cannot draw conclusions as to whether self-
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monitoring has significant additional benefits over purely providing patients with 
information; particularly as results suggest that education alone can improve patients’ 
anticoagulation control. As usual hospital care currently includes educational 
components, such as an information session, or an education based consultation, 
improving this service may prove more cost effective than self management. 
 
Whilst the educational components of the interventions did focus on important areas 
of risk (i.e. side effects, medication recommendations), they did not include education 
specific to patients’ indication for treatment. Studies suggest that AF patients have 
limited knowledge of their condition (Lane, et al., 2006; Coelho-Dantas, et al., 2004; 
Tang, et al., 2003; Nadar, et al., 2003), which may influence the perceptions they 
form about their illness and their treatment (Steed, Newman, & Hardman, 1999). 
Thus it is essential that patients form an accurate understanding of their illness and 
make appropriate lifestyle changes. 
 
Few studies provided AF specific data on psychological outcomes such as anxiety, 
depression and quality of life, and those that did found no significant differences 
between groups. Only one self monitoring study reported QoL as an outcome (Khan, 
Kamali, Kesteven, Avery, & Wynne, 2004), finding no significant difference in QoL 
scores on any of the SF-36 sub scales, other than emotional role limitation (mean 
difference 13.33, 95% CI 0.85 to 25.81, p=0.04). Only one decision aid trial reported 
anxiety as an outcome (Thomson, et al., 2007).  They found that anxiety fell 
significantly in both groups pre- to post-clinic (mean change -4.57 (95% CI) -6.30 to -
2.84), but there was no evidence of a significant difference in anxiety between the 
two groups (F (1, 95) = 0.001; p=0.98). None of the self-monitoring trials measured 
anxiety, a factor which may have an influence on patient’s self-efficacy to perform 
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regular blood tests. Furthermore, the trial which measured QoL used a generic 
measuring tool (SF-36). It is necessary to include disease-specific measures of QoL 
to accurately assess the impact of the intervention. Numerous studies suggest that 
AF patients suffer from high levels of anxiety (Thrall, Lip, Carroll, & Lane, 2007), yet 
none of the interventions were designed with this in mind.  
 
2.7.4 Potential biases in the review process 
 
Our search strategy included a comprehensive search of several electronic 
databases, meticulous hand-searching of reference lists of included and excluded 
papers, recent conference proceedings, and personal communications with experts 
in this area.  Further, the titles and abstracts of all studies identified by the search 
strategy were reviewed independently by two reviewers and disagreements were 
resolved by consensus.  Data extraction of the included studies was also under taken 
independently by two reviewers.  Therefore the potential for bias in the review 
process was minimal and it is unlikely that important studies were missed.   
 
2.8 Conclusions 
 
2.8.1 Implications for practice 
 
Patients participating in both educational interventions and self-monitoring 
interventions (with education) spend more time within the therapeutic INR range 
(Christensen, et al., 2006; Gadisseur, et al., 2004; Khan, et al., 2004), inevitably 
decreasing the prevalence of adverse thromboembolic events and 
mortality. However, there are not enough trials to draw clear conclusions (about 
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whether self-monitoring has a greater influence on treatment control than education 
alone), consequently more trials are needed to examine the impact of intensive 
educational interventions on anticoagulation control. Further, self-management may 
not be a feasible option for the majority of the patients requiring anticoagulation, due 
to the training required (Fitzmaurice, Hobbs, Murray, Holder, Allan, & Rose, 2000). In 
addition, the associated costs of self-monitoring may prevent wide-scale uptake 
(Fitzmaurice, Hobbs, Murray, Holder, Allan, & Rose, 2000), particularly with imminent 
arrival of new anticoagulants which do not require monitoring (Lip, et al., 2011). Thus 
education may become the primary focus for clinical practice, as patients will still 
need to understand the disease, the need for treatment, and the risks and benefits of 
anticoagulation, as well as the importance of adherence to the treatment regimen in 
order to avoid adverse events. 
 
2.8.2 Implications for research 
 
This review highlights the need for AF-specific trials in larger cohorts and among 
warfarin-naive AF patients, since the number of AF patients within the trials was 
limited, with most patients being warfarin-experienced.  Furthermore, the trials that 
were included all focused on self-monitoring and decision aids. None of the trials 
specifically looked at other types of intervention such as intensive education, or 
behaviour change interventions which are driven to improve psychological outcomes 
(i.e. motivational interviewing and cognitive behavioural therapy). In addition, such 
trials should account for the potential confounding effects of patient education levels 
and the varying quality of the control group care. Future studies should set out to 
understand the mechanisms by which interventions are successful, exploring the 
psychological implications for patients suffering from this long-term chronic condition. 
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3 Intervention development  
 
Evidence from the systematic review (see Chapter 2) supports the need for a 
behavioural intervention that targets AF patients who are newly prescribed OAC. By 
improving knowledge of AF and OAC, it seems possible to increase patients’ time 
spent within therapeutic INR range. However, it is also important to consider the 
mechanisms by which an intervention with this patient group is successful, and 
include a theoretical basis which considers the literature surrounding adherence to 
medication.  
 
Complex interventions have been described as interventions that ‘contain several 
interacting components’ (Craig, Dieppe, Macintyre, Michie, Nazareth, & Petticrew, 
2008). This type of intervention is used widely within public health practice and the 
National Health Service (NHS). The Medical Research Council (MRC) published a 
framework for the development and evaluation of RCTs for complex interventions, 
including a pre-clinical or theoretical phase (MRC, 2000). However, complex 
interventions have evolved in both the design and evaluation process, and the 
original framework has been criticised for lacking attention to the early phase of 
piloting and developing the intervention (Hardeman, Sutton, Griffin, Johnston, White, 
& Wareham, 2005). Rather than a linear development process, the new guidelines 
propose a more pragmatic process of intervention design, whereby each phase 
informs the other (Anderson, 2008). Thus, whilst the evaluation process is essential 
(primarily through an RCT design), the development of the intervention, through the 
literature reviews, theoretical models or modelling processes and outcomes, is 
equally as important (see Figure 3.1). Using these principles the development 
process may inform the piloting procedures and the evaluation of the intervention or 
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pre-specified outcomes. This chapter aims to document the development process of 
the intervention, including the components which informed its final development. 
 
3.1 Theoretical background 
 
3.1.1 Beliefs about medication 
 
Research into patients’ beliefs about medications suggests utilising the ‘Necessity-
Concerns Framework’ to understand the key beliefs which are influencing whether 
patients adhere to prescribed treatment or not (Horne, Weinmann, & Hankins, 1999). 
The models suggests that patients hold beliefs about the  necessity of their 
prescribed medication (Specific-Necessity), and concerns about prescribed 
medication, based on beliefs about danger of dependence and long-term toxicity, as 
well as the disruptive effects of the medication (Specific-Concerns). The model also 
describes general beliefs about medication, assessing beliefs that medicines are 
addictive and harmful, (General-Harm) and that medicines are over-prescribed by 
doctors (General-Overuse). These beliefs, and the way in which patients balance 
their concern about medications, have been widely used in predicting adherence in a 
variety of chronic conditions including rheumatoid arthritis (Neame & Hammond, 
2005), asthma (Jessop & Rutter, 2003), type II diabetes (Farmer, Kinmonth, & 
Sutton, 2006) and depression (Aikens, Nease, Nau, Klinkman, & Schwenk, 2005). 
  
Figure 3.1: Key elements of the development and evaluation process adapted from 
Craig et al (Craig, Dieppe, Macintyre, Michie, Nazareth, & Petticrew, 2008)
 
It has been suggested that several factors influence adherence, and these factors 
are either intentional or un
patients make a decision not to take their treatment as a result of their personal 
motivations and/or beliefs. Unintentional non
skills or ability to take their medications (e.g. problems with remembering to take 
tablets). Patients may report either or both, and indeed there may be an overlap 
between the two concepts (e.g. where patients perceive medications as being 
unnecessary, they maybe m
necessity-concerns framework has also been found to predict both intentional and 
non-intentional adherence in patient
illnesses (Clifford, Barber, & Horne, 2008)
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Some patients are particularly at risk of non-adherence, which can be explained by 
the model. For example, asthma and cardiac patients are significantly more likely to 
perceive that the costs of their medication outweigh the benefits, in comparison to 
oncology or dialysis patients (Horne, Weinmann, & Hankins, 1999). Concerns about 
medication could have arisen from potentially mistaken beliefs, for example, that 
regular use results in adverse effects or dependence, as both groups often rely on 
medication for long-term management of their condition. These beliefs can result in 
intentional non-adherence (see Table 3.1).  
 
Table 3.1: Examples of patients’ self-reported reasons for non-adherence classified 
as unintentional and intentional (Clifford, Barber, & Horne, 2008). 
 
Unintentional reasons Intentional reasons 
I was away from home and forgot to take 
my medicines with me. 
I was worried about the side effects so I 
reduced the dose. 
I was tired and I forgot. I miss doses because I feel I am taking 
too many. 
I went out for the evening and forgot to 
take medicines with me. 
I do not take water tablets (diuretics) 
when going out of the house. 
I was in a hurry and forgot. I miss the evening dose because it keeps 
me awake. 
 
 
A comparison of beliefs about medications between adherent, unintentional non-
adherent and intentionally non-adherent patients, found significant differences in 
medication related beliefs in patients with a range of chronic illnesses, after being 
newly prescribed medication for the last ten days (Clifford, Barber, & Horne, 2008). 
Compared with adherers, intentional non-adherers had significantly lower scores on 
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the necessity subscale of the BMQ (p=0.012), higher scores on the concerns 
subscale (p=0.008), and lower scores on the necessity-concerns differential 
(p=0.001). There were no significant differences between adherers and unintentional 
non-adherers (Clifford, Barber, & Horne, 2008). Evidently whilst unintentional non-
adherers may benefit from memory aids (i.e. reminders, tablet dosettes), intentional 
non-adherers may need to address both their perceptions of their medication and 
misinformation, by increasing patient education surrounding their treatment. 
Intentional non-adherers appear to doubt their personal need for their medication and 
have concerns about taking it compared to adherers. They may also view their 
concerns about the medication as more important than their concerns about the 
illness itself. Whilst these findings are not derived from a specific AF population, the 
study did test a cohort which was similar to AF patients (i.e. aged ≥75, stroke, 
coronary artery disease, asthma, diabetes, rheumatoid arthritis).  
 
Other studies have given more insight into how we can utilise this model for the 
purpose of intervention development. A study examining beliefs about medication in 
diabetes patients found the majority strongly agreed with statements about the 
benefits of taking medication (Farmer, Kinmonth, & Sutton, 2006). However, negative 
beliefs that taking medication would cause unpleasant side effects and lead to weight 
gain were held by 24.1% and 13.9% of people, respectively. Beliefs about benefits 
were strongly associated with intention to take medication regularly. Two beliefs were 
associated with reduced medication adherence: firstly that changes to their daily 
would make it more difficult to take diabetes medicines regularly (P < 0.001), and 
secondly that taking medications led to weight gain (P < 0.05). Thus by emphasising 
the importance and the benefits of medication, it may be possible to increase 
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adherence. Further it seems pertinent to address any misconceptions surrounding 
the potential harm of the medication prescribed. 
 
In heart failure patients, the most frequently identified benefit of medication 
adherence (to diuretics) was decreasing the chance of being hospitalized (81%), and 
the most commonly reported barrier was disruption of sleep (78%) (Bennett, Lane, 
Welch, Perkins, Brater, & Murray, 2005). Heart failure patients perceived both 
benefits of treatment and the barriers to adherence, which can inform tailored 
intervention development, in a similar way to the diabetes cohort. The implications of 
these findings suggest that in order to improve adherence rates, patients must 
understand the need for treatment and tackle any concerns they have about taking it. 
The intervention must incorporate the needs of both unintentional and intentional 
non-adherers (see Table 3.2). 
 
Table 3.2: Key recommendations regarding beliefs about medications 
Key recommendations based on the literature surrounding beliefs about medication 
• Address unintentional non-adherence by using reminders/memory 
aids/dosettes. 
• Address intentional non-adherence by discussing with the patient their 
individual barriers to adherence and the benefits of their prescribed 
medication. 
• Discuss with patients the consequences of their illness, risks associated with 
treatment and how this related to their perceived barriers to medication 
adherence. 
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3.1.2 Illness perceptions 
 
Patients’ barriers to adherence may also relate to their perceptions of their illness. 
The common sense model (CSM) suggests there are five dimensions which form our 
illness representations, these include (i) identity- symptoms and the label attributed to 
the illness; (ii) consequences- expected physical, social and economic implications; 
(iii) timeline- acute, chronic or cyclical duration; (iv) causes- personal ideas about 
causes; and (v) cure/control- the extent to which a patient believes they will recover 
from or control their illness. Items of the illness perception questionnaire (IPQ) 
(Broadbent, Petrie, Main, & Weinmann, 2006) were theoretically-derived to assess 
each of the above components. 
 
Illness representations have been studied with a range of chronic illnesses including; 
heart disease (Cooper, Lloyd, Weinman, & Jackson, 1999; Steed, Newman, & 
Hardman, 1999), cancer (Buick & Petrie, 2002), chronic obstructive pulmonary 
disease (Scharloo, Kaptein, Weinman, Hazes, Breedveld, & Roojimans, 1999), 
diabetes (Griva, Myers, & Newman, 2000; Paschalides, Wearden, Dunkerley, Bundy, 
Davies, & Dickens, 2004); myocardial infarction (French, Lewin, Watson, & 
Thompson, 2005) and rheumatoid arthritis (Scharloo, Kaptein, Weinman, Hazes, 
Breedveld, & Roojimans, 1999; Murphy, Dickens, Creed, & Bernstein, 1999; Pimm & 
Weinman, 1998). These studies suggest links between illness representations and 
outcomes such as coping (Scharloo, et al., 1998; Scharloo, Kaptein, Weinman, 
Vermeer, & Rooijmans, 2000; Moss-Morris, Petrie, & J, 1996) and medication 
adherence (Cooper, Lloyd, Weinman, & Jackson, 1999; Weinman, Petrie, Sharpe, & 
Walker, 2000). 
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In myocardial infarction (MI) patients illness representations predicted various 
outcomes; slower return to work was associated with higher concern (r=.43, p<.03) 
and higher treatment control beliefs (r=.44, p<.03). The Brief-IPQ at discharge further 
predicted cardiac anxiety (Eifert, et al., 2000) and quality of life (Spertus, et al., 1995; 
Ware, Snow, Kosinski, & Gandek, 1993) three months after MI. Thus, illness 
representations are a key aspect of a patient’s recovery from their illness and play an 
important role in how individuals cope with their treatment strategy. 
Whilst patients are encouraged to adhere to treatment recommendations, general 
practitioners and physicians rarely discuss the behaviours required to become 
adherent and overcome perceived barriers (Theunissen et al., 2003). The CSM of 
illness representations suggests that patients’ appraisal of somatic changes such as 
symptoms and functions can explain both patient care seeking and a patient’s 
management of their condition (Cameron, Leventhal, & Leventhal, 1993; Horne, 
2003; Skelton & Croyle, 1991). For example, symptoms of illness may be attributed 
to ‘normal’ ageing (Horowitz, Rein, & Leventhal, 2004) or psychological stress 
(Cameron et al., 1993), thus not prompting treatment seeking behaviour.  
 
Many patients may harbour strong, but medically unsupported beliefs about their 
medical condition, derived from the media, extreme cases, or general beliefs about 
health and illness. The CSM suggests that patients rely on a set of ‘mental tools’ to 
understand somatic stimuli such as duration, location and severity of symptoms; a 
concept supported by research with hypertensive (Meyer, Leventhal, & Guttman, 
1985) and diabetes patients (Skinner & Hampson, 2001). For example, changes in 
adolescents’ perception of the severity of their diabetes were associated with an 
increase in adherence. Further, the more diabetes patients believed their treatment 
would control their diabetes, the more likely they were to adhere to dietary 
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recommendations (Skinner & Hampson, 2001). By understanding patients’ illness 
representations we are able to understand how patients self-regulate their illness and 
this represents an important opportunity for intervention development. 
 
Two studies have examined illness representations in AF patients. One cross-
sectional study compared the differences between symptomatic and asymptomatic 
AF patients (Steed, Newman, & Hardman, 1999); they found participants’ 
representations differed on the identity subscale between symptomatic and 
asymptomatic patients (m (SD) 7.87 (3.4) vs. 4.00 (2.8) respectively; p<0.001), but 
not on the other subscales (Steed, Newman, & Hardman, 1999). As the identity sub-
scale is particularly focussed on symptoms, there is an obvious difference between 
the two groups. However, the findings suggest that AF patients with different 
expressions of the arrhythmia are similar on the other subscales. 
 
A recent cross-sectional study with mixed cohort of AF patients provided further 
insight into the role of illness perceptions. The authors found that patients believed 
psychological factors, such as age and heredity, caused AF (McCabe, Barnason, & 
Houfek, 2011). Stronger beliefs that AF is cyclic and unpredictable (r=0.30), having 
psychological causes (r=0.36) and greater consequences (r=0.58) were associated 
with more negative emotion. Those patients with the greatest illness coherence, 
reported fewer negative emotions relating to their AF (r=-0.38) and held stronger 
beliefs that their AF was controllable with treatment (r= 0.33) (McCabe, Barnason, & 
Houfek, 2011).  The evidence from this study suggests that by improving patients’ 
illness coherence, and their understanding of causality, we may improve their beliefs 
surrounding the controllability of their illness, potentially promoting adherence. 
However, the systematic review (Chapter 2) suggests that there are no studies to 
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date utilising the CSM within AF interventions, or indeed any studies examining 
illness perceptions in AF patients over time. 
 
A behavioural intervention, utilising a CSM framework, integrating each of the five 
components that contribute to the formation of illness representations, may therefore 
be suitable for AF patients, who often exhibit poor knowledge of their condition and 
its treatment (Lane et al., 2006; Nadar et al., 2003). It is particularly important for this 
patient group to increase knowledge and illness coherence, as non-adherence to 
warfarin carries significant health risks. McAndrew and colleagues focussed on the 
use of CSM for intervention design and suggest integrating the five components and 
monitoring the change between current status and the desired endpoint(s) 
(McAndrew, et al., 2008).   
 
The development of a ‘top-down’ conceptual framework for AF, involves ensuring 
patients recognise that AF is present, even if they are asymptomatic. For example, 
focussing on each of the common sense model components, to allow patients with 
AF to appraise information and formulate their own illness representation. Thus the 
top-down elements of the intervention are educational, providing information 
regarding causality, consequences, expected timeline and potential areas for the 
control of AF and its symptoms.  This approach encourages patients to view AF as 
both chronic and treatable, and provides patients with a model to correctly interpret 
bottom-up inputs generated by their actions (i.e., their INR results and treatment 
outcomes). This strategy is relevant for AF patients, as depending on the type of AF 
(paroxysmal, persistent or permanent), each patient may represent and manage their 
condition in a different manner (e.g. they may only adhere to treatment when 
symptoms are acute, which may be infrequently), consistent with symptom severity. 
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Below the requirements for patients to create a cognitive representation of AF are 
summarised: 
 
Create an illness identity: help patients understand which symptoms are/are not 
associated with AF, common co-morbidities,  the risks of stroke in addition to the 
reasons for prescribing anticoagulant medication and the emotions individuals 
associate with the illness (e.g. ‘I am afraid of what will happen’). 
 
Understand the consequences: help patients understand the physical, social and 
economic implications of both AF and treatment with anticoagulation. Patients need 
to be provided with information about the risks associated with atrial fibrillation e.g., 
the main risk associated with AF is stroke.  
 
Identifying their illness timeline: patients can be made aware of the duration of their 
illness and treatment given information about the different types of AF, and how this 
relates to the risk of stroke.  
 
Understanding the causes of AF: patients need to be made aware of their personal 
ideas about the causes of AF and how they relate to the scientific evidence.  
 
Identifying a cure or control for their illness/symptoms: patients can be presented with 
information pertaining to the control of their INR (with control of factors affecting 
warfarin metabolism), pharmacological control of their AF symptoms, and explore the 
factors that may affect their symptoms including caffeine intake, exercise and 
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alcohol. Of particular relevance are the key lifestyle factors which affect INR control 
including diet, alcohol intake and other medications and supplements, as for many 
patients there is no ‘cure’ for AF. 
 
Patients’ common sense models of their physical health and illness can be influenced 
by subjective cognitions (i.e. symptoms, moods, and experienced dysfunction). AF 
patients maybe particularly affected by the presence or absence of their symptoms; 
which in turn can impact on their quality of life (Smith, Lip, & Lane, 2010). However, 
all patients have the same risk of stroke, regardless of their symptom burden (Flaker, 
Belew, Beckman, & Investigators, 2005). Therefore it is important that patients do not 
use a symptom prototype as a subjective cue to identify their illness. 
 
An additional intervention component which replaces automatic control with volitional 
control is needed within the intervention. This involves patients; (a) knowing what to 
do to minimise the risk, thus controlling their health outcomes (e.g. dietary change, 
alcohol intake and use of anticoagulants) and (b) relying on objective rather than 
subjective indicators (identity, using INR as a meter for control, rather than 
symptoms) to evaluate the efficacy of treatment (control and consequences); 
(Cameron & Leventhal, 2003; McAndrew, et al., 2008). The bottom-up approach 
focuses on behavioural change by using an action plan. By discussing their concerns 
about treatment and developing their own plan for integrating the treatment regimen; 
patients may be more likely to manage their illness effectively, a concept which also 
fits in with the Necessity-Concerns Framework (McAndrew, et al., 2008; Horne, 
Weinmann, & Hankins, 1999).  
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Table 3.3: Key recommendations regarding illness perceptions 
Key recommendations based on literature surrounding illness perceptions 
• Guide patients through the different components of the CSM, to increase 
illness coherence. 
• Focus on objective indicators of illness/treatment control (i.e. INR results) 
rather than symptoms. 
• Use a personal action plan to encourage volitional control over treatment 
success. 
 
 
3.1.3 Behaviour change techniques 
 
The NICE guidelines for behaviour change, specify three important goals in 
intervention design (1) be specific about content; (2) spell out what is done, to whom, 
in what social and economic context, and in what way; (3) make it clear which 
underlying theories have been utilised, with explicit links between actions and 
outcomes (NICE, 2007). Psychological theories are numerous and many have 
overlapping constructs (Michie, Johnston, & Abraham, 2005; NICE, 2007). In order to 
evaluate how and why an intervention works or doesn’t work, these theories need to 
be simplified into an accessible format. A recent taxonomy of techniques developed a 
set of reliable and distinct theory-linked definitions of behaviour change techniques 
(BCTs; Abraham & Michie, 2008). Each of these 26 techniques has led to successful 
behaviour change in previous interventions with a range of chronic illnesses, based 
on several overlapping theories (Abraham & Michie, 2006).  
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Whilst the techniques chosen for this intervention are not specifically linked to one 
theory, each BCT did correspond with the key recommendations derived from the 
systematic review, theoretical models and focus groups. The techniques are listed 
below: 
 
3.1.3.1  Provide general information on behaviour-health link 
 
The common sense model suggests patients need to identify a cure or control for 
their illness (see Section 3.1.2). In order to gain control over symptoms and 
outcomes, it is essential to educate patients about the link between behaviour and 
health outcomes. The intervention group were presented with information relevant to 
their necessary behavior change, i.e. how they can maintain their INR and thus 
improve health outcomes (see example Figure 3.2). For patients taking warfarin this 
included advice on alcohol intake, diet, and other medications and supplements, and 
susceptibility to bleeding and stroke risk with non-adherence.  
 
Figure 3.2: Excerpt from the patient information booklet highlighting the behaviour-
health link (for more detail see the Patient Booklet, Appendix 3). 
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3.1.3.2 Provide information on consequences 
 
The common sense model suggests that patients need to understand the 
consequences of their illness (Section 3.1.2). Thus as part of the intervention session 
patients are asked to calculate their own risk of stroke (Figure 3.3) using the CHADS2 
scoring system (Gage, Waterman, & Shannon, 2001) which assesses which 
antithrombotic treatment they will be prescribed based on current clinical guidelines. 
This process allows for the formulation of an AF illness identity, an awareness of the 
associated risks and the need for treatment. For AF patients the relationship between 
behaviour and health outcomes includes the susceptibility to stroke and 
thromboembolism. Patients are asked to draft action plans to minimise this risk. The 
consequences of not adhering to antithrombotic treatment and lifestyle 
recommendations are an increased risk of stroke and bleeding complications. These 
risks are presented as expert patient narratives, discussing their personal 
experiences of bleeding associated with warfarin and non-adherence to lifestyle 
recommendations in the DVD. Bleeding risks are also illustrated as annotated pie 
charts within the booklet to reinforce the information given during the educational 
session. Patients are provided with safety information regarding side-effects, 
when/how and who to contact in an emergency and the symptoms of a high INR 
(illness representations Section 3.1.2).  
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Figure 3.3: Excerpt from the patient booklet, used in combination with the patient 
worksheet to assess personal risk of stroke. 
 
3.1.3.3  Prompt barrier identification  
 
Patients are encouraged to think about potential barriers to adhering to 
recommendations (Figure 3.4) and to design a personal action plan to overcome 
these barriers. This technique addresses the concept of intentional non-adherence, 
derived from beliefs about medication theory (Section 3.1.1). This may include 
barriers to performing lifestyle changes (e.g. specific occasions where they are likely 
to drink more units of alcohol, or change their dietary intake) or psychological barriers 
(e.g. fear of taking a treatment that they associate with negative experiences with a 
former relative). This process takes place throughout the intervention session. 
Patients are presented with barriers which other patients have identified and ways in 
which they made these changes through the ‘expert’ patient narratives. Following the 
patient narratives on the DVD, patients are given a handout which asks them to list 
their main concerns about taking warfarin. Patients can then raise these concerns 
within the group discussion, or talk to the researcher following the session (beliefs 
about medication Section 3.1.1). 
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Figure 3.4: An excerpt from the patient worksheet used to prompt a discussion 
regarding barriers to OAC adherence. 
 
SECTION C: Medication concerns 
When prescribed a new life-long treatment such as warfarin, patients often come 
across problems and concerns which can prevent them from taking their medication 
and successfully reducing their risk of stroke. These can be psychological concerns 
for example; worrying about side effects and the burden of the medication or practical 
concerns for example; how you will remember to take the medication? what to do if 
you miss a dose etc. 
 
 
3.1.3.4  Provide instruction  
 
Many patients may also un-intentionally fail to adhere to treatment recommendations. 
This concept is linked into the beliefs about medication literature (Horne, Weinman, 
Barber, Elliot, & Morgan, 2005), suggesting that providing reminders and instructions 
could improve memory for certain behaviours, subsequently reducing the risk of 
unintentional non-adherence. This technique involves telling the patient how to 
perform specific health behaviours. For the purpose of this intervention this included 
consultant cardiologist narratives, describing in detail on the patient DVD, ‘what do if 
you miss a dose of anticoagulation’, ‘how to remember to take your tablets’, and 
‘when to seek medical attention’. Patients are also encouraged to formulate a 
personal action plan which will include memory aids for their tablets doses and what 
to do in an emergency (See patient DVD, Appendix 3). 
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3.1.3.5  Prompt self-monitoring of behaviour 
 
The Cochrane systematic review (Chapter 2), suggests that self-monitoring can 
improve adherence to OAC medication. Whilst this intervention does not include INR 
self-monitoring, patients are encouraged to keep a record of their dietary intake, 
alcohol units, medications and supplements for two weeks (see Figure 3.5) following 
the intervention using the ‘patient diary’ booklet provided. Patients are asked to 
monitor whether their INR results are out of range and if this coincided with any 
changes in the recorded lifestyle factors. This encourages the use of INR results as 
an objective indicator of anticoagulation control, aiming to allow patients to formulate 
accurate illness representations. At the back of the booklet patients can refer to a list 
of questions (see Figure 3.6). This is a self-reflective tool, encouraging patients to 
assess what has changed within their lifestyle, and whether those changes may have 
had an impact on their INR scores. This diary is for patient self-monitoring only and 
does not form part of the outcome assessment (see patient diary, Appendix 3). 
 
3.1.3.6 Teach to use prompts/ cues  
 
A further technique, adopted to reduce un-intentional non-adherence, is the use of 
prompts or cues (see beliefs about medication, Section 3.1.1). Patients are 
encouraged to identify environmental prompts which can be used to remind them to 
take their tablets. This could include times of day or particular contexts. They also 
watch other ‘expert’ patients describe their memory-cues, including the use of tick 
lists, pill boxes and reminders. They discuss the roles of their partner (if they have 
one) within their treatment regimen. Patients are then encouraged to discuss their 
own memory-aid methods (see patient DVD, Appendix 3). 
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3.1.3.7 Provide opportunities for social comparison 
 
It was evident when piloting the intervention materials with patient focus groups that 
patients benefit from discussing their experiences with others and from listening to 
patients’ related treatment experiences. Thus, the intervention was designed to allow 
for social comparison between patients within the intervention sessions, via patient 
discussion. Social comparison is also employed by including patient narratives within 
the intervention DVD. During the intervention development stages ‘expert’ patients 
were invited to be filmed during an interview to discuss their illness perceptions, 
previous concerns about taking warfarin, the lifestyle changes they made, and their 
consultation when first diagnosed with atrial fibrillation (see patient DVD, Appendix 
3). These narratives formed the basis of the patient DVD. 
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Figure 3.5: Example of patient diary to monitor alcohol intake, vitamin K rich foods and associated health problems. 
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Figure 3.6: Self reflective tool from the patient diary 
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3.2 Developing the intervention materials 
 
3.2.1 Piloting intervention materials with ‘expert’ patient focus groups 
 
Once the theoretical basis for intervention development was established and 
appropriate educational information had been gathered (based on clinical guidelines 
published by the National Institute for Clinical Excellence) (NICE, 2006), various 
presentation methods were piloted. The key objective of the pilot study was to 
establish preferred communication methods for the educational information and to 
ensure the information could be understood by using the ‘teach back’ method. 
Patients were asked to relay the key message that the information was trying to 
convey, or to explain the information to the researcher and/or other participants. 
During the focus group six warfarin-experienced patients with AF (three males and 
three females) were presented with information slides. The same information was 
also presented to four patients who were new to warfarin (within the interviews). Four 
key areas were discussed which led to the subsequent modification of the 
intervention materials. Two of the topics focussed on illness identity information (i.e. 
the description of patient symptoms, the description of types of AF). The other two 
examples focussed on information that formed part of education regarding 
consequences (risks of treatment and risks of AF). 
 
3.2.1.1  Description of symptoms 
 
Patients were presented with a slide which described the symptoms associated with 
AF, taken from a published article outlining associated symptoms (Lane & Lip, 2009). 
They were asked whether this clearly described the symptoms they attributed to their 
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AF. Two key factors were raised. Firstly, some patients are asymptomatic and felt 
this should be clearly stated within the materials. One male AF patient stated [M2] - “I 
can only say that on the last article on….other people with atrial fibrillation, I had no 
symptoms at all and it came about by a routine inspection... symptoms I am talking 
about the chest discomfort, the light headedness, the tiredness, or fainting... none of 
that”.  
 
Secondly, for several patients their symptoms had previously been misattributed to 
other causes and a clear list of symptoms clarified the identity of their illness. One 
female patient explains, [F1] - “when I first started experiencing palpitations and 
tiredness and slight shortage of breath... occasionally... I was told that it was all part 
of erm... oooh grief... … it was related to the work I was doing at the time and it was 
an occupational hazard... well you do get stuff with blood pressure don't you... high 
blood pressure”. Thus, a clear list of symptoms is included in the intervention 
materials, noting that some patients may also be asymptomatic (experiencing no 
symptoms at all). 
 
3.2.1.2  Types of AF 
 
Patients were presented with three clear definitions of the different types of AF 
derived from current clinical guidelines (NICE, 2006): 
• Paroxysmal: multiple episodes that typically last less than 48 hours and stop 
by themselves 
• Persistent: episodes that last longer than 7 days, or stop when treated 
• Permanent: continuous AF for more than 1 year 
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Patients were asked whether they understood the definitions, which category they 
fitted into, and why. All of the patients appeared to be able to quickly categorise 
themselves (see quotations below), and thus the descriptions were kept the same. 
 
[M2]- “out of that... number three will be the nearest to me... permanent continuous 
atrial fibrillation... for more than 1 year and I would say 50 years... [laughs] that's how 
long I can go back...” 
Researcher – “how about everybody else?” 
[F1] –“I have spent 3 years since I was diagnosed with it. With atrial fibrillation” 
Researcher – “and which category would you fall into?” 
[F1] –“ mmm I would say probably the first one... comes and goes...”  
 
3.2.1.3  Risks associated with warfarin  
 
Patients were shown three different presentation methods for the same risk 
information. The information related to the risks of stroke associated with AF and the 
risks of bleeding associated with treatment with warfarin. Presentation methods 
included two traditional methods; [1] pie charts, [2] bar charts and one more novel 
method, [3] pictograms (denoting each percentage as a smiley face, previously used 
as a decision making tool by Man-Son-Hing and colleagues; Man-Son-Hing, et al., 
1999). Patients were asked which method they preferred and which they understood. 
All patients agreed that the pie chart presentation method was clearer for a range of 
statistical risk information. One patient described how time-consuming the pictogram 
method was  [F1]-“ because otherwise you are going to be sitting there ages as I 
say…counting how many faces are there on there…whereas with the circle you 
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got…straight away”. Based on the feedback from the focus group, pie charts were 
used to present risk information within the educational booklet. 
 
3.2.1.4  Stroke risk associated with AF 
 
Patients were presented with a diagram (of a torso, heart, nervous system and brain) 
describing the formation of clots within the atrium (top chamber) of the heart and the 
subsequent risk of stroke (see patient booklet, Appendix 3). They were asked 
whether the diagram was useful and whether they understood information they were 
presented with. The dialogue indicated that this diagram provided the informational 
link between the risk of blood clots and the risk of stroke. 
 
[F1]- “well its explaining what can happen in the sections of the heart and how erm, 
as it there, clots can form and erm” 
[M1] – “go to the brain” 
[F1] – “yeah… can go to the brain and that can cause erm strokes or whatever and at 
the same time, it is also showing how the different movements of the heart, the 
pumping of the heart” 
[M1] – “oh yes” 
[F1] – “can effect erm… this distribution shall we say unless it is controlled with a 
thinning… drug or whatever. That’s how I look at it” 
 
Another patient described how the information provides an explanation for the need 
for anticoagulation with warfarin [F2]-  “it would help you to know why you have been 
given your medication and what it was gonna do to help prevent you… you know 
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having the blood clot in first place”. The original diagram was digitalised and adapted 
for use within the educational booklet. 
 
This pilot study represents a pragmatic approach to intervention design. Patients 
were able to read the materials and comment on their understanding of the 
information, the method of presentation and the information they felt needed to be 
added to the final intervention session. Many of these patients also took part in the 
DVD filming, allowing them to voice their concerns about their personal barriers to 
taking warfarin, and how they were able to cope with their diagnosis and treatment. 
These interviews were presented as ‘patient diary’ clips within the DVD and provide 
one element of social comparison within the intervention. These AF patients played 
an important role in shaping the content of the intervention, to ensure it was both 
relative and relevant for the target group.  
 
Table 3.4: Key recommendations based on focus group outcomes 
Key recommendations based on the focus group pilot study 
Symptoms –list the common symptoms, specifying that AF patients can be both 
symptomatic and asymptomatic 
Risk presentation –the use of pie charts, rather than other methods demonstrated. 
Stroke diagram –visual aids within the intervention materials can prove useful. 
Social comparison – patient narratives were added to the intervention materials, 
voicing barriers to adherence and questions to the physician. 
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3.2.2  Intervention outline 
 
The intervention consists of a group session (between 2-6 patients) for one hour, 
where patients are shown a DVD of information, asked to complete worksheets, and 
take part in a group discussion. The intervention is delivered by the same researcher 
for each session (a Health Psychologist in-training, DEC), who designed and piloted 
the intervention under supervision. The information on the DVD consists of three 
chapters; (1) AF causes, etiology and warfarin (this section follows on to a worksheet 
and discussion about personal risks associated with AF and the need for 
anticoagulation treatment); (2) how to control INR (including key lifestyle 
recommendations such as diet, alcohol and other medications and supplements); 
and (3) expert patients discussing concerns, barriers to adherence and coping with 
lifestyle changes. An open discussion follows the DVD, eliciting key concerns 
surrounding lifestyle changes. Following each chapter patients are encouraged to 
note down the key lifestyle changes that they will make, including any barriers to 
adhering to recommendations, as part of their personal action plan. A consultant 
cardiologist is also filmed answering the frequently asked questions with an 
evidenced-based appraisal of the concern or problem. This section includes side 
effects, psychological morbidity, memory aids and maintaining INR control.  
 
Patients are then encouraged to discuss their own concerns about their condition, 
and their treatment and draft a personal action plan to integrate lifestyle changes into 
their everyday routine. The DVD is presented with a variety of approaches; [1] expert 
patient narratives, [2] mock consultations, [3] pictorial examples of dietary 
components, alcohol and other medications and [4] expert consultant interview 
excerpts. In addition to the interactive group sessions, patients are also given an 
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educational booklet, which has more detailed information and reiterates key safety 
points. The complete intervention pack also contains a treatment diary (whereby 
patients can self-monitor the factors which affect the stability of their INR), an alert 
card and their session worksheet. The table below describes the content of the 
intervention, the mode of delivery and the relevant theoretical components (See 
Table 3.5). 
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Table 3.5: A table outlining the intervention components 
Content Mode of 
delivery 
Description Model component(s) and/or behavioural 
change technique 
Definition Booklet, DVD Definition of AF given by consultant cardiologist and explained 
within the booklet. The booklet also includes symptoms 
associated with AF and the different types of AF are defined. 
Illness identity 
Diagnosis DVD Patients give narrative examples of their experiences of AF 
diagnosis. For some patients this maybe through routine 
health checks; for others it is following a TIA or stroke. 
Patients give further examples of what AF means to them and 
how they would describe the condition to other patients. 
Illness identity 
Provide opportunities for social comparison 
Cause 
 
Booklet, DVD The causes of AF are described by a consultant cardiologist; 
these include age and associated co-morbidities. The causes 
are also described within the educational booklet, 
documenting factors which increase the risk of AF and a 
graph illustrating the increase in numbers of AF patients with 
age. 
Understanding the causes of AF 
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Prognosis DVD, Booklet The consultant describes the risk of stroke associated with AF 
on the DVD. The booklet describes the risk of stroke and uses 
a pictorial illustration of how blood clots can form and cause 
stroke. 
Identifying an illness time-line 
Identifying a control for illness/symptoms 
Provide information on consequences 
Stroke risk DVD, 
Worksheet 
The patient education booklet describes why AF patients are 
prescribed warfarin and how to calculate their risk of stroke. 
The booklet also uses pie charts to illustrate the potential risk 
of stroke and how this risk is reduced using different 
treatments. During the intervention session the patients 
calculate their personal risk of stroke and identify which 
treatment they would be recommended [using CHADS2 risk 
stratification acronym (Gage, Waterman, & Shannon, 2001)]. 
Patients are also encouraged to document and discuss their 
own action plan for stroke risk reduction. 
Provide information on consequences 
Identifying a control for illness/symptoms 
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Treatment DVD, Booklet The consultant cardiologist describes the need for warfarin 
and reasons for prescribing it within the DVD. There is further 
explanation of how antiplatelet [aspirin] and anticoagulant 
[warfarin] treatments work on different components within the 
blood. A pie chart illustrates the risks associated with warfarin 
i.e. bleeding and what types of bleeding can occur. 
Identifying a control for illness 
Provide information on consequences 
INR  DVD, 
Booklet, 
Patient Diary 
Explanation of the process of INR monitoring and how to 
maintain an INR within therapeutic range are presented in 
various formats within the DVD. Lifestyle recommendations 
[including diet, alcohol intake and other medications and 
supplements] are given with visual examples. Further, a mock 
lifestyle consultation for each recommendation is presented. 
Finally patient narratives give examples of the changes that 
other patients have made in order to maintain their INR within 
therapeutic range. Patients are encouraged to formulate their 
own personal action plan which includes personal lifestyle 
changes, in order to maintain INR control. They are also 
asked to keep a self-monitoring diary for the first two weeks 
following the intervention session; this includes monitoring 
lifestyle factors that affect INR control.  
Identifying a control for illness 
Prompt self-monitoring of behaviour 
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Memory aids DVD Patient narratives within the DVD give examples of the 
memory aids that patients use for remembering to take their 
tablets. The consultant cardiologist also gives instructions on 
what actions to take if patients miss a dose of warfarin. 
Provide opportunities for social comparison 
Teach to use prompts/cues 
Provide information on consequences, 
provide instruction 
Target unintentional non-adherence 
Side effects 
 
 
DVD, Booklet Patients give narrative examples on the DVD of the side 
effects they have experienced. These include bleeding, 
bruising, or in some cases no side effects at all. Patients also 
give examples of their initial concerns about bleeding side 
effects and how they overcame these concerns. The 
consultant cardiologist provides safety information on the DVD 
including what to do if patients experience bruising and/or 
bleeding side effects. Both patient narratives and the 
consultant explain how to ensure that medications are 
compatible with warfarin. 
Provide opportunities for social comparison 
Provide information on consequences 
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Patient 
barriers 
DVD, 
Worksheet 
Patients describe their initial concerns about their diagnosis 
and treatment, and how they have coped with them. The 
consultant cardiologist describes the impact of AF and 
anticoagulation on quality of life and psychological health. 
During the discussion and using the worksheet patients are 
encouraged to discuss their own concerns about their illness 
and treatment, including ways in which they may overcome 
any perceived psychological barriers. 
Provide opportunities for social comparison 
Prompt barrier identification 
Target intentional non-adherence 
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4 Method 
 
The development of the TREAT intervention began in February 2009, a process which took 
10 months. This process also included setting up the randomised controlled trial, which 
would form the evaluation of the intervention, including gaining ethical approval and consent 
from the local research and development group.  This chapter documents the quantitative 
methods included in the trial evaluation (See Figure 4.1 for trial procedure timeline). 
 
4.1 Patients 
 
Between December 2009 and May 2011, all AF patients newly referred for anticoagulant 
therapy at the outpatient AF or OAC clinics at City Hospital, Sandwell District General 
Hospital, Good Hope Hospital, Russell’s Hall Hospital and Heartlands Hospital who met the 
inclusion criteria, were eligible to participate.  The diagnosis of AF was made by a 
cardiologist or general practitioner and documented by 12-lead electrocardiogram (ECG) or 
holter monitoring, demonstrating the presence of rapid, irregular fibrillatory waves and/or 
irregular ventricular response (Lip & Tse, 2007). Individualised annual risk of stroke was 
determined using stroke risk stratification schemes. At the beginning of the recruitment 
phase the most common stroke risk stratification schemes used were the NICE guidelines 
(low/moderate/high risk) (NICE, 2006) and CHADS2 (Gage, Waterman, & Shannon, 2001). 
Those patients at moderate to high risk of stroke (CHADS2 score ≥2) were eligible for OAC. 
In August 2010 new guidelines were published and therafter patients were stratified 
according to the latest ESC guidelines (ESC, 2010) and the updated CHA2DS2-VASc system 
(see section 1.2.3.2).  Those patients with a CHA2DS2-VASc score ≥1 were eligible for OAC 
under the new guidelines. Patients who were eligible for OAC therapy received a standard 
explanation of the need for such therapy, and the risks/benefits of OAC treatment. Those 
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patients who were accepting of anticoagulant therapy with warfarin, were approached to 
participate in the present study.  Patients were excluded from participation if they were aged 
<18 years old, had any contraindication to warfarin, had previously received warfarin, had 
valvular heart disease, were cognitively impaired or had dementia, were unable to speak or 
read English, or had any disease likely to cause their death within the subsequent 12 
months. 
 
Power for the primary endpoint was calculated based on sample size calculations employed 
by Connolly and colleagues (Connolly, et al., 2008). A sample size of 78 patients (based on 
a 20% attrition rate) in each group was estimated to provide at least 95% power to detect a 
difference of 3% in the standard deviation of the TTR of INR, at a significance level of 0.05.  
This calculation assumes that usual care would have slightly poorer INR control than 
intervention (TTR between 58-65% in usual care and ≥65% in the intervention). 
 
For the secondary endpoint of improvement in knowledge following the intervention, the 
sample size was calculated based a study by Khan and colleagues (Khan, Kamali, 
Kesteven, Avery, & Wynne, 2004).  A sample size of 100 patients (allowing for a 20% 
attrition rate in completion of the questionnaires) would have at least 80% power to detect an 
18.5% increase in knowledge about the condition and factors affecting INR control between 
baseline and follow-up.   
 
During the study time period, 619 patients with documented AF, not currently on 
anticoagulant therapy, were assessed for eligibility. Three hundred and thirty one (53%) of 
the patients assessed were eligible for participation within the trial.  Of those patients 
excluded from the study, 68 (21%) were scheduled for cardioversion, 156 (50%) had 
previously received warfarin, 24 (8%) had valvular heart disease, 63 (20%) were cognitively 
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impaired and 4 (1%) had terminal cancer that prevented them from taking part. Of 331 
eligible participants, 234 (71%) declined to participate, most commonly due to mobility 
issues and time constraints. A further 97 (29%) chose to participate, provided written 
informed consent, and completed a baseline questionnaire. During the randomisation 
process 46 patients were randomised to the intervention group and 51 were randomised to 
usual care (for recruitment flow diagram see Figure 4.2). 
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Figure 4.1: Gant chart of study procedure 
 
 
2009 2010 2011 
  J F M A M J J A S O N D J F M A J J A S O N D J F M A M J J A S O N D 
Ethics and R&D approval                
Study set-up                       
Focus groups & 
transcription             
Qualitative data analysis             
Patient booklet edit, 
design and print               
DVD film and edit               
TREAT study recruitment                                       
Quantitative data analysis                           
Thesis write-up                                                                       
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4.2 Procedure 
 
All patients with documented AF, who were accepting of OAC were approached to 
participate in this study following their first outpatient appointment, prior to commencing 
warfarin treatment. The purpose of the study was explained to the patient and they were 
subsequently given an information sheet (see Appendix 1) detailing the study. The 
investigator then posted baseline questionnaires to the home address of patients willing to 
participate. Where the investigator could not explain the aims of the study face-to-face, 
patients were contacted by telephone. The research protocol and protocol amendments 
were approved by the Black Country Local Ethics Research Committee.  Written informed 
consent was provided by each patient. 
The telephone or face-to-face interview permitted the collection of social and demographic 
data including: age, gender, occupational status, number of years in education, body mass 
index (BMI), postcode (for socio-economic status index) and ethnicity. The patients were 
also posted a series of baseline questionnaires:  The Beliefs about Medication Scale (Horne, 
Weinmann, & Hankins, 1999), the Hospital Anxiety and Depression Scale (Zigmond & 
Snaith, 1983), the Brief Illness Perception Questionnaire (Broadbent, Petrie, Main, & 
Weinmann, 2006), the Atrial Fibrillation Quality of Life Questionnaire (Badier, Arribas, 
Ormaetxe, Peinado, & Sainz de los Terreros, 2007), and the Atrial Fibrillation Knowledge 
Questionnaire (Lane, Ponsford, Shelley, Sirpal, & Lip, 2006) to complete. Patients completed 
their baseline questionnaires at home and were provided with a stamped addressed 
envelope to return them. Further interrogation of hospital records allowed for collection of 
baseline clinical measures (e.g. body mass index (BMI), AF history, ECG, blood pressure, 
left ventricular function). 
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Figure 4.2: Consort flow diagram illustrating recruitment process and follow-up.
 
Assessed for eligibility 
Excluded (n=315) 
• Due for cardioversion 
(n=68) 
• Previous warfarin (n=156) 
• Cognitive impairment 
(n=63) 
• Valvular heart disease 
(n=24) 
• Terminal cancer (n=4) 
 
Declined to participate 
(n=234) 
• Time consuming 
• Mobility 
Discontinued study (n=0) 
Lost to follow-up (questionnaires)  
(n= 14) 
Allocated to intervention (n=46) 
• Received allocated 
intervention (n=43) 
• Did not receive allocated 
intervention (n=3; were unable 
to attend the intervention 
session) 
Discontinued study 
(n=2) 
1x due to mental health 
problems 
1x questionnaire 
burden 
Lost to follow-up 
(questionnaires) (n=26) 
Allocated to usual care  
(n= 51) 
Received usual care (n=54) 
 
Allocation 
Follow-Up 
Randomised (n=97) 
SW OAC (n=28); City AF 
(n=17); GH (n=2); City OAC 
(n=9); RH OAC (n=33); 
Heartlands (n=8) 
Enrolment 
 
At the stage of randomisation the primary researcher checked to ensure the patient met the 
eligibility criteria and did not meet any of the exclusion criteria. If the patient was willing to 
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take part, consent was obtained prior to randomisation. A computer generated list 
randomised patients in blocks of four and on an individual basis with stratification by (a) age 
(<70 and ≥70 years)/sex and (b) specialist AF clinic versus ‘general’ cardiology clinic, to 
receive either ‘usual care’ or the intensive educational intervention, in addition to ‘usual 
care’. The randomisation schedule was designed by an independent trials unit and the 
random allocation was obtained by the researcher telephoning an associate researcher (who 
was not involved in the data collection or data entry). The primary researcher was blinded to 
patient identification to ensure allocation concealment.  A third researcher matched patient 
identification numbers (generated by the primary researcher) with randomisation codes 
(generated by the associate researcher). Once the random allocation was obtained, baseline 
data was collected and an intervention session arranged. Patients who refused to be 
randomised were offered their respective hospitals ‘usual care’ package. Follow-up 
questionnaires were sent to patients via the post at one, two, and six months after 
randomisation. Completeness of the questionnaires was checked by another researcher (not 
involved in the analysis of the data) and the patient was contacted via telephone if any 
questions were not completed. 
 
4.2.1 Usual Care 
 
Fifty one patients were randomised to receive usual care alone. All patients receive the 
standard ‘yellow booklet’ to identify that they are taking OAC therapy.  This book contains is 
generic for all patients taking OAC (including deep vein thrombosis, pulmonary embolism 
etc) and including key safety information including dietary advice (a brief paragraph 
instructing patients not to miss meals and keep diet stable), medication (to inform 
GP/physician if they start a new medication) and emergency contact information. The usual 
care booklet does not provide any information on indications for warfarin (i.e. AF). A recent 
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addition to this process is the use of an education check list, used by prescribers. This 
includes areas the physician should cover in their initial warfarin consultation, including when 
and how to take tablets, factors that affect metabolism, and INR testing. 
 
On observation, the usual care procedure varied slightly between the recruiting hospitals. At 
City and Heartlands Hospitals all new patients were seen within the general OAC clinic for 
an INR check. They were then counselled for approximately 5-10 minutes individually by the 
pharmacist or specialist nurses to discuss individual concerns. At Good Hope Hospital a 
specialist nurse manages a daily clinic for new patients; each patient has their INR checked 
and are counselled individually for approximately 10-15 minutes. This counselling also 
included a more comprehensive explanation of the link between AF and thrombosis. At 
Russell’s Hall Hospital patients are counselled firstly as a group (nurse talks; this takes 
approximately 15-20 minutes). Patients are then seen individually to prescribe the dose and 
discuss personal recommendations. This process is generic for all patients taking OAC, and 
not specific to AF.  
 
4.2.2 Educational Intervention 
 
Forty six patients were randomised to the intensive educational intervention arm of the 
study. Three patients did not receive the intervention. Two patients were ill during the month 
following warfarin commencement; one patient could not be contacted. Those patients that 
did not receive the intervention were moved to the usual care arm. These participants 
attended a group session where they were shown a DVD containing information about the 
need for oral anticoagulants, the risks and benefits associated with OAC therapy, potential 
interactions with food, drugs, and alcohol, and the importance of monitoring and controlling 
their INR. The DVD (see Appendix 3) also included an expert patients’ discussion of 
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experiences with AF and warfarin. The group sessions were interactive and patients were 
given the opportunity to ask questions throughout. Patients were also given a copy of the 
intervention booklet. The booklet (see Appendix 3) served to reinforce the information and 
enable the patient to refer to it in the future.  The intervention development and components 
are described in more detail in Chapter 3. 
 
4.3 Measures 
 
4.3.1 Primary outcome: Time within therapeutic range 
 
All patients attended the anticoagulant outpatient clinic at their respective hospital to have 
their INR checked using a capillary sample.  The frequency of the INR visits was at the 
discretion of the OAC clinic. The OAC clinic staff were blinded to the intervention arm the 
patient was randomised to, ensuring monitoring and follow-up were as ‘naturalistic’ as 
possible.  Every INR result, from baseline to the end of the study (6-months), was recorded 
on an INR log sheet. INR is a measure of blood clotting time. It gives an indication of 
whether patients are within the therapeutic range necessary to reduce their risk of clotting 
and potentially stroke. The INR reading is extremely sensitive and can be influenced by non-
adherence to medications and lifestyle recommendations. Thus, INR is an objective 
measure of patient adherence. The proportion of time each patient spent in the therapeutic 
INR range (2.0 to 3.0) was calculated by the method of linear interpolation using data from 
months one to 12 (to allow attainment of the correct dose of warfarin during the first four 
weeks). Time spent within target therapeutic range (TTR) was calculated using a method 
developed by Rosendaal and colleagues (Rosendaal, Cannegieter, van der Meer, & Briet, 
1993). Linear interpolation assumes that the INR value between two measurements will vary 
linearly from the value of the first, to the values of the second INR measurement. The INR is 
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treated as gradually increasing or decreasing over the interval. Person-time spent at each 
intensity of anticoagulation can then be calculated as a percentage of total person-time 
which lies within the target range. INR results from the first seven days after treatment is 
started or restarted, the time after permanent discontinuation of OAC, and time >5 days from 
temporary discontinuation, were not included in the calculation. Whilst it was not possible to 
blind the researcher to which arm patients were randomised to for the purpose of 
intervention facilitation, all of the follow-up data, including INR results were collected and 
added to a coded database. Patients were followed-up by an associate researcher, who had 
not input into the study to reduce bias. The randomisation code was only broken when the 
data had been analysed. However, the same researcher (DEC) delivered the intervention 
and carried out the analysis. 
 
4.3.2 Secondary outcome: Patient knowledge 
 
The knowledge questionnaire was previously designed and piloted by our research group 
(Lane, Ponsford, Shelley, Sirpal, & Lip, 2006) to assess patients’ knowledge of their 
condition, AF, and anticoagulant treatment. The 14 questions encompass knowledge on the 
name of their condition; their awareness of consequences of, and severity of, the disease 
and potential benefits/side effects of anticoagulant therapy (see Appendix 2).The questions 
can be divided into two subscales (1) knowledge of atrial fibrillation and (2) knowledge of 
oral anticoagulation. Patients gave qualitative answers to questions which were later coded, 
indicating whether the patients were ‘aware’ or ‘not aware’ of the answer. Some of the 
questions provided qualitative evidence such whether patients perceived AF as a low risk, 
moderate risk or high risk condition. Seven questions directly tested patients’ knowledge of 
their treatment and their condition. Where questions were answered correctly they were 
given a score of one, this gave a total knowledge score of zero to seven. The original piloted 
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questionnaire was delivered as an interview. The wording of the questions was adapted 
slightly to ensure they were suitable as a postal questionnaire. 
 
4.3.3 Explanatory outcomes 
 
4.3.3.1 The Beliefs about Medication Scale (BMQ) 
 
The BMQ (Horne, Weinmann, & Hankins, 1999) is an 18-item questionnaire that has been 
widely used in studies assessing beliefs about medications in patients with a variety of 
chronic conditions including rheumatoid arthritis (Neame & Hammond, 2005), asthma 
(Jessop & Rutter, 2003), Type II diabetes (Farmer, Kinmonth, & Sutton, 2006) and 
depression (Aikens, Nease, Nau, Klinkman, & Schwenk, 2005). It was designed to assess 
commonly held beliefs about medication; including both specific and general medication 
beliefs (Horne, Weinmann, & Hankins, 1999). 
 
The BMQ was derived from a pool of items (from common beliefs about medications within 
the literature). Further items were also formed from interviews with haemodialysis and 
myocardial infarction patients. Principal Component Analysis (PCA) found a high degree of 
separation between general and specific medication beliefs. This resulted in an 18-item, 4-
factor structure. The BMQ-Specific comprises two 5-item factors assessing beliefs about 
necessity of prescribed medication (Specific-Necessity) and concerns about prescribed 
medication based on beliefs about danger of dependence, long-term toxicity and the 
disruptive effects of the medication (Specific-Concerns). The BMQ-General comprises two 4-
item factors assessing beliefs that medicines are addictive, harmful, poisons which should 
not be taken continuously (General-Harm) and that medicines are over-prescribed by 
doctors (General-Overuse). The two sections can be used separately or in combination.  
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Items within each scale are both positive and negative statements. Each statement is scored 
using a five-point Likert scale.  A score of “1” indicates that a patient strongly disagrees, 
ranging to a score of “5” if the patient strongly agrees with the statement. The patients are 
asked first to score a set of statements based on their beliefs about their specific AF 
medications. They are then asked to score a second set of statements based on their beliefs 
about medications in general. Scores for each scale are summed, divided by the total 
number of items in the scale, and multiplied by 5 to give a scale score ranging from 5 to 25. 
Higher scores on the scales indicate stronger beliefs in the concepts represented by the 
scale. The necessity-concerns differential is also calculated by subtracting the concerns 
subscale from the necessity subscale score. If the score on the differential is negative, this 
indicates that the patients rate their concerns about their medication higher than their beliefs 
about the necessity of taking it. If the score is positive, then the opposite applies; suggesting 
that a patient’s belief in the necessity of taking the medication is stronger than their concerns 
about potential adverse effects. Scores range from -20 to 20. 
 
Discriminant validity of the scales was originally tested on the basis of each scale’s ability to 
distinguish between different illnesses and treatment modalities. For example, as expected, 
patients attending a complementary clinic had significantly higher scores on the General-
Overuse (t=5.89, p<0.001) and General-Harm (t= 1.94, p<0.05) scale than those patients 
presenting a prescription at a pharmacy (Horne, Weinmann, & Hankins, 1999). 
 
The assessment of criterion validity of each of the sub scales was based on several 
predictions. For example, the subscale Specific-Necessity should predict that patients with 
stronger beliefs in the necessity of their medication would be less likely to cope without it. 
This was evident as there were negative correlations between the scale scores and the 
statement “I can cope without my medicines” (ρ= -0.44; p<0.001).  
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BMQ-Specific and BMQ-General scales have satisfactory internal consistency scores in all 
of the patient groups tested (asthmatic, renal, diabetic, cardiac, psychiatric and general 
medical); with the exception of General-Harm scale in three groups. Cronbach’s alpha 
coefficients range from α = 0.47 to 0.83 for General-Harm, 0.60-0.80 for General-Overuse, 
0.63-0.80 for specific concerns and 0.55- 0.80 for Specific-Necessity. The low internal 
consistency of the General-Harm sub-scale was found in some illness groups (asthmatic, 
cardiac and general) and not others. The authors attributed this disparity to the premise that 
patients with certain illnesses develop a more coherent representation of medication in 
general, which may be influenced by their personal experience with prescribed medication.  
 
4.3.3.2 The Hospital Anxiety and Depression Scale (HADS) 
 
The HADS is a widely used self-assessment scale for detecting states of depression and 
anxiety in the setting of a hospital medical outpatient clinic (Zigmond & Snaith, 1983). The 
scale has been used to predict post–intervention outcomes in conditions such as myocardial 
infarction (Mayou, et al., 2000); to screen for depression in patients who manage chronic 
conditions, such as diabetic patients (Engum, Mykletun, Midthjell, Holen, & Dahl, 2005) and 
as a screening tool for general hospital populations (Michopoulos, et al., 2007). 
 
The HADS is a 14-item questionnaire, incorporating an anxiety subscale (HADS-A, n=7) and 
a depression subscale (HADS-D, n=7). It is possible to obtain separate anxiety and 
depression scores, and an overall ‘distress’ score.  This test was not intended to measure 
somatic illness outcomes; hence any symptoms of anxiety and depression which were also 
related to physical disorder (i.e. such as headaches, fatigue and insomnia) were excluded. 
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Patients are presented with four statements and asked to indicate to what extent they agree 
with each statement and are given a choice ranging between “not at all” and “very often”. 
The order of the responses were alternated in an attempt to prevent response bias. The 
scoring device is not present on the patient questionnaire to prevent biased responses.  The 
scores on each item range from zero to three.  Overall scores range from zero to 42, with 
higher scores indicating greater distress. 
 
Analyses of sensitivity and specificity can also be carried out. For each scale a score of 
seven or less was classified a non-case, 8-10 a doubtful case and 11 or more a definite case 
(Zigmond & Snaith, 1983). Reliability testing revealed a 1% false positive and 1% false 
negative rate for the depression subscale; analogous figures for the anxiety scale were 5% 
and 1%, respectively (Zigmond & Snaith, 1983). The optimal balance between sensitivity 
and specificity for HADS as a screening instrument has been achieved most frequently using 
a cut-off score of ≥8 for both scales. This gives sensitivities and specificities for both sub-
scales of approximately 0.80 (Zigmond & Snaith, 1983). Bjelland and colleagues suggest 
that this cut-off score is higher in community samples (score of ≥9), but consistently found 
that with relative variability, a score of ≥8 was the optimal threshold for primary care 
populations (Bjelland, Dahl, Haung, & Neckelmann, 2002). In studies which found much 
lower cut-off values, this was attributed to differences in the administration of the scale, as in 
both studies the HADS was administered in part (as separate sub scales) or as an interview 
(Lam, Pan, Chan, Chan, & Munro, 1995; Johnson, Burvill, Anderson, Jamrozik, Stewart-
Wynne, & Chakera, 1995).  
 
The internal consistency was calculated for the original validation, anxiety item correlations 
ranged from 0.41 to 0.76 (p<0.01). Analysis of the depression scale led to the elimination of 
one weak subscale item; remaining items had correlations ranging from 0.30 to 0.60 
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(p<0.02). The weakest of the anxiety items were also removed to ensure an equal balance 
of items on the two subscales. Cronbach’s alpha coefficient of internal consistency was 
reported in 15 of the reviewed studies and ranged from 0.68-0.93 (mean 0.83) for HADS-A 
and 0.67-0.90 (mean 0.82) for HADS-D (Bjelland, Dahl, Haung, & Neckelmann, 2002). 
 
4.3.3.3 The Atrial Fibrillation Quality of Life Questionnaire (AF-QoL-18) 
 
The AF-QoL is an 18-item health-related quality of life scale, developed specifically for AF 
patients, which can be applied to any of the types of AF (e.g. paroxysmal or permanent) 
(Badier, Arribas, Ormaetxe, Peinado, & Sainz de los Terreros, 2007). The pool of items was 
derived from a bibliography review of the most relevant descriptions of the impact of AF on 
patient quality of life. Items generated formed the basis for an elaborated survey for 
identifying AF-related symptoms, which was then assessed by three AF specialists. Further 
specialist focus groups were undertaken to eliminate any discrepancies and semi-structured 
interviews of AF patients identified appropriate phrases and expressions. By means of 
Classic Test Theory (Krahn, Manfreda, Tate, Mathewson, & Cuddy, 1995), Item Response 
Theory (Croker & Algina, 1986) and Rasch Analysis (Bond & Fox, 2001), the original item 
pool was reduced to 40. Following a pilot study and subsequent factor analysis seven items 
dealing with psychological QoL and 11 items focussing on physical QoL remained (Badier, 
Arribas, Ormaetxe, Peinado, & Sainz de los Terreros, 2007). 
 
Response scales include instructions to indicate how strongly the patient agrees with each 
statement as a possible outcome of their AF. Responses range from “strongly disagree” to 
“strongly agree”. The scoring for each dimension and the global scoring are calculated by 
adding up the corresponding items and standardizing the result. Values close to zero show a 
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worse health state while values close to 100 show a better health state of the patient with 
AF. In order to standardise the scoring, recommended formulas were used.  
 
Internal consistency is excellent for the global questionnaire (α 0.91) and both the 
psychological AF-7 (α 0.89) and physical AF-11 (α 0.90) domains. The original AF-QoL-40 
and reduced AF-QoL-18 versions were also compared and correlations were above 0.80 for 
the original instrument and the each of the reduced domains. Each factor showed high 
correlation with the AF-QoL-18 global score, but correlations with the reduced domains were 
lower (α 0.51) (Badier, Arribas, Ormaetxe, Peinado, & Sainz de los Terreros, 2007). 
 
4.3.3.4  The Brief Illness Perception Questionnaire (IPQ-B) 
 
The original Illness Perception Questionnaire is a widely used measure of illness 
representations outlined by Leventhal’s Self-Regulatory Model (Leventhal, Nerenz, & Steele, 
1984; Leventhal, et al., 1997). The model suggests five components underlie the cognitive 
representation of illness. These translate to the five scales assessing (i) identity- symptoms 
patients associated with the illness and what they attribute to the illness; (ii) consequences- 
expected physical, social and economic implications; (iii) timeline- acute, chronic or cyclical 
duration; (iv) causes- personal ideas about causes; and (v) cure/control- the extent to which 
a patient believes they will recover from or control their illness. Items of the original IPQ 
(Weinman et al, 1996) were theoretically-derived to assess each of the above components.  
Subsequent studies following the initial validation revealed a variation in internal consistency 
of the subscales and a revised version was released, incorporating changes to the 
cure/control and timeline subscales, i.e. the revised IPQ-R (Moss-Morris, Weinman, Petrie, 
Horne, Cameron, & Buick, 2002). Analysis of the data suggested that items loaded onto two 
separate factors within the cure/control subscale; (1) personal control and self-efficacy 
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beliefs and (2) belief in the treatment or recommended advice. Hence, two separate 
subscales were derived. Problems with low internal consistency on the timeline subscale led 
to the development of new items to assess cyclical time beliefs, which were previously 
overlooked (Moss-Morris, Weinman, Petrie, Horne, Cameron, & Buick, 2002). The revised 
questionnaire also incorporated items assessing emotional representation, a concept which 
formed part of the original model but was not included in the original version. 
 
The IPQ-R has over 80 items and is particularly prohibitive where patients are very ill, elderly 
and when repeated measures designs are employed (Broadbent, Petrie, Main, & Weinmann, 
2006). Thus a Brief Illness Perception Questionnaire (Brief-IPQ) was devised using a single-
item scale approach to assess perceptions on a linear scale (Broadbent, Petrie, Main, & 
Weinmann, 2006). The Brief-IPQ has eight items which represent the best summarised 
question from each subscale of the IPQ-R. All of the items are rated on a zero to ten 
response scale. The first five items assess illness representations i.e. consequences (item 
1), timeline (item 2), personal control (item 3), treatment control (item 4) and identity (item 5). 
Two items assess emotional representations i.e. concern (item 6) and emotions (item 8). 
One item assesses illness comprehensibility (item 7). The final item is part of the causal 
scale from the IPQ-R; patients are asked to list in rank-order the three most important factors 
that have caused their illness. Responses can be grouped into categories (e.g. such as 
heredity, stress and lifestyle) and analysed. The term ‘illness’ in the questionnaire is 
replaced with AF and the term ‘treatment’ replaced with warfarin, to ensure the scale is 
illness specific.  
 
Structural validity was determined using principal component analysis (PCA). Items loading 
onto more than one factor were eliminated and items with loadings of more than 0.5 were 
interpreted as being representative of a particular factor. Good test-retest reliability was 
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demonstrated for both time points ranging from .48 to .70 (p<.001) at 3 weeks, and .42 
(p<.01) to .75 (p<.001) at 6 weeks (Broadbent, Petrie, Main, & Weinmann, 2006).  
Concurrent validity measures were carried out in the renal, diabetes and asthma samples, 
patients were asked to complete both the Brief-IPQ and the IPQ-R. The majority of items 
correlated moderately and significantly with their corresponding subscale; personal control 
and treatment control α = .80; emotional representations α =.88) (Broadbent, Petrie, Main, & 
Weinmann, 2006). Data from renal dialysis inpatients was used to evaluate test-retest 
reliability over a three week period. The dimensions showed good stability over this period 
with significant but low correlations (.33 and .32; p<.001) (Broadbent, Petrie, Main, & 
Weinmann, 2006).  
 
4.3.3.5 Reliability Analysis for the TREAT sample 
 
Where the measures used for the TREAT study were recorded as scale data and included 
more than one item for each scale they were analysed for internal consistency. Baseline 
results from the TREAT study sample were entered into the analysis. All of the scales 
demonstrated high levels of internal consistency with α scores ranging from 0.632 to 0.914 
(See Table 4.1). 
 
Table 4.1: Cronbach’s alpha coefficient outcomes for the TREAT study sample 
 Number of items Cronbach’s alpha coefficient 
HADS-Anxiety 7 0.884 
HADS-Depression 7 0.821 
BMQ-General harm 4 0.632 
BMQ-General overuse 4 0.833 
BMQ-Specific concern 5 0.767 
  
175 
 
BMQ-Specific necessity 5 0.796 
AF-QOL-Physical 8 0.914 
AF-QoL-Psychological 7 0.868 
 
4.3.4 Clinical Variables 
 
Baseline clinical variables including concomitant medications, type of AF (paroxysmal, 
persistent, and permanent), duration of AF, ECG details, blood pressure, left ventricular 
function, smoking status, and alcohol intake were recorded from patients’ hospital records. In 
addition, the numbers of stroke risk factors (CHADS2 and CHA2DS2-VASc) were also 
documented from patient records (ESC, 2010; Gage, Waterman, & Shannon, 2001) (for 
more detail on these guidelines see section 1.2.3.2). IMD scores were calculated using 
patients post-code to an indication of socio-economic status (from: 
https://www.npeu.ox.ac.uk/birthplace/lcm/imd).  
 
4.3.4.1 Concomitant medication  
 
Prescription of all other concomitant medications at baseline was also recorded. In 
particular, any other antithrombotic treatment (e.g. heparin, clopidogrel, and aspirin), 
antihypertensives, antiarrhythmics, metabolic and anti-inflammatory treatment and other 
drugs which may affect INR, including vitamins, antibiotics H2 blockers and herbal remedies 
were documented. For example, some antibiotics, particularly co-trimoxazole, macrolides 
and fluoroquinolones increase the risk of haemorrhage when taken with warfarin, by 
inhibiting vitamin K synthesis or hepatic warfarin metabolism (Juurlink, 2007). Therefore, it 
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was necessary to record any medications which may affect whether a patient remains within 
optimum therapeutic INR range (2.0-3.0).  
 
4.3.4.2 Stroke and bleeding incidence 
 
The incidence of minor and major bleeding, stroke, TIA and mortality was recorded at each 
of the follow-up points using clinical records. Data concerning the cause of death (cardiac or 
non-cardiac), reasons for any interruption of anticoagulation and the number of, and reasons 
for hospitalisation were also recorded.  
 
Definitions of major bleeding were determined by using the International Society of 
Thrombosis and Haemostasis guidelines (Schulman & Kearon, 2005). Major bleeding 
constitutes a clinically important primary endpoint in many randomised trials, particularly in 
anticoagulation studies. Major bleeds are defined as those which result in death, are life 
threatening, cause chronic sequelae or consume major health-care resources. The criteria 
are as follows: 
 
1) Fatal bleeding, and/or  
(2) Symptomatic bleeding in critical area or organ, such as intracranial, intraspinal, 
intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment 
syndrome and/or  
(3) Bleeding causing a fall in haemoglobin level of 20 g L-1 (1.24 mmol L-1) or more, or 
leading to transfusion of two or more units of whole blood or red blood cells (Schulman & 
Kearon, 2005). 
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4.4 Study outcomes 
 
The primary endpoint is the proportion of time spent in the therapeutic INR range, 2.0 to 3.0, 
calculated by the method of linear interpolation (Rosendaal, Cannegieter, van der Meer, & 
Briet, 1993). Secondary endpoint is patients’ knowledge. Explanatory outcomes are (1) 
beliefs about medication and (2) illness representations. Ancillary analyses will explore the 
relationship between INR control and incidence of minor and major bleeding, stroke, and 
thromboembolic events (given that the trial is not powered to detect these differences).   
 
4.5 Data reduction and analysis 
 
Data was analysed using SPSS for windows (Version 18.0). All tests were two tailed, where 
p-values ≤ 0.5 they were considered statistically significant. All nominal data was coded. 
Categorical variables were analysed using the chi-square statistic. The fisher’s exact test 
was used where there were expected frequencies of less than five in any cell. Continuous 
variables were compared using independent t-tests. Where descriptive statistics suggest that 
the data was not normally distributed (or the Levene’s test for variance is significant p<0.05) 
a Mann Whitney-U test for non-parametric data was used. Analysis for the primary outcome 
was an on- treatment analysis, an intention-to-treat analysis is also included, controlling for 
any effects of drop-out or cross-over of participants. Three patients that were randomised to 
the intervention group did not receive the intervention. These patients were included as 
usual care in the on-treatment analysis, and as intervention group in the intention-to-treat 
analysis. The cross-over participants TTR results were 64%, 42%, and 62%. 
 
To measure the change in variables across time (at four time points including baseline, one, 
two and six month follow-ups) and between groups (intervention and usual care groups), 
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data for each psychological outcome was entered into separate two-factor mixed ANOVA 
analyses. Where the assumptions of the test were violated (via Mauchley’s test of sphericity 
p<0.05), a more conservative p-value was reported (Greenhouse-Geisser). 
 
To test whether outcome variables such as; beliefs about medication subscale scores and 
illness representation scores predicted TTR multiple stepwise entry multiple regression 
analyses were used. Where it was of interest to determine whether factors correlated with 
the primary outcome (TTR), but data was not normally distributed, Spearman’s correlation 
coefficient was used. This test works by ranking the data and then applying the Pearson’s 
equation.  
 
The primary analysis was a comparison of the primary outcome (TTR) between the 
intervention and usual care groups, including factors which may predict TTR. Secondary 
analysis was a comparison of knowledge scores between groups. Explanatory analyses 
considered factors which may predict the differences in TTR between groups, such as illness 
perceptions and beliefs about medication. Further analyses examined psychological 
morbidity of the two groups to ensure the intervention did not have an adverse effect on 
patients. 
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5 Results 
 
5.1 Baseline demographic characteristics of the AF patients 
 
There were 46 patients randomised to the intervention group, of which 3 crossed-over to the 
usual care arm, leaving 43 patients. Fifty two patients were randomised to usual care, but 
with the addition of the cross-over patients the group was eventually 55 patients. At baseline 
all of the intervention group patients completed the questionnaire follow-ups, three failed to 
complete all of the questionnaires in the usual care arm. The attrition rates from the 
questionnaire follow-ups increased over time, with the greatest attrition at the two month 
follow-up (see Table 5.1). 
 
Table 5.1: Attrition rates from baseline to 6 month follow-up 
 Baseline 1 month 2 months 6 months 
Usual Care 52 40 (77%)  30 (57%) 32 (61%) 
Intervention 43 32 (74%) 27 (63%) 29 (67%) 
 
Data for the primary outcome (TTR) was collected for 38 patients in the intervention group 
(minus cross-over patients) and 52 patients in the usual care arm (plus cross-over patients). 
 
5.1.1  Patient demography 
 
The demographic characteristics of the patients in the intervention and usual care groups 
are summarised in Table 5.2. No significant differences were found between the intervention 
and usual care groups with regard to age, sex, socio-economic status, education level or 
ethnicity. The mean (SD) age of the total cohort was 72.9 (8.2) years. The majority (48.5%) 
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of the patients were aged between 65 and 74 years old, male (63.6%), White British, Irish or 
European (97%), with a median (IQR) of 10 (9.5 to 12) years in education. The median 
socio-economic status scores suggest a moderate level of deprivation; however, there were 
a large variation of scores within the cohort (IQR = 9.3 to 37.1). 
 
 
5.1.2 Clinical Characteristics 
 
Analysis of the baseline clinical characteristics (Table 5.3) found no significant differences 
between the intervention and usual care groups on any of the variables including body mass 
index (BMI), type of AF, duration of AF, and alcohol/tobacco consumption. The majority of 
patients were overweight, with a mean (SD) BMI of 28.4 (5.4). There were more paroxysmal 
AF patients (30.9%) overall than persistent and permanent AF patients, although there were 
no significant differences between groups. Most of the patients had only been recently 
diagnosed with AF (median 3.0 months; IQR 1.0-14.0). Both patient groups reported drinking 
fewer units of alcohol than the recommended weekly number (Median=4; IQR = 0 to 12); few 
patients were current smokers (4%), but nearly half (46.5%) of the total patient cohort were 
ex-smokers. 
 
5.1.3  Stroke risk factors 
 
There were no significant differences between patients in the intervention and usual care 
groups in their baseline stroke risk factors (Table 5.4). Both groups had a high proportion 
(65.7% of total cohort) of hypertensive patients. More patients in the usual care group were 
75 or older (42.6%) than in the intervention group (30.2%), although this difference was not 
significant. The median CHADS2 score for the total cohort was 2 (IQR 1-3), suggesting a 
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high risk of stroke among patients overall. More patients had suffered a previous TIA 
(10.1%) than a previous stroke (5.1%).  
 
5.1.4  Current medication 
 
There were no significant differences between the intervention and usual care groups in their 
baseline prescribed medication (Table 5.5). Only about one third of the patients were 
prescribed a beta blocker (36.4%), statin (34.3%), and/or diuretic (31.3%), with a slightly 
higher proportion receiving an angiotensin-converting enzyme inhibitor (ACE-I; 40.4%). Of 
note, few patients received antiplatelet therapy for stroke thromboprophylaxis prior to 
initiating warfarin. 
 
5.1.5  Baseline psychological factors 
 
Patients exhibited similar baseline levels of depression and anxiety in both groups (Table 
5.6). However, the intervention group demonstrated a significantly worse baseline quality of 
life (p=0.01) than the usual care group. Anxiety scores were relatively high (in both groups) 
at baseline. All patients demonstrated good baseline knowledge scores, with patients 
answering more than half of the questions correctly. 
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Table 5.2: Patient baseline demographic characteristics 
 
Demographic characteristics All participants Intervention Usual Care x2 t z p-value 
Age, years 72.9 (8.2) 72.5 (7.4) 73.2 (8.7)  0.43  0.67 
Age, years 
  <65 
  65-74 
  ≥75 
 
14(14.4) 
47(48.5) 
36(37.1) 
 
5(11.6) 
25(58.1) 
13(30.2) 
 
9(16.7) 
22(40.7) 
23(42.6) 
2.90    
0.25 
Sex 
 Males 
 Females 
 
63(63.6) 
34(34.3) 
 
29(67.4) 
14(32.6) 
 
34(63) 
20(37) 
0.21    
0.67 
Ethnicity 
White (British, Irish and 
European)‡ 
 
96 (97) 
 
43(100) 
 
53(98.1) 
0.81    
1.00 
Years in education † 10 (9.5 to 12) 10 (10 to 12) 10 (9 to 12)   -0.41 0.82 
Socio-economic status† 20.9 
(9.3 to 37.1) 
23.6 
(9.7 to 37.9) 
20.6 
(8.4 to 34.7) 
  -0.59 0.61 
‡ Only one patient in the study was not White British/Irish/European; Chi-squared, independent samples t-test, Mann-Whitney and Fishers 
exact tests used as appropriate; Mean (SD) or N (%) are reported where appropriate; † Median (IQR) is reported where data is not normally 
distributed. 
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Table 5.3: Patient baseline clinical characteristics 
Clinical characteristics All participants 
 
Intervention 
 
Usual Care 
 
x2 t z p-value 
Body Mass Index (kg/m2) 28.4 (5.4) 28.9 (5.6) 27.98(5.22)  -0.85  0.39 
Type of AF 
  PAF 
  Persistent 
  Permanent 
 
30 (30.9) 
22 (22.6) 
24 (24.7) 
 
12(31.6) 
11(28.9) 
15(39.5) 
 
18(47.4) 
11(28.9) 
9(23.7) 
0.21    
0.26 
Duration of known AF in months † 3.0 (1.0 to 14.0) 3.0 (1.0 to 24.0) 2.0 (1.0 to 9.75)   -0.47 0.52 
Alcohol units per week † 4.0 (0 to 12) 4.0 (0 to 14) 3.5 (0 to 10)   -0.92 0.39 
Current smoker 
Ex smoker 
Non smoker 
4 (4) 
46 (46.5) 
46 (46.5) 
2 (4.7) 
23 (53.5) 
18 (41.9) 
2 (3.8) 
23 (43.5) 
28 (42.8) 
1.15   0.63 
Chi-squared, independent samples t-test, Mann-Whitney and Fishers exact tests used as appropriate. 
Mean (SD) or N (%) is reported where appropriate; † Median (IQR) is reported where data is not normally distributed. 
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Table 5.4: Patient baseline stroke risk factors 
Stroke risk factors 
N (%) 
†Median (IQR) 
All 
participants 
 
Intervention 
 
Usual 
Care 
 
x2 z p-value 
C Congestive 
Heart Disease/ 
LV dysfunction‡ 
17 (17.2) 9 (33.3) 8 (36.4) 0.05  1.00 
H Hypertension 65 (65.7) 33 (86.8) 32 (82.1) 0.33  0.39 
A Age ≥75 36 (37.1) 13 (30.2) 23 (42.6) 2.90  0.25 
D Diabetes 
mellitus 
15 (15.2) 7 (18.9) 8 (21.1) 0.05  0.52 
S2 Stroke/TIA 5 (5.1) 1(2.6) 4 (10.3) 2.78a  0.35 
 10 (10.1) 5(13.2) 5 (12.8) 0.01  1.00 
 Total CHADS2 
score† 
2 (1-3) 2 (1-2) 2 (1-3)  -0.89 0.29 
LV = Left ventricular; TIA = transient ishaemic attack, Chi-squared or Mann Whitney-U tests 
were used where appropriate, aFisher’s exact tests used to calculate p-value. 
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Table 5.5: Patient baseline medication 
Current 
medication  
n (%) 
All 
participants 
 
Intervention 
 
Usual Care 
 
x2 p-value 
Calcium channel 
blockers 
23 (23.2) 9(21.4) 14(26.9) 0.38 0.63 
Beta-blocker 36 (36.4) 20(47.6) 16(30.8) 2.79 0.14 
Anti-platelet 11 (11.1) 6 (14) 5 (9.3) 0.49a 0.53 
Angiotensin-
converting-
enzyme inhibitor 
40 (40.4) 21(50) 19(36.5) 1.72 0.21 
Statin 34 (34.3) 16(38.1) 18(34.6) 0.12 0.83 
Digoxin 16 (16.2) 7(16.7) 9(17.3) 0.01 1.00 
Diuretic 31 (31.3) 15(35.7) 16(30.8) 0.26 0.66 
aFisher’s exact test used to calculate p-value, Chi squared test used were appropriate, n (%) 
reported. 
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Table 5.6: Patient baseline scores for psychological variables 
Psychological factors All participants 
 
Intervention 
 
Usual Care 
 
t z p-value 
Anxiety† 7.0 (3.0 to 10.0) 6.0 (3.8 to 9.0) 7.0 (3.0 to 10.7)  -0.28 0.76 
Depression† 4.0 (2.0 to 8.0) 4.0 (2.0 to 7.0) 4.0 (2.0 to 8.0)  -0.07 0.97 
Quality of life 45.9 (22.2) 39.7 (20.2) 50.9 (22.6) -0.14  0.01 
Knowledge 5.6 (2) 5.9 (1.8) 5.4(2.1) -1.05  0.29 
Independent t test and Mann-Whitney tests used as appropriate. Mean (SD) reported; † Median (IQR) is reported where data is not normally 
distributed. 
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5.2 Primary outcome analyses 
 
5.2.1 Time within therapeutic range 
 
Patients receiving the intervention spent significantly more time in therapeutic INR range 
than patients receiving usual care (78.5% vs. 66.7% respectively; t=-2.65; p=0.01, see Table 
5.7 and Figure 5.1). Patients in the usual care group spent significantly more time with a 
sub-therapeutic INR (INR<2.0) than patients in the intervention group (23.1% vs. 13.3% 
respectively; t=2.51; p=0.01). There were no significant differences between the groups in 
the proportion of supra-therapeutic INRs. Both the intervention and usual care groups 
attended the anticoagulant clinic a similar number of times (mean number of visits 6.7 vs. 7.2 
respectively; t=0.94; p=0.35). 
 
Table 5.7: The proportion of time spent within therapeutic range stratified by treatment 
group. 
 
   On-treatment analysis Intention-to-treat 
analysis 
Mean % 
(SE) 
 
Intervention* 
(n=38) 
Usual*Care 
(n=52) 
t p-value t p-value 
TTR Overall 
INR>3 
INR<2 
Number INR 
visits 
78.5 (3.2) 
10.2 (2.9) 
13.3 (2.2) 
6.7 (2.0) 
66.7 (3.0) 
13.2 (2.3) 
23.1 (2.9) 
7.2 (3.0) 
-2.65 
0.82 
2.51 
0.94 
0.01 
0.42 
0.01 
0.35 
-2.18 
0.98 
1.91 
0.28 
0.03 
0.33 
0.06 
0.83 
INR = international normalised ratio, TTR = time in therapeutic range, *percentage of TTR is 
based on the on-treatment analysis
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5.2.2 Predicting time in therapeutic range 
 
To establish whether any of the key baseline demographics influenced the TTR, sex, age 
and education were included in a multiple regression model as predictors of TTR. Whilst 
TTR was slightly higher in women than in men (74.74% vs. 70.23% respectively; t=-0.93, 
p=0.37), differences were not significant. There were also no significant differences between 
age categories (<65, 65-74, ≥ 75 years; p=0.48), or years spent in education (p=0.31).  
 
Figure 5.1: Graph illustrating mean TTR percentages for each patient, between groups.  
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5.3  Secondary outcome analyses 
 
5.3.1 Knowledge 
 
5.3.1.1  Knowledge of atrial fibrillation 
 
There are no baseline differences between the intervention and usual care groups on any of 
the knowledge questions (Table 5.8). Baseline scores were high for both groups, with 90.7% 
of the intervention group and 82.7% of the usual care group aware of their primary diagnosis 
of AF. At one month more patients in the intervention group were aware that AF is a cardiac 
rhythm abnormality (96.9% vs. 82.9%; χ2 3.58; p<0.05). At the one month follow-up the 
intervention group were significantly more aware of the risks of AF (i.e. predisposing to 
stroke and clots) than the usual care group (χ2 9.30; p<0.01). However, there are no 
significant differences between groups for any of the other knowledge questions relating to 
AF. 
 
5.3.1.2 Knowledge of oral anticoagulation 
 
There were no baseline differences between groups in their knowledge of any of the 
questions relating to OAC (Table 5.9). However, at the one month follow-up there were 
significant differences between the intervention and usual care group’s knowledge of risks 
associated with OAC. The majority (84.4%) of the intervention group were aware of the 
factors affecting INR compared to only about a third in the usual care group (36.7%). 
However, differences between groups were not significant. More patients in the intervention 
groups were aware of their target INR (87.5%), than in the usual care group (72.5%) at one 
month, but these differences were non-significant (p=0.06). At one month the majority of 
patients in the intervention group were aware of the bleeding risks associated with oral 
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anticoagulants (78.1%), compared to just over half of the patients in the usual care group 
(53.7%); the differences between groups were significant (χ2 4.69; p<0.05). At six months the 
majority of patients in the intervention group were still aware of the risks associated with 
OAC (89.7%) compared to just over half of the usual care patients (56.3%); a difference that 
was significant (χ2 8.44; p<0.01). 
 
5.3.1.3 Total knowledge scores 
 
Analysis of the total knowledge scores for both groups demonstrates that patients scored 
highly at baseline (Table 5.10), as they answered six out of nine questions correctly on 
average. Knowledge scores increased slightly in the intervention group over time, remaining 
at a median score of seven at all subsequent time points. Total knowledge scores for the 
usual care group remained the same from baseline to the two month follow-up (median = 6), 
increasing slightly to a median of seven at the six month follow-up. 
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Table 5.8: Patient perceptions of atrial fibrillation, at each time point, by group allocation 
 Baseline 1 month 2 months 6 months 
Intervention Usual 
care 
χ
2
 Intervention Usual 
care 
χ
2
 Intervention Usual 
care 
χ
2
 Intervention Usual 
care 
χ
2
 
Patients awareness of primary diagnosis of AF 
Aware 39 
(90.7) 
43 
(82.7) 
1.27 31 
(96.9) 
37 
(90.2) 
1.23 26 
(96.3) 
30 
(96.8) 
0.01 29 
(100) 
29 
(93.5) 
na 
Not aware 4 
(9.3) 
9 
(17.3) 
 1 
(3.1) 
4 
(9.8) 
 1 
(3.7) 
1 
(3.2) 
 0 
(0) 
2 
(6.5) 
 
Patients understanding that AF is a cardiac rhythm abnormality 
Aware 35 
(83.3) 
41 
(78.8) 
0.30 31 
(96.9) 
34 
(82.9) 
3.58* 26 
(96.3) 
29 
(93.5) 
0.22 27 
(93.1) 
25 
(80.6) 
2.01 
Not aware 7 
(16.7) 
11 
(21.2) 
 1 
(3.1) 
7 
(17.1) 
 1 
(3.7) 
2 
(6.5) 
 2 
(6.9) 
6 
(19.4) 
 
Perception of the severity of AF 
Not serious 3 
(7) 
8 
(14.8) 
2.75 5 
(15.6) 
9 
(14.6) 
0.46 5 
(18.5) 
5 
(16.1) 
0.06 5 
(17.2) 
5 
(15.6) 
1.01 
Serious 25 
(58.1) 
33 
(61.1) 
 22 
(68.8) 
26 
(63.4) 
 18 
(66.7) 
21 
(67.7) 
 20 
(69) 
25 
(78.1) 
 
Very 
serious 
13 
(30.2) 
10 
(18.5) 
 5 
(15.6) 
6 
(14.6) 
 4 
(14.8) 
5 
(16.1) 
 4 
(13.8) 
2 
(6.3) 
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Awareness of AF predisposing to stroke 
Aware 23 
(56.1) 
32 
(62.7) 
0.42 29 
(90.6) 
24 
(58.5) 
9.30** 23 
(82.1) 
22 
(71) 
1.01 22 
(75.9) 
17 
(56.7) 
2.42 
Not aware 18 
(43.9) 
19 
(37.3) 
 3 
(9.4) 
17 
(41.5) 
 5 
(17.9) 
9 
(29) 
 7 
(24.1) 
13 
(43.3) 
 
*P<0.05; **p<0.01 
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Table 5.9: Patient perceptions of anticoagulation therapy between groups, at each time point 
 Baseline 1 month 2 months 6 months 
Intervention Usual 
care 
χ
2
 Intervention Usual 
care 
χ
2
 Intervention Usual 
care 
χ
2
 Intervention Usual 
care 
χ
2
 
Awareness of anticoagulation therapy preventing blood clots 
Aware 39 
(90.7) 
42 
(79.2) 
1.07 28 
(87.5) 
36 
(87.8) 
0.002 24 
(88.9) 
27 
(90) 
089 26 
(89.7) 
29 
(93.5) 
0.29 
Not 
aware 
4 
(9.3) 
11 
(20.8) 
 4 
(12.5) 
5 
(12.2) 
 3 
(11.1) 
3 
(10) 
 3 
(10.3) 
2 
(6.5) 
 
Awareness that anticoagulation prevents stroke 
Aware 36 
(83.7) 
39 
(75) 
2.32 29 
(90.6) 
32 
(78) 
2.07 23 
(85.2) 
24 
(77.4) 
0.56 25 
(86.2) 
23 
(74.2) 
1.35 
Not 
aware 
7 
(16.3) 
13 
(25) 
 3 
(9.4) 
9 
(22) 
 4 
(14.8) 
7 
(22.6) 
 4 
(13.8) 
8 
(25.8) 
 
Aware of bleeding risks associated with anticoagulants 
Aware 30 
(69.8) 
30 
(56.6) 
1.75 25 
(78.1) 
22 
(53.7) 
4.69* 21 
(77.8) 
17 
(54.8) 
3.36‡ 26 
(89.7) 
18 
(56.3) 
8.44** 
Not 
aware 
13 
(30.2) 
23 
(43.4) 
 7 
(21.9) 
19 
(46.3) 
 6 
(22.2) 
14 
(45.2) 
 3 
(10.3) 
14 
(43.8) 
 
Aware of target INR 
Aware 27 32 0.07 28 29 2.43 21 18 2.07 21 22 0.02 
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(64.3) (61.5) (87.5) (72.5) (77.8) (60) (72.4) (71) 
Not 
aware 
15 
(35.7) 
20 
(38.5) 
 4 
(12.5) 
11 
(27.5) 
 6 
(22.2) 
12 
(40) 
 8 
(27.6) 
9 
(29) 
 
Aware of factors which may affect INR levels 
Aware 20 
(47.6) 
26 
(50) 
0.05 27 
(84.4) 
27 
(36.7) 
2.70 22 
(78.6) 
17 
(56.7) 
3.15 22 
(75.9) 
21 
(67.7) 
0.49 
Not 
aware 
22 
(52.4) 
26 
(50) 
 5 
(15.6) 
13 
(32.5) 
 6 
(21.4) 
13 
(43.3) 
 7 
(24.1) 
10 
(32.3) 
 
*P<0.05; **p<0.01; ‡ Differences almost reaching significance at p=0.06; Na= test value unavailable as there were limited cell counts 
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Table 5.10: Overall knowledge scores 
Knowledge score 
Median (IQR) 
Intervention Usual care 
Baseline 6 (5-7) 6 (4-7) 
1 month 7 (7-8) 6 (5-8) 
2 months 7 (6-8) 6 (5-8) 
6 months 7 (6-7) 7 (4-7) 
 
 
To determine whether there were any significant differences in knowledge across the follow-
up time points between the intervention and usual care groups and in relation to age and 
sex, a two-factor mixed model ANOVA was carried out (Table 5.11). There were significant 
differences in knowledge within groups across time (F (3, 47) = 6.4; p<0.01). There were no 
significant differences between groups (F (1, 47) = 3.3; p = 0.07) and the interaction between 
knowledge and the treatment group was not significant (F (3, 47) =1.9; p=0.13).  
 
Table 5.11: Differences in knowledge between groups and across time  
 F df p-value 
Time 6.4 3 <0.01 
Group 3.3 1 0.07 
Time*group 1.9 3 0.13 
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5.3.1.4 Knowledge and time within therapeutic range 
 
As the knowledge scores were not normally distributed, a Spearman’s correlation coefficient 
was carried out to determine whether knowledge at baseline, one, two and six months 
predicted TTR across the follow-up period (Table 5.12). The findings suggest that patient 
knowledge at baseline, one and two month follow-ups do not predict TTR, whereas 
knowledge at the six month follow-up significantly predicts overall TTR (r=0.245; p=0.04). 
 
Table 5.12: Knowledge as a predictor of time within therapeutic range 
 Correlation coefficient p-value 
Baseline knowledge 0.105 0.17 
1 month knowledge -0.029 0.41 
2 month knowledge 0.094 0.25 
6 month knowledge 0.245 0.04 
 
 
5.3.2 Explanatory outcome analyses 
 
5.3.2.1  Illness Perceptions 
 
At baseline 59 (61%) patients gave an answer for the perceived ‘cause’ of their illness, with 
most non-respondents stating that they did not know the cause. However, of those patients 
that named a possible cause at baseline (see Table 5.13), the majority of patients in the 
intervention and usual care groups thought there was a psychological cause (40.0% vs. 
41.1% respectively).  At the 1 month follow-up, more patients in both groups believed that 
there was an external cause of their AF (48.5% intervention group vs. 50.0% in the usual 
care group), although around a third still believed there was a psychological cause (33% in 
both groups). At the 2 and 6 month follow-ups, patients in the intervention group were more 
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likely to believe there was an external cause of their illness (i.e. age, other cardiac 
illness/surgery or hereditary disposition), compared to usual care patients who more often 
stated a psychological cause. 
 
There were no significant differences between the groups in their perception of cause of AF 
at any time point, other than at the six month follow-up. The change in the perception of 
cause of AF appears to be due to the changing perceptions of the intervention group who 
were more likely to perceive the cause as external (73.9%) (e.g. age, hereditary or previous 
illness), whereas patients in the usual care group were more likely to perceive the cause of 
their AF as psychological (42.9%). Differences between groups at perception of cause at six 
months were significant (χ2=6.31; p=0.04). IPQ scores between groups (see Table 5.14) 
suggest that; (1) patients in both groups view their illness as having a moderate affect on 
their life (consequences); (2) patients perceived their illness as long-term (timeline); (3) 
patients felt they had a moderate level of control over their illness (personal control), this 
increased slightly in both groups by the six month follow-up; (4) patients felt their treatment 
could have a ‘helpful’ impact on their illness in both groups, at all time points (treatment 
control); and (5) patients scored a moderate score for ‘how much do you experience 
symptoms?’ (Identity), suggesting that some patients maybe very symptomatic, whilst others 
are asymptomatic. Patients in the intervention group scored higher on illness coherence, 
lower on emotional representation (how much their illness affected them emotionally), and 
lower on illness concern than the usual care group. However, none of these differences were 
significant. 
 
Mixed two-way ANOVAs were carried out to determine whether illness perceptions changed 
across time (within groups) and whether the group patients were assigned to (between 
groups) influenced illness perceptions. There were no significant differences within or 
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between groups on perceived consequences of AF, perception of the timeline of AF, 
personal control of illness, treatment control, illness identity, illness coherence or illness 
concern (Table 5.15). There were significant differences within groups emotional 
representation of illness (F (3, 49) = 3.3 (3, 49); p= 0.03) across time. However, there were 
no significant differences between groups.  
 
5.3.2.1.1 Illness perceptions and time within therapeutic range 
 
Separate multiple regression analyses were carried out entering all of the IPQ factors for a 
given time point, from baseline, month 1, 2, and 6. None of the models predicted TTR. 
However, at 1 month follow-up, there was a significant negative correlation between illness 
concern and TTR (r= -0.199; p=0.05). Thus the higher patients concern, the lower the TTR.  
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Table 5.13: Patients’ perceived cause of atrial fibrillation 
N (%) Baseline  χ2 1 month  χ2 2 months  χ2 6 months  χ2 
 Intervention 
(n=25) 
Usual 
care 
(n=34) 
 Intervention 
(n=24) 
Usual 
care 
(n=24) 
 Intervention 
(n=19) 
Usual 
care 
(n=19) 
 Intervention 
(n=23) 
 
Usual 
care 
(n=21) 
 
Psychological  10 (40.0) 14 (41.2) 1.38 8 (33.3) 8 (33.3) 0.15 3 (15.8) 9 (47.4) 4.47 3 (13.0) 9 (42.9) 6.31* 
External  6 (24.0) 12 (35.3)  11 (45.8) 12 (50.0)  12 (63.2) 8 (42.1)  17 (73.9) 8 (38.1)  
Lifestyle  9 (36.0) 8 (23.5)  5 (20.8) 4 (16.7)  4 (21.1) 2 (10.5)  3 (!3.0) 4 (19.0)  
*P<0.05; psychological: includes answers relating to psychological morbidity including stress, anxiety, depression and bereavement; lifestyle: 
includes factors related to patients lifestyle habits such as smoking, excess drinking, obesity and excessive exercise; externals: includes factors 
that patients cannot control including hereditary disposition, following surgery or other chronic illness.  
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Table 5.14: Mean (SD) scores for IPQ factors from baseline to 6 month follow-up. 
Mean (SD) Baseline 1 month 2 months 6 months 
 Intervention Usual 
care 
Intervention Usual care Intervention Usual care Intervention Usual care 
Consequences 4.3 (2.3) 5.0 (2.5) 4.1 (2.6) 4.6 (2.7) 4.7 (2.8) 4.9 (2.4) 4.2 (2.8) 4.9 (2.5) 
Timeline 8.8 (2.5) 9.2 (1.7) 8.8 (2.1) 8.2 (2.7) 8.8 (1.9) 8.8 (1.9) 8.6 (2.5) 8.5 (2.6) 
Personal control 4.3 (3.1) 4.9 (3.1) 4.2 (2.9) 4.7 (2.6) 4.8 (2.8) 5.0 (2.7) 5.6 (2.9) 5.6 (2.9) 
Treatment control 7.1 (2.3) 7.7 (2.3) 7.9 (1.9) 7.6 (1.7) 7.9 (1.6) 7.2 (1.8) 7.3 (1.9) 7.8 (2.1) 
Identity 4.2 (2.7) 4.1 (2.9) 4.3 (3.0) 4.1 (2.7) 4.6 (2.8) 4.1 (2.6) 3.8 (2.8) 4.2 (3.1) 
Coherence 6.0 (7.8) 5.9 (2.9) 6.2 (2.6) 5.7 (3.1) 7.1 (2.4) 5.9 (2.9) 7.2 (2.3) 6.1 (2.8) 
Emotional 
representation 
4.2 (2.7) 5.8 (3.3) 4.2 (2.9) 5.8 (3.3) 4.9 (3.0) 5.7 (3.1) 3.8 (2.9) 5.1 (3.1) 
Illness concern 5.8 (3.1) 7.3 (3.1) 5.6 (3.1) 7.3 (2.9) 5.9 (2.9) 6.6 (3.1) 5.4 (3.1) 6.3 (3.1) 
Scores range from 1 to 10 for each of the outcomes.  
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Table 5.15: Time and group differences in illness perceptions 
 
 F df p-value 
Time (Consequences) 0.9 3 0.46 
Group (Consequences) 0.9 1 0.36 
Time*Group 0.4 3 0.79 
Time (Timeline) 1.7 3 0.19 
Group (Timeline) 0.2 1 0.89 
Time*Group 1.6 3 0.21 
Time (Personal control) 1.7 3 0.18 
Group (Personal control) 0.3 1 0.61 
Time*Group 0.2 3 0.92 
Time (Treatment control) 0.5 3 0.70 
Group (Treatment control) <0.01 1 0.99 
Treatment control*Group 1.9 3 0.15 
Time (Identity) 0.4 3 0.78 
Group (Identity) 0.01 1 0.91 
Time*Group 0.6 3 0.63 
Time (Coherence) 0.8 3 0.51 
Group (Coherence) 2.3 1 0.14 
Time*Group 1.2 3 0.23 
Time (Illness concern) 1.5 3 0.23 
Group (Illness concern) 2.5 1 0.12 
Time*group 1.9 3 0.14 
Time (Emotional 
representation) 
3.3 3 0.03 
Group (Emotional 
representation) 
2.8 1 0.10 
Time*Group 0.7 3 0.57 
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5.3.2.2 Quality of life 
 
Descriptive statistics (Table 5.16) indicate that patients in the intervention group scored 
lower at baseline on all subscales, suggesting worse QoL than in the usual care group. QoL 
increases in the intervention group at the one month follow-up. At subsequent follow-ups 
there are no significant differences in scores between groups. Large standard deviation 
scores suggest a large variation of scores in both groups. 
 
Mixed two-way ANOVAs were carried out to determine whether there were differences in 
QoL between the intervention and usual care groups and across time (Table 5.17). Results 
suggest there are no significant differences between groups or within groups QoL. Thus 
group allocation does not affect QoL outcomes, and QoL did not change over time.  
 
5.3.2.2.1 Changes in quality of life over time 
 
Baseline QoL analyses suggest significant differences between the intervention and usual 
care groups (see Table 5.6). ANOVA analyses suggested no differences in QoL over time or 
between groups (Table 5.17), but these methods do exclude any patients that did not take 
part in all follow-ups. QoL change scores were subsequently calculated between each time 
point to determine whether there was a significant difference between intervention and usual 
care groups (Table 5.18). The psychological and global QoL scores in the intervention group 
and usual care group increased from baseline to one month. Physical QoL scores increased 
in the intervention group from baseline to one month, but they neither increased nor 
decreased in the usual care group. There was a significant difference between the 
intervention and usual care groups global quality of life scores improved significantly more 
than in the intervention group (9.7 vs. 3.5; z = -2.4; p=0.01) from baseline to one month. 
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Table 5.16: Mean (SD) scores for patient quality of life between groups, from baseline to 6 month follow-up 
 Baseline 
(n = 97 ) 
1 month 
(n = 72) 
2 months 
(n = 55) 
6 months 
(n =59) 
QoL Subscale Intervention 
 
Usual care 
 
Intervention 
 
Usual care 
 
Intervention 
 
Usual care 
 
Intervention 
 
Usual care 
 
Physical 36.1 (26.4) 50.2 (27.3) 46.6 (26.2) 50.6 (29.9) 44.1 (25.9) 43.3 (25.2) 42.6 (20.9) 47.8 (26.9) 
Psychological 39.5 (20.8) 50.6 (26.3) 
 
53.5 (24.9) 50.5 (28.8) 51.9 (25.2) 46.4 (29.2) 53.6 (24.9) 50.5 (28.8) 
Global  39.6 (20.2) 50.9.6 (22.6) 51.3 (21.8) 50.4 (24.8) 48.6 (21.8) 44.7 (23.3) 48.6 (21.8) 44.7 (23.3) 
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Table 5.17: Group and time differences in patient quality of life  
 F df p-value 
Time (Physical QoL) 0.97 3 0.40 
Group (Physical QoL) 0.05 1 0.82 
Time*Group 1.14 3 0.34 
Time (Psychological QoL) 0.52 3 0.67 
Group (Psychological 
QoL) 
0.09 1 0.77 
Time*Group 1.59 3 0.19 
Time (Global QoL) 0.95 3 0.37 
Group (Global QoL) 0.04 1 0.83 
Time*Group 2.54 2 0.09 
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Table 5.18: Change in quality of life scores across time and by group 
 
BL to 1 month BL to 2 months BL to 6 months 1 to 2 months 2 to 6 months 
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 12.5 
(-2.8 to 
32.2) 
7.1 
(-10.7 to 
14.3) 
-1.8 3.5  
(-3.6 to 
32.1) 
5.4  
(-12.5 to 
14.3) 
-
0.8 
12.5  
(-2.7 to 
32.1) 
7.1  
(-10.7 to 
14.3) 
-
1.8 
-1.9 
(-14.1 
to 7.1) 
-0.5 
(-8 to 
3.6) 
-
0.2 
1.9 
(-21.6 o 
15.0) 
0.5 
(-7.1 to 
14.3) 
-
0.2 
P
h
y
s
i
c
a
l
  6.7 
(-4.7 to 
14.8) 
0 
(-8.6 to 
10.9) 
-1.8 0  
(-3.1 to 
12.5) 
-3.1  
(-18.7 to 
12.5) 
-
1.3 
0  
(-3.1 to 
12.5) 
3.1  
(-13.3 to 
10.9) 
-
0.5 
0 
(-7.0 to 
3.9) 
-9.4 
(-15.6 
to 9.4) 
-
1.2 
1.6 
(-12.5 to 
3.3) 
10.9 
(-3.1 to 
15.6) 
-
1.6 
G
l
o
b
a
l
 
 
9.7 
(0.7 to 
18.1) 
3.5 
(-6.6 to 
9.7) 
-
2.4** 
4.2  
(-5.5 to 
15.3) 
-1.4  
(-13.5 to 
11.1) 
-
1.7 
4.2  
(-5.5 to 
15.3) 
-1.4  
(-13.5 to 
11.1) 
-
1.7 
-0.7 
(-9.7 to 
4.5) 
-3.5 
(-10.8 
to 2.4) 
-
0.5 
0 
(0 to 0) 
0 
(0 to 0) 
1.0 
BL = Baseline, QoL = quality of life; IQR = inter-quartile range, **p=0.01, Mann Whitney-U test was used to calculate p-value and z scores. 
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5.3.2.3 Beliefs about medication 
 
Patients’ beliefs about medication (Table 5.19) scores suggest that the usual care group 
scored higher on specific concerns about medication at all time-points than the intervention 
group. The usual care group also score higher on general harm scales at all time points. 
Whilst the mean score for perceived general harm drops in the intervention group after 
baseline, the score for this subscale increases in the usual care group. Scores on the 
specific necessity subscale are similar for both groups. The scores on the subscale ‘general 
overuse’ remain consistent across time in the intervention group, while perceived general 
overuse scores increase after baseline in the usual care group. Scores for the necessity-
concerns differential are positive for both the usual care and the intervention group, thus 
patients beliefs in the necessity of taking medication are stronger than their concerns about 
adverse events. This differential is more apparent in the intervention group, who also score 
lower on specific concerns about their medications at all time points. 
 
Several mixed two-way ANOVAs were carried out to determine whether patient group 
influenced beliefs about medication outcomes and further whether beliefs about medication 
changed across time. There was a significant difference between groups’ perception of 
general harm of medication (F (3, 51) = 2.16; p<0.01). There was also a significant 
interaction between general harm scores across time and between groups (F (3, 51) =1.85; 
p = 0.03). 
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Table 5.19: Mean (SD) scores on beliefs about medication subscales from baseline to 6 month follow-up 
Mean (SD) 
†Median (IQR) 
Baseline 1 month 2 months 6 months 
 Intervention Usual care Intervention Usual care Intervention Usual care Intervention Usual care 
General Harm 8.1 (2.1) 9.1 (2.2) 8.3 (2.1) 10.1 (2.9) 8.5 (1.7) 10.2 (2.5) 7.9 (2.0) 10.3 (2.6) 
General overuse 10.4 (3.0) 11.3 (2.9) 10.4 (3.7) 12.9 (2.9) 10.9 (3.4) 12.0 (2.9) 10.7 (3.5) 12.0 (2.6) 
Specific necessity 18.3 (3.7) 18.7 (4.2) 18.7 (3.5) 18.4 (3.9) 18.9 (3.6) 18.8 (3.4) 19.1 (3.2) 18.8 (4.1) 
Specific concern 14.0 (3.7) 16.6 (4.2) 13.2 (3.4) 15.3 (2.3) 13.5 (3.5) 14.8 (4.6) 13.0 (3.9) 15.8 (5.3) 
Necessity-concerns 
differential† 
4.0 (1.0 to 
8.0) 
3.0 (-1.0 to 
5.5) 
5.0 (2.0 to 
8.0) 
2.5 (0.25 to 
6.0) 
5.0 (1.0 to 
10.0) 
3.0 (0 to 
7.0) 
5.0 (1.5 to 
9.5) 
3.0 (-1.0 to 
5.75) 
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Table 5.20: Group and time differences in perceived general harm  
 f df sign 
Time 2.55 3 0.06 
Group 10.53 1 0.002 
Time*Group 1.85 3 0.03 
 
There were no significant changes across time in perception of general overuse of 
medication (Table 5.21). However, differences between groups’ perceptions were nearly 
significant (F (3, 50) = 2.65; p=0.06), as was the interaction between time and group (F (3, 
50) = 2.14; p = 0.11). 
 
 Table 5.21: Group and time differences in perceived general overuse 
 f df sign 
Time 1.98 3 0.13 
Group 3.53 1 0.06 
Time*Group 2.14 3 0.11 
 
There were no significant differences between groups or across time in perceptions of the 
specific necessity of treatment for AF (Table 5.22).  
 
Table 5.22: Group and time differences in specific necessity  
 f df sign 
Time 0.64 3 0.59 
Group 0.003 1 0.96 
Time*Group 0.39 3 0.76 
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There were significant differences between groups’ perception of their specific concerns 
related to their current medication (F (1, 51) =5.84; p=0.01; Table 5.23). However, there 
were no significant differences across time and the interaction between time and group 
factors were not significant. 
 
Table 5.23: Group and time differences in specific concerns about medication 
 F df p-value 
Time 2.19 3 0.11 
Group 5.84 1 0.01 
Time*Group 0.85 3 0.44 
 
There were significant differences across time (F (3, 51) = 2.87; p=0.04) and between 
groups (F (1, 51) = 4.09; p=0.04) in the differential between perceived medication necessity 
and perceived medication concerns (Table 5.24). However, the interaction between time and 
group factors was not significant. 
 
Table 5.24: Group and time differences in necessity-concern differential 
 F df p-value 
Time 2.87 3 0.04 
Group 4.09 1 0.04 
Time*Group 6.19 3 0.57 
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5.3.2.3.1 Beliefs about medication and time within therapeutic range 
 
When entering all scores for BMQ subscales, General Harm scores at 1 month were the only 
scores that predicted TTR (F(1,72)= 4.08; p=0.048). The Pearson’s r correlation suggests a 
negative correlation (r=-0.241; p= 0.021) suggesting that as perceived general harm scores 
increase, TTR decreased. 
 
Spearman’s correlation coefficient was used to determine whether the necessity concern 
differential at each time-point correlated with TTR (Table 5.25). Baseline differential scores 
significantly correlated with TTR at six months (r=0.217; p=0.04). The correlation was 
positive suggesting patients with lower scores on specific concern and higher scores on 
specific necessity (thus higher differential scores) also spent more time in the therapeutic 
range.  
 
Table 5.25: Correlations between necessity-concerns differential scores and 6 month TTR 
 Correlation coefficient p-value 
Baseline 0.217 0.04 
1 month 0.202 0.09 
2 months 0.129 0.35 
6 months 0.090 0.51 
 
 
5.3.3 Anxiety and Depression 
 
At baseline, median anxiety scores for the total cohort were just below the cut-off for clinical 
significance (≥ score of 8; Table 5.26). At subsequent follow-ups anxiety scores in both 
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groups increased significantly, indicating that patients are highly anxious (>10).  A similar 
pattern was exhibited with regard to depression scores. Whilst at baseline patients have 
lower scores (median (IQR) 4.9 (2-8), these scores increased significantly at each follow-up 
above the clinical cut-off (score ≥8) suggesting over half of the patients in both groups were 
depressed (See Figure 5.2). The prevalence of depression cases doubled from baseline to 
one month (25.5% to 55.6%), as did the prevalence of anxiety (41.5% to 95.4%). 
 
Figure 5.2: Number of anxiety and depression cases over time by treatment group 
 
A case of anxiety or depression was determined by a patient scoring ≥8 on the subscales of 
the HADS questionnaire. 
 
A mixed model two-way ANOVA was used to determine whether there were differences in 
anxiety between intervention and usual care groups and across time. A conservative p-value 
(Greenhouse-Geisser) was adopted as the assumptions of the test were violated. There 
were significant changes in anxiety scores across time (F (3, 46) = 25.2; p<0.01; Table 
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5.26), but there were no significant differences in anxiety scores between the intervention 
and usual care groups (F (1, 46) = 0.57; p = 0.45). 
  
Table 5.26: Anxiety and depression during first 6-month  
 Baseline 1 month 2 months 6 months 
 Intervention Usual 
care 
Intervention Usual 
care 
Intervention Usual 
care 
Intervention Usual 
care 
Anxiety 
cases 
(HADS-A 
score ≥8) 
17 (40.5) 22 
(42.3) 
31 (96.9) 37 
(92.5) 
23 (92.0) 26 
(89.7) 
29 (100) 25 
(89.3) 
Anxiety 
Score† 
6 
(3.7-9) 
7.0 
(3-
10.7) 
13 
(11-13.7) 
12 
(10-
14) 
12 
(10-14) 
12 
(9-
14) 
12 
(11-14) 
12 
(10-
13.7) 
Depression 
cases  
(HADS-D 
score ≥8) 
9 (21.4) 15 
(28.8) 
15 (46.9) 25 
(62.5) 
22 (88.0) 25 
(86.2) 
23 (79.3) 26 
(92.9) 
Depression 
score† 
4 (2-7) 4 (2-
8) 
7 (5-9) 8 (7-
9) 
8 (8-9) 9 (8-
10) 
9 (8-9) 9 (8-
10) 
HADS-A = anxiety; HADS-D = depression; †Median (IQR) or n (%) reported 
 
Table 5.27: Differences in anxiety scores across time and between groups 
 F df p-value 
Time 25.2 3 <0.01 
Group 0.57 1 0.45 
Time*Group 27.4 3 0.09 
 
Friedman’s ANOVA was carried out to determine whether there were significant differences 
in anxiety across time for the total patient cohort. This test was chosen as the data violates 
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the assumptions of the repeated-measures ANOVA, as it is not normally distributed. Results 
suggest that there were significant differences in the anxiety scores across the different time 
points (χ2 = 26.49; p<0.001; Table 5.28). Patients exhibited the highest anxiety levels at 6 
months and the lowest anxiety at baseline.  
 
Table 5.28: Anxiety changes across time for the total cohort 
 Mean rank Chi square p-value 
Baseline 1.71 26.49 <0.001 
1 month 2.76 
2 month 2.63 
6 month 2.90 
 
 
A mixed model two-way ANOVA was used to determine whether there were differences in 
depression between intervention and usual care groups and across time (Table 5.29). A 
conservative p-value (Greenhouse-Geisser) was adopted as the assumptions of the test 
were violated. There were significant changes in depression scores across time (F (3, 46) = 
37.7; p<0.01), but there were no significant differences in depression between groups (F (3, 
46) = 0.69; p = 0.55). 
 
Table 5.29: Differences in depression scores across time and between groups 
 F df p-value 
Time 37.7 3 <0.01 
Group 0.69 3 0.55 
Time*Group 2.54 1 0.12 
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Friedman’s ANOVA was also carried out to determined whether there were any significant 
differences within groups’ depression across time in the total patient cohort (Table 5.30). 
Results suggest that there were significant differences in depression across time (r=50.65; 
p<0.001). Patients’ depression scores got progressively worse over time, exhibiting the 
lowest levels at baseline and the highest at six months.  
 
Table 5.30: Depression changes across time 
 Mean rank Chi square p-value 
Baseline 1.50 50.65 <0.001 
1 month 2.41 
2 month 2.88 
6 month 3.21 
 
 
 
5.3.4 Adverse events 
 
Observations of adverse events in both groups suggest more events occurred in the usual 
care group (total events = 8); including three ischaemic (non-fatal) strokes, three episodes of 
bleeding (one major and two minor) and one death (not cardiac related) versus one event 
(peripheral embolism) in the intervention group. 
 
5.4 Overall study model 
 
Factors that had been found to be significantly associated with TTR in the exploratory 
analyses were entered into a linear regression model (backwards entry). These factors 
included six month follow-up knowledge scores, the assigned group (usual care and 
intervention), one month follow-up scores for general harm and illness concerns and 
  
215 
 
baseline scores for the necessity-concerns differential. One factor remained in the model as 
a significant predictor of TTR, group assignment was a significant predictor (t=2.0, SE= 5.8, 
p=0.05).
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6 Discussion 
 
 
6.1 Discussion of the key findings 
 
6.1.1 Time within therapeutic range 
 
The primary outcome for the TREAT study was time spent within therapeutic INR 
range (TTR), a measure which is sensitive to whether patients adhere to treatment 
recommendations. There was a statistically significant difference between the 
intervention and usual care group (78.5% vs. 66.7% respectively; p=0.01); 
suggesting greater adherence to medication and lifestyle recommendations in those 
patients receiving the intervention (see results Section 5.2.1). TTR is an objective 
measure (utilising blood samples to calculate INR), therefore, these results are a 
reliable indicator of differences in levels of adherence, in contrast with subjective self-
report studies. By increasing the provision of information required to formulate 
accurate beliefs and perceptions surrounding AF and warfarin, patients may be more 
able and willing to adhere, in the long-term, to treatment recommendations. The 
clinical implications of this finding are important as the effectiveness of treatment, 
including warfarin, is often undermined by low levels of adherence (Sabate, 2003; 
Wan, et al., 2008; Gladstone, et al., 2009); and maintaining the therapeutic range of 
2.0 to 3.0 is imperative for stroke risk reduction (Singer, et al., 2009; Hylek, Evans-
Molina, Shea, Henault, & Regan, 2007) and to reduce the risk of treatment-
associated bleeding complications.  
 
Findings from the ACTIVE-W trial suggested that where TTR values ≤ 58%, one 
cannot expect any net benefit (i.e. stroke risk reduction, from being on oral 
anticoagulation (OAC)), and that a TTR ≥65% is critical to achieve clinical benefit 
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(Connolly, et al., 2008). Thus, the mean TTR for both groups in the TREAT study 
were relatively good, perhaps an indication of improvements made to usual care 
education procedure (e.g. a recently introduced mandatory education checklist). 
However, another study, using record-linkage data from hospitalised inpatients, 
suggested warfarin treatment offered no or limited clinical benefit (reduced stroke 
and mortality) unless a patient could maintain their therapeutic range for more than 
71% of the time (Morgan, McEwan, Tukiendorf, Robinson, Clemens, & Plumb, 2009). 
Thus, the use of a theory-driven intervention could help to ensure that patients 
starting warfarin would benefit from ‘good’ INR control.  
 
The number of visits in both the intervention and usual care groups were comparable 
in the TREAT study (6.7 vs. 7.2, respectively), with very little variation. This suggests 
that the intervention improved INR control without requiring additional resources from 
OAC clinics (i.e. an increased number of visits). At the individual level fewer visits to 
OAC clinics has also been associated with better INR control, perhaps because only 
those patients with unstable INR results are reviewed more frequently (Smith, Lip, & 
Lane, 2011) 
 
The usual care group spent significantly more time with sub-therapeutic (<2.0) INRs 
(23.1% vs. 13.3%; p= 0.01), thereby increasing their risk of ischaemic stroke 
(Morgan, McEwan, Tukiendorf, Robinson, Clemens, & Plumb, 2009; Gladstone, et 
al., 2009). Patients in both the intervention and usual care groups spent less time 
with a supra-therapeutic INR (INR >3.0) (10.2% vs. 13.2% respectively); however, 
any time spent with an INR >3.0 increases the risk of bleeding events (Hylek, Evans-
Molina, Shea, Henault, & Regan, 2007). It is important that patients are aware of 
factors which affect INR control, such as how many units of alcohol are safe to drink 
per day, which foods are high in vitamin K, what to do if they miss a dose of warfarin 
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and which medications can impact on warfarin metabolism. When equipped with this 
information, patients have the potential to make informed decisions about their own 
treatment adherence. Previous research has demonstrated that a brief educational 
intervention (the precursor/pilot to the present study) covering these topics can 
significantly improve knowledge of factors influencing INR control (Lane, Ponsford, 
Shelley, Sirpal, & Lip, 2006). Physicians also need to ensure they are using 
appropriate risk stratification guidelines (Fang M. C., et al., 2011; ESC, 2010; 
Kirchhof, et al., 2011), to ensure that where the risk of bleeding significantly 
outweighs the level of risk reduction provided by OAC, patients are considered for an 
alternative treatment and that discussion of a patient’s treatment preferences are 
considered in clinical-decision making. 
 
6.1.2 Patient knowledge 
 
The TREAT study results suggest there were significant changes in patients’ 
knowledge of OAC and AF across time (F (3, 47) = 6.4; p<0.01). However, there 
were no significant differences between the intervention and usual care group (F (1, 
47) = 3.3; p = 0.07). Both groups scored highly on knowledge questions at baseline, 
thus any differences between groups on follow-up were small (see results Section 
5.3.1). The high baseline knowledge scores could stem from recent improvements 
made to the usual care hospital procedure, such as an educational check list 
received by both groups prior to their baseline assessment.  
 
Subsidiary analysis of the relationship between knowledge and TTR suggests that 
knowledge could play a role in patient adherence. At baseline, one and two month 
follow-ups knowledge did not predict TTR, whereas their knowledge score at six 
months did (p=0.04). This indicates that where patients’ knowledge regarding their 
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illness and their treatment is sustained, patients are more likely to remain within 
target therapeutic range. The relationship between knowledge and adherence is 
unclear; however, it is possible that improving patient knowledge could reduce 
intentional and unintentional non-adherence (Horne, Weinman, Barber, Elliot, & 
Morgan, 2005).  Non-adherence is intentional when patients make a decision not to 
take their treatment as a result of their personal motivations or beliefs. Where these 
beliefs are inaccurate, or they perceive the barriers as too great, they are unlikely to 
adhere. Equally, improved knowledge of specific questions (e.g. ‘what should I do if I 
miss a dose of warfarin?’) could reduce unintentional non-adherence; which refers to 
an individual’s skills or ability to take their medications (e.g. problems with 
remembering to take tablets). Evidence suggests that patients often report either or 
both types of non-adherence, with occasional overlap between the two concepts (e.g. 
where patients perceive medications as being unnecessary, they maybe more likely 
to forget to take it) (Horne, 2001; Horne, Weinman, Barber, Elliot, & Morgan, 2005). 
 
Previous studies have also highlighted the link between knowledge and INR control 
(Tang, Lai, Lee, Wong, Cheng, & Chan, 2003; Khan, Kamali, Kesteven, Avery, & 
Wynne, 2004). One prospective study examined knowledge and INR control in a 
mixed indication Chinese cohort (n=122), taking warfarin for varying lengths of time 
(mean months = 43.1±39.8). Tang and colleagues provided brief counselling and an 
educational booklet, and focussed on factors that affect INR control, including drug 
interactions, alcohol and dietary advice. They found poor baseline knowledge with an 
overall score of 0.48±0.18 (maximum score = 1.0), and, similarly to the present study, 
there was a positive correlation between patients’ knowledge of warfarin treatment 
and the number of INR values within range (r 0.20; p=0.024) (Tang, Lai, Lee, Wong, 
Cheng, & Chan, 2003). However, they also found an inverse relationship between 
age and knowledge score of the patient (r -0.43; p<0.001) and a positive association 
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between duration of warfarin treatment and knowledge (r 0.18; p=0.044). The TREAT 
findings do not support the relationship between age and knowledge, and as patients 
were new to warfarin, the relationship between duration of treatment and knowledge 
was not explored. Thus, it is difficult to compare these results for several reasons 
including the use of a non-trial design, a mixed indication cohort, and patients with 
varying durations of treatment; all factors that may influence the outcomes. However, 
findings do indicate that improving knowledge has a significant benefit on therapeutic 
outcomes; highlighting the impact of educating patients about the potential risks 
associated with their treatment.  
 
The systematic review (Chapter 2) found that the provision of an educational 
intervention improved TTR when compared to usual care and self monitoring (Khan, 
Kamali, Kesteven, Avery, & Wynne, 2004; Gadisseur, Kaptein, Breukink-Engbers, 
van Der Meer, & Rosendaal, 2004). Two of the trials included a comparison between 
education only groups and usual care (Khan, Kamali, Kesteven, Avery, & Wynne, 
2004; Gadisseur, Kaptein, Breukink-Engbers, van Der Meer, & Rosendaal, 2004). 
Both of these studies provided similar interventions to TREAT by including 
educational materials, and a group training session. Khan and colleagues recruited 
AF patients and found TTR in the education group increased from a mean 61.1 ±15.1 
during the six months prior, to 70.4 ±24.5 during the six months after the study began 
(mean difference 8.8, 95% CI: -0.2-7.8, p=0.054) (Khan, Kamali, Kesteven, Avery, & 
Wynne, 2004). Gadisseur and colleagues provided unpublished data on the AF 
patients in the trial and found, following the intervention, TTR in the education group 
was 75% (95% CI: 66.19-83.80) compared with 67.1% (95% CI: 59.18-74.98) in the 
usual care alone group and 70.32% (95% CI: 55.33-85.31) in the self-monitoring plus 
education group (Gadisseur, Kaptein, Breukink-Engbers, van Der Meer, & 
Rosendaal, 2004). TTR in the TREAT intervention group is comparable with these 
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two trials; however, the intervention differs substantially, with the inclusion of theory-
driven components. Furthermore, the TREAT trial recruited patients who were newly-
prescribed OAC, rather than those patients who had prior experience of warfarin, as 
duration is known to have an impact on knowledge and potentially INR control (Tang, 
Lai, Lee, Wong, Cheng, & Chan, 2003). Thus TREAT highlights the benefits of 
intervening at the commencement of OAC, when patients are initially adapting to the 
integration of the warfarin regime. 
 
Between groups analysis of specific knowledge questions suggests that patients in 
the intervention group were more aware of risk information pertaining to bleeding 
(associated with OAC) and clot or stroke (associated with AF) (see Section 5.3.1). 
Patients’ perception of risk can have an important influence on their adherence, and 
furthermore their decision to initiate warfarin (Protheroe, Fahey, Montgomery, & 
Peters, 2000; Howitt & Armstrong, 1999; Man-Son-Hing, et al., 1999; McAlister, et 
al., 2005; Devereaux, Anderson, Gardner, Putnam, & Flowerdew, 2001; Fuller, 
Dudley, & Blacktop, 2004; Thomson, et al., 2007). Previous qualitative evidence 
suggests that patients who decided not to take warfarin do not see themselves at 
high risk of stroke (Howitt & Armstrong, 1999). Further evidence suggests that 
provision of a decision aid (including risk information) reduces the number of patients 
prepared to take warfarin (Fuller, Dudley, & Blacktop, 2004). The impact of increased 
knowledge of risk in the intervention group could therefore play an important role in 
treatment adherence; enhancing patients’ understanding of the link between AF and 
stroke, and hence the need for adherence. Behavioural change techniques, such as 
social comparison, may have aided the process of increased risk awareness. Patient 
narratives on the intervention DVD discuss risks associated with AF and treatment, 
and provide a clear link between health and behaviour. Risk information was also 
presented as pie charts, in addition to stroke algorithms (i.e. CHADS2), whereby 
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patients calculated their own risk of stroke. The intervention highlights the importance 
of giving patients adequate information to make informed decisions; this allows them 
to ‘trade-off’ the risk of stroke with the risk of bleeding and justify their lifestyle 
changes, a concept which has been highlighted by previous decision aid studies 
(McAlister, et al., 2005; Man-Son-Hing, et al., 1999). 
 
Many patients do not view AF as a ‘high risk’ condition, despite its association with 
stroke. A previous study carried out by our research group found that only half of the 
patients considered AF a serious condition, and only 9% considered it a ‘very 
serious’ condition (Lane, Ponsford, Shelley, Sirpal, & Lip, 2006; Nadar, Begum, Kaur, 
Sandhu, & Lip, 2003; Lip, Kamath, Jafri, Mohammed, & Bareford, 2002). The results 
of the TREAT study suggest that more patients perceive AF as ‘serious or very 
serious’, than previously found; at baseline 61% of the usual care patients and 58% 
of the intervention group viewed AF as a ‘serious condition’, a further 18.5% vs. 30% 
respectively, viewed their condition as ‘very serious’. This may explain why TTR is 
high in both groups, as where patients view their condition as serious; they may 
place more value on the treatment that is required for risk reduction. Since Lane and 
colleagues published the pilot study (Lane, Ponsford, Shelley, Sirpal, & Lip, 2006) 
there have been more initiatives focussing on the role of education locally, which may 
explain this change in perception (such as the use of an education checklist).  
 
The communication of risk information is important. Several decision aid trials have 
proposed new ways of communicating OAC risk with patients (Man-Son-Hing, et al., 
1999; Thomson, et al., 2007; McAlister, et al., 2005), and those measuring the impact 
on INR control have found significant benefits (McAlister, et al., 2005). The 
communication of risk within the TREAT intervention included the provision of 
information regarding risk of stroke and potential risks of bleeding, avoiding either 
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‘positive’ or ‘negative’ framing of the treatment. It is possible that by allowing patients 
to formulate their own decision to take a treatment, based on the risk information 
available, that they maybe more satisfied with their decision; indeed one study found 
that patients’ judgement of the minimal level of benefit for which they would take 
warfarin (versus aspirin), predicted those patients who were prepared to start taking it 
(Howitt & Armstrong, 1999). 
 
6.1.3 Beliefs about medication 
 
There is a dearth of trialled theory-based interventions, despite the overwhelming 
evidence and guidelines to support their use (Horne, Weinman, Barber, Elliot, & 
Morgan, 2005; MRC, 2000; NICE, 2007). For example, previous evidence has 
highlighted the link between patients’ beliefs about their medication and adherence 
(see Section 3.1.1 for a full discussion). By targeting those beliefs, and potentially 
improving adherence to medication, we may subsequently improve clinical outcomes.  
 
Where patients view their medication as harmful, they are less likely to adhere 
(Clifford, Barber, & Horne, 2008; Menckeburg, et al., 2008; Horne, Weinman, Barber, 
Elliot, & Morgan, 2005). This has been related to perceived ‘toxicity’ of medications, 
and patients’ views surrounding the impact of side effects in the long- and short- term 
(Horne, Weinman, Barber, Elliot, & Morgan, 2005). Indeed, the present study found 
significant differences between the intervention and usual care group in their 
perception of medication harm in general (F (3, 51) = 2.16; p<0.01) and a significant 
interaction between general harm scores across time and between groups (F (3, 51) 
=1.85; p = 0.03). The usual care group perceived medication as more harmful than 
the intervention group at all time points. At the one month follow-up, patient scores 
for the general harm subscale predicted the amount of time patients spent within 
                                               
  
224 
 
 
therapeutic range (p=0.04). It seems an obvious assumption that perceiving 
medications as harmful represents a barrier to adherence, and yet this is rarely 
considered in intervention design. Patients must undergo a personal risk evaluation 
when choosing to start a new medication, perhaps taking into consideration potential 
side effects (i.e. bleeding and bruising), perceived toxicity/potency of medication 
(Horne, Weinman, Barber, Elliot, & Morgan, 2005) and risk reduction associated with 
warfarin. This procedure is reliant on their ability to balance the risks associated with 
their treatment with those associated with their condition (i.e. stroke risks associated 
with AF vs. bleeding risks associated with warfarin).  
 
Many AF patients may have preconceived ideas about how harmful warfarin is; for 
example patients are more willing to take warfarin when they are blinded to the name 
of the treatment (Holbrook, Labiris, Goldsmith, Ota, Harb, & Sebalt, 2007; Fuller, 
Dudley, & Blacktop, 2004), highlighting the negative connotations this treatment has. 
It is important that patients do not rely on inaccurate perceptions of harm, and that 
their risk evaluation draws upon reliable knowledge. The TREAT findings suggest 
that by reducing patients’ perception of harm, it may be possible to increase 
adherence levels. This was achieved by discussing patient barriers within the 
intervention session; including inaccurate perceptions. ‘Expert’ patient narratives 
discussed their own experiences of bleeding and bruising, and the intervention group 
were able to assimilate this risk information into their own belief system. 
 
The intervention group scored lower on perceived over-prescription and overuse of 
medication by health care professionals at all time points (including baseline); these 
differences were greater following the intervention, but there were no significant 
differences between groups. Previous cross-sectional (n=321) evidence has 
suggested our general beliefs about medication remain stable over time, including 
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our general beliefs about whether medicines are over-used or over-prescribed 
(Porteous, Francis, Bond, & Hannaford, 2010). This may explain why there were no 
significant changes post-intervention. However, it is also possible that experiencing a 
new treatment regime, and receiving an appropriate intervention, could change 
perceptions, as evidenced by the fluctuating perception of general harm across time 
in this study. An assessment of patients’ general beliefs about medication can prove 
useful, even if we are unable to target them within a behavioural intervention; as 
where patients perceive medications as overused and even harmful, they may be 
less likely to adhere (Horne, Weinman, Barber, Elliot, & Morgan, 2005).  
 
There were no significant differences between groups or across time in their 
perception of the specific necessity for the medications for AF. Both groups scored 
highly on this subscale at all time-points, suggesting that all patients within the trial 
view their medication for AF as highly necessary. Previous research has found that 
those patients scoring higher on the necessity sub-scale are more likely to adhere to 
treatment recommendations (Horne, Weinmann, & Hankins, 1999; Menckeburg, et 
al., 2008; Bane, Hughes, & McElnay, 2006; Horne, Weinman, Barber, Elliot, & 
Morgan, 2005). Data from one cross-sectional study, found significant associations 
between specific necessity scores and both self-reported adherence and prescription 
refill adherence for the previous 12-months (Menckeburg, et al., 2008). Whilst this 
was a retrospective study and with a younger sample (18-45 year old asthmatics), it 
does highlight the link between patients’ beliefs about medication and their 
adherence levels. Similarly, a cohort of patients attending a cardiac outpatient clinic 
(n=122), were more likely to adhere to treatment where they scored highly on the 
specific necessity subscale (Bane, Hughes, & McElnay, 2006). Although specific 
necessity did not predict TTR in the TREAT study, it may have influenced whether 
patients adhered to behavioural recommendations; as there was no inclusion of a 
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self-reported adherence measure, which has been significantly associated with 
perceived necessity for numerous conditions (Horne, Weinmann, & Hankins, 1999). 
 
There were significant differences between the intervention and usual care groups 
perception of specific concern about their AF medications (F (1, 51) =5.84; p=0.01). 
Patients in the intervention group were less concerned about their medication at all 
time points; with no significant changes across time. Previous evidence suggests that 
those patients scoring higher on the specific concern subscale are less likely to 
adhere to medication (Horne, Weinmann, & Hankins, 1999; Menckeburg, et al., 2008; 
Neame & Hammond, 2005). This could provide some explanation as to why the 
intervention group spent more time in therapeutic range, although results do not 
suggest a causal link between specific concerns and TTR. 
 
Using the sub-scales of the beliefs about medication questionnaire, it is possible to 
calculate a necessity-concerns differential score. This represents the difference 
between patients’ concerns about their AF medication and their perception of its 
necessity; and there were significant differences across time (F (3, 51) = 2.87; 
p=0.04) and between groups (F (1, 51) = 4.09; p=0.04) on this measure. The 
intervention group scored higher, suggesting patients perceived the necessity for 
warfarin as more important than their concerns about taking it. Baseline differential 
scores significantly correlated with TTR at six months (p=0.04), suggesting those 
patients with lower scores on specific concern, and higher scores on specific 
necessity (thus higher differential scores), also spent more time in therapeutic range. 
This supports previous evidence with depressed patients taking selective serotonin 
reuptake inhibitors; whereby high necessity and low concern scores surrounding their 
anti-depressants were associated with greater self-reported adherence (Aikens, 
Nease, Nau, Klinkman, & Schwenk, 2005).  
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In both the intervention group and the usual care group, the median differential score 
was positive at all time points. This suggests that all patients regarded the necessity 
of their treatment to outweigh the concerns or costs of the regime, supporting 
evidence from a cross-sectional study with cardiac clinic patients, where 94.5% of 
patients scored highly on the necessity of medication sub-scale (Bane, Hughes, & 
McElnay, 2006). Evidently AF patients view the reduction of stroke risk, and 
subsequently the need for treatment, as more important than the potential bleeding 
risks associated with warfarin. This also supports qualitative evidence surrounding 
patients’ perceptions of warfarin and their willingness to accept bleeding risks in 
order to reduce their risks of suffering from a stroke (Fuller, Dudley, & Blacktop, 
2004). Thus, AF patients’ perception of risk is extremely important, as those patients 
who understand the necessity of the warfarin regime are more likely to adhere. 
 
6.1.4 Quality of life 
 
At baseline the intervention group had significantly poorer quality of life (QoL) than 
those receiving usual care, although these differences were not apparent at 
subsequent time points (see results section 5.3.2.2.1). However, due to attrition rates 
at the two and six month follow-ups, the analyses of variance only included those 
patients who took part at each time point. Therefore the findings may not be 
representative of those patients who did not complete the questionnaire at each time 
point. Subsidiary analyses of the change in QoL from baseline to the one month 
follow-up suggest significant differences in the global QoL subscale between groups 
(p=0.01). Global QoL (an inclusive measure of psychological and physical quality of 
life) increased in both groups following baseline; therefore this increase was 
significantly greater in the intervention group. When compared to healthy controls, 
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patients with coronary heart disease or the general population (Thrall, Lane, Carroll, 
& Lip, 2006; Howes, Reid, Brandt, Ruo, Yerkey, & Prasad, 2001; Dorian, Jung, & 
Newman, 2000), QoL is substantially impaired in AF; patients score poorest on 
general health, vitality, physical, social and emotional role functions (Carlsson, 
Miketic, Windeler, Cuneo, Haun, & Micus, 2003; Gronefield, Lilienthal, Kuck, & 
Hohnloser, 2003; Hagens, Ranchor, Van Sonderen, Bosker, Kamp, & Tijssen, 2004; 
Thrall, Lane, Carroll, & Lip, 2006). As many AF patients are highly symptomatic 
(ESC, 2010) symptom relief can improve reported quality of life (Thrall, Lip, Carroll, & 
Lane, 2007; Smith, Lip, & Lane, 2010). However, where the burden is psychological 
or stemming from other factors, such as the warfarin treatment regime, improving 
QoL may be more difficult.   
 
Few studies have examined how quality of life changes over time, following diagnosis 
and/or treatment onset. The TREAT results suggest that both groups appear to have 
a relatively stable QoL score across time, with similar physical and psychological 
burden. As the majority of patients are older (≥65 years), at moderate to high risk of 
stroke (CHADS2 score 3), with numerous co-morbidities (e.g. diabetes, hypertension, 
chronic obstructive pulmonary disease), they may also be dealing with the treatment 
and symptom burden of other conditions or older age; and it may be difficult to 
determine specific causal factors. One study examining psychological morbidity in 
‘lone’ AF (‘lone’ signifying the absence of other cardiac morbidity and predisposing 
factors)  found no significant differences in QoL between AF patients and mean 
population norms (Lane, Langman, Lip, & Nouwen, 2009); therefore, perhaps the 
psychological morbidity exhibited in AF is largely determined by the co-morbidities 
that are common in older patient groups. 
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6.1.5 Illness perceptions 
 
Numerous studies in the literature have examined at the relationship between illness 
perceptions and whether or not patients adhere to their treatment regimes (Cooper, 
Lloyd, Weinman, & Jackson, 1999; Steed, Newman, & Hardman, 1999; Buick & 
Petrie, 2002; Scharloo, et al., 1998; Griva, Myers, & Newman, 2000; French, Lewin, 
Watson, & Thompson, 2005). Very few studies have developed interventions which 
aim to change illness perceptions, and subsequently improve adherence levels. The 
present study findings suggest that there were no significant differences between 
groups across any of the illness perception questions other than perceived cause 
(see results Section 5.3.2.1). This contradicts previous evidence where interventions 
using the principles of the common sense model have found changes illness 
perceptions (Petrie, Weinman, Sharpe, & Buckley, 1993; Fischer, et al., 2010). For 
example one 12-week rehabilitation programme, consisting of individualised 
counselling, tailored exercises and group education for patients with chronic 
obstructive pulmonary disease, found significant increases in personal control and 
perceived timeline following the intervention (Fischer, et al., 2010). However, 
previous studies have used a more individualised intervention approach; assessing 
unique illness perceptions, and targeting specific problematic areas (Petrie, 
Weinman, Sharpe, & Buckley, 1993; Fischer, et al., 2010). Thus, the TREAT 
intervention, which aims to be accessible for the lay educator within usual hospital 
care, and generic in its approach, may not have the same impact, but rather help to 
prevent the formation of inaccurate illness representations.  
 
At baseline, the majority of patients thought that there was a psychological cause 
(e.g. stress or bereavement; 41%), or an external cause of their illness (e.g. age or 
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previous morbidity; 31%); fewer blamed lifestyle factors (e.g. smoking, diet or lack of 
exercise; 29%). At the one month follow-up, more patients believed that there was an 
external cause of their AF (48%), rather than a psychological cause (33%). At each 
follow-up, the intervention group were more likely to perceive the cause as external, 
while patients in the usual care group were more likely to perceive the cause of their 
AF as psychological. These differences were significant at 6 months (p=0.04). This 
indicates that patients did change their perception of cause after receiving the 
intervention.  
 
Patients in the intervention group had a more accurate perception of their illness 
following the intervention, stating established causal factors including age, male 
gender, hypertension, valvular heart disease, heart failure, coronary artery disease, 
diabetes (Benjamin, Levy, & Vaziri, JAMA, 1994; Gami, et al., 2007; Furberg, Psaty, 
Manolio, Gardin, Smith, & Rautaharju, 1994; Krahn, Manfreda, Tate, Mathewson, & 
Cuddy, 1995; Schnabel, et al., 2009), and genetic factors (Amar, et al., 2006; Fox, et 
al., 2004). AF patients have previously reported psychological causes of AF 
(McCabe, Barnason, & Houfek, 2011), despite evidence to the contrary; which could 
contribute to the emotional burden of their illness. On the contrary coronary artery 
disease (CAD) patients are more likely to believe that lifestyle factors caused their 
illness (Astin, Closs, McLenachan, Hunter, & Priestly, 2009); and changing lifestyle 
factors represents an area patients are able to control, as opposed to external factors 
such as age, or other co-morbidities. This may explain why AF patients in both 
treatment groups felt in control of their treatment, but not of their illness.  
 
The lack of symptom predictability; or the cyclic nature of symptom presentation may 
leave patients feeling out of control (McCabe, Barnason, & Houfek, 2011). Indeed 
patients with paroxysmal AF and those with unpredictable symptoms have exhibited 
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the poorest QoL in a previous study (Thrall, Lane, Carroll, & Lip, 2006). The 
treatment regimen may provide them with an opportunity to feel in ‘control’ of their 
medication regime by providing regular feedback from blood tests and INR results, as 
well as an opportunity to adapt their lifestyle to ensure they remain within therapeutic 
range. The intervention aimed to enhance patients’ perceived control by focussing on 
the objective indicators of treatment regulation, and ensuring patients are aware that 
the presence or absence of symptoms is not an indication of illness control or 
recovery.  
 
There were significant differences within groups for emotional representation of 
illness across time; suggesting that the extent to which AF affects patients 
emotionally fluctuated across the six month period. Previous evidence with lone-AF 
patients has found significant changes in energy and general health perception 
across time, but no change in physical and social functioning (Lane, Langman, Lip, & 
Nouwen, 2009). These changes could be a result of diagnosis, as McCabe and 
colleagues found that a diagnosis of AF induces negative emotions (McCabe, 
Barnason, & Houfek, 2011). Having AF made patients feel anxious (59%), afraid 
(43%), depressed (37%) and angry (26%) (McCabe, Barnason, & Houfek, 2011) and 
the psychological burden of AF was also apparent in other studies (Carlsson, Miketic, 
Windeler, Cuneo, Haun, & Micus, 2003; Gronefield, Lilienthal, Kuck, & Hohnloser, 
2003; Hagens, Ranchor, Van Sonderen, Bosker, Kamp, & Tijssen, 2004; Thrall, 
Lane, Carroll, & Lip, 2006). Thus the emotional impact of diagnosis and treatment 
may fluctuate over time; and the psychological morbidity associated with AF appears 
to be similar to other cardiac conditions, including patients treated with PCI (Astin, 
Closs, McLenachan, Hunter, & Priestly, 2009), or awaiting CABG (Hermele, Olivio, 
Namerow, & Oz, 2007).  
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Illness concern at the first follow-up was found to predict TTR (r= -.199; p=0.05). This 
evidence contradicts previous studies with MI patients, which found illness 
perceptions do not predict attendance to cardiac rehabilitation (French, Lewin, 
Watson, & Thompson, 2005). Our findings suggest that patients who are more 
concerned about their illness were less likely to adhere, and overcoming these 
barriers or concerns by discussing them with the health care practitioner should form 
part of the usual care procedure. Qualitative evidence suggests that AF patients’ 
concerns surrounding illness can include worry about the impact upon their family 
and relationships; including being viewed as lazy or unproductive by co-workers 
when symptoms prevented them from being able to carry out work related tasks 
(McCabe, Schumacher, & Barnason, 2011). It is possible that those patients who are 
most concerned about their illness and its impact, may avoid the further social 
‘burden’ of treatment recommendations (including attending regular blood checks, 
avoiding excessive alcohol intake, and dietary limitations).  
 
The high scores on the ‘timeline’ question suggest that patients viewed their illness 
as continuing indefinitely, a result that did not fluctuate significantly over time or 
between groups. This perception could be an accurate reflection of their diagnosis, 
as AF is often a lifelong illness, typically treated with anticoagulation indefinitely 
(ESC, 2010). One problem with using the IPQ-B is that it does not assess patients’ 
perception of the cyclic nature of their illness. Previous evidence suggests AF 
patients view their illness as cyclic rather than long-term (McCabe, Barnason, & 
Houfek, 2011). However, McCabe and colleagues had a higher percentage of 
symptomatic paroxysmal patients (64%) in their study, thus the results may be 
affected by the differences between samples. 
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There is limited evidence evaluating psychological burden and changes across time 
within this patient group, thus the TREAT intervention is the first of its kind to utilise 
psychological theory as a basis for an intervention for AF patients and may provide a 
design platform for future development. Finally, the validity of the IPQ-B has been 
deliberated in recent articles (van Oort, Schroder, & French, 2011). Thus, it is 
possible that some of the differences between groups were not identified due poor 
sensitivity of the evaluation tools (for an extended discussion see limitations, Section 
6.2). 
 
6.1.6 Anxiety & depression  
 
There were no significant differences between groups in terms of anxiety and 
depression levels at baseline or throughout follow-up. This suggests the intervention 
did not have a positive or negative effect on psychological morbidity. Whilst the 
intervention was not designed to reduce anxiety or depression levels, findings do 
indicate that giving patients more information did not have a negative impact on their 
psychological morbidity. Of those trials included in the systematic review of 
behavioural interventions (see Chapter 2), only one measured anxiety (Thomson, et 
al., 2007).  Anxiety fell significantly in both groups pre- to post-intervention, mean 
change -4.57 (95% CI) -6.30 to -2.84), but there was no evidence of a significant 
difference in anxiety between the two groups (F (1, 95) = 0.001; p=0.98) (Thomson, 
et al., 2007). This supports the present findings, that receiving more information does 
not increase anxiety. However, in the study by Thomson and colleagues anxiety 
levels dropped, in contrast to the increase in the TREAT study; which may be partly 
explained by differences between cohorts. Notably, patients in the Thomson et al 
study had previously taken warfarin, thus may have been less anxious about the 
medication regime due to prior experience. Furthermore, they trialled a decision aid, 
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whereby not all patients chose to take warfarin (some took aspirin), thus the study 
findings are not comparable. 
 
The levels of anxiety and depression increased dramatically in both groups following 
post-baseline (p<0.001; see results section 5.3.3). As all patients were diagnosed 
prior to baseline, this indicates that the diagnosis of AF was not causing the distress, 
but rather the commencement of treatment with warfarin was having a significant 
negative impact. The warfarin regime requires several changes to a patient’s lifestyle. 
Regular INR monitoring is achieved via blood testing, which often takes place at a 
community GP surgery or hospital outpatient clinic. Furthermore, patients are given 
lifestyle recommendations based on the numerous factors which can influence 
warfarin metabolism (including dietary intake, alcohol restrictions and potential 
medication interactions). This may explain the significant increase in anxiety in both 
groups after baseline and the continued feelings of anxiety during the ensuing six 
months. Despite the necessary lifestyle changes, very few patients chose not to take 
warfarin; a finding supported by Fuller and colleagues (Fuller, Dudley, & Blacktop, 
2004). One qualitative study suggested that whilst patients reported the impact the 
treatment regime had, from minor inconveniences (e.g. INR tests affecting travel 
plans) to major complications (e.g. severe bleeding), the medication regime was 
placed at the centre of their daily routine (Coelho-Dantas, Thompson, Manson, 
Tracy, & Upshur, 2004). Thus, whilst patients continue to take their treatment, they 
may remain reticent or anxious about doing so.  
 
Findings support those of other studies suggesting patients with AF in general have 
higher levels of anxiety and depression than population norms or healthy- and 
disease- controls (Frasure-Smith, et al., 2009; Thrall, Lip, Carroll, & Lane, 2007; 
Lane, Langman, Lip, & Nouwen, 2009). Whilst the TREAT intervention did not aim to 
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improve psychological morbidity, the findings support the additional need for 
inclusion of intensive behavioural interventions aimed at reducing anxiety levels 
specifically for AF patients initiating warfarin or other anticoagulation treatment, in 
conjunction with a routine psychological screening process within outpatient clinics.  
 
Screening is particularly important as previous studies with AF and comparable 
cardiac conditions, such as heart failure, suggest that those patients with significant 
psychological morbidity also face poorer clinical prognosis in terms of cardiovascular 
mortality (Frasure-Smith & Lesperance, 2006; Lett, et al., 2004). Psychological mood 
state, specifically anger, has been found to trigger ventricular arrhythmia in patients 
with implantable cardioverter-defibrillators (Lampert, Joska, Burg, Batsford, 
McPherson, & Jain, 2002). Moreover, the AF-CHF trial of 974 AF patients with 
congestive heart failure found elevated BDI-II depression scores significantly 
predicted cardiovascular death (Hazard Ratio 1.30, 95% CI 1.16-1.46, p<0.001), 
arrhythmic death (HR 1.36, 95% CI 1.15-1.60, p=0.001) and all-cause mortality (HR 
1.23, 95% CI 1.11-1.37, p<0.001) (Frasure-Smith, et al., 2009). Thus, physicians 
need to consider the impact of psychological morbidity on patients’ clinical outcomes. 
 
Psychological morbidity is an important factor predicting arrhythmic disturbance, 
stroke and mortality (Frasure-Smith & Lesperance, 2006; Lampert, Joska, Burg, 
Batsford, McPherson, & Jain, 2002; Lett, et al., 2004). The systematic review 
reported in Chapter 2 found none of the interventions specifically targeted 
psychological morbidity in this high risk AF group. In a similar cohort of coronary 
artery disease patients, one review (of 16 trials) found behavioural interventions 
(including cognitive behavioural therapy (CBT), psychodynamic psychotherapy and 
counselling) targeting depression, have had a small but beneficial effect on 
depression severity and remission rates when compared to usual care; these effects 
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were significant in the short and long term (Baumeister, Hutter, & Bengel, 2011). 
Short term effects were also found in pharmacological intervention studies with 
selective serotonin reuptake inhibitors; with a significant 1.8-fold (95% CI 1.18 to 
2.74) reduction in depression (Baumeister, Hutter, & Bengel, 2011). However, there 
appears to be a dearth of high quality trials examining the impact of intensive 
psychological interventions in chronic physical illness (Lane, Chong, & Lip, 2009; 
Baumeister, Hutter, & Bengel, 2011).  
 
It essential that AF patients are screened for depression and anxiety within outpatient 
clinics at diagnosis and post-treatment initiation when they face the greatest risk of 
psychological morbidity; as the results of the TREAT trial suggest that this may occur 
when patients begin a new and complex treatment regime. The AF-CHF trial 
identified patient characteristics significantly associated with depression, including 
those patients who were women, non-white, unmarried, and with fewer years in 
education (p<0.001) (Frasure-Smith, et al., 2009). By identifying more factors 
associated with depression and anxiety it may be possible to development a risk 
profile and screening procedure to form part of the usual care process. 
 
6.2 Strengths and Limitations 
 
There are some limitations with the TREAT study design and evaluation which need 
to be considered when interpreting the findings. The demography of the cohort 
reflects the typical presentation of AF, for example, there were more males than 
females (63.6% vs. 34.3%), this reflects the prevalence of AF in clinical practice 
(Lloyd-Jones, et al., 2004). Similarly, the TREAT cohort were mostly 65-74 years 
(48.5%), or older (aged ≥75; 37.1%), which also supports previous epidemiological 
findings (Stewart, Hart, & Hole, 2001). Whilst a specific diagnosis of ‘type’ of AF was 
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not available for all patients, for those who were categorised, there were a high 
percentage of PAF patients (30.9%). Similarly in clinical practice PAF patients 
represent 25 to 62% of AF cases seen by physicians and GPs (Kannel, Wolf, & 
Benjamin, 1998; Takahashi, Seki, Imataka, & Fujii, 1981).  
 
The majority of the TREAT participants were of white ethnicity, which does not reflect 
the multi-ethnic community of the West Midlands; but it does reflect the disease 
prevalence, as AF is predominantly seen in White populations (Shen, et al., 2010). 
Inclusion of a more ethnically diverse population may have altered the findings; as 
one local study found ethnic differences in patient knowledge surrounding OAC 
(Nadar, Begum, Kaur, Sandhu, & Lip, 2003). However, cross-sectional research in 
the US (n= 430,317), searching electronic echocardiography archives, suggests the 
prevalence of AF is much higher in Whites (44.9%), than Black (9.4%), Asian (7.5%) 
or Hispanic (19%) ethnicities (Shen, et al., 2010). Thus perhaps the TREAT 
participants are more representative of those patients presenting with AF, than of the 
local ethnic population. Nonetheless, to ensure that the intervention materials are 
applicable for all AF patients, they would need to be available in a range of 
languages, as well as being culturally sensitive (e.g. including specific dietary 
requirements). 
 
The symptoms patients experience and the predictability of a patient’s ventricular 
rate is an important determinant of QoL (Thrall, Lane, Carroll, & Lip, 2006) and 
therefore patients who are more symptomatic, with uncontrolled AF, may be more 
likely to report poorer quality of life (Smith, Lip, & Lane, 2010); yet the TREAT study 
did not include an assessment of patients’ symptoms at baseline or over time, which 
may be reflected within the results.  Equally symptoms may influence patients’ illness 
perceptions, as the identity question within the IPQ-B specifically asks about 
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symptoms, and there have been significant differences between symptomatic and 
asymptomatic patients on this item in previous studies (Steed & Newman, 1999). 
Since the design of the TREAT trial, the new ESC guidelines recommend 
classification of symptoms using the EHRA scoring system (see Section 1.2.1) as an 
important indicator of AF burden (Lip, et al., 2011). Therefore, future research should 
include an indication of the level of symptom burden for AF patients, and potentially 
examine any differences between groups. 
 
This trial was also limited by its small sample size. Whilst other trials have found 
significant differences between groups with similar samples e.g. (Khan, Kamali, 
Kesteven, Avery, & Wynne, 2004), it is possible that many important relationships 
between factors studied remained undetected, due to a lack of statistical power (type 
II error). This is especially the case in the follow-up outcomes, as attrition increased 
as the study progressed, with the most notable levels at the two and six month 
follow-ups (44% and 42% attrition respectively, see results section 5.1). Furthermore, 
the use of a mixed models analysis allowed some flexibility in treating time as a 
continuous variable, accurately assessing the model regression line for time, rather 
than relying on an estimate of means. However, the use of a repeated measure 
design only includes a participant’s data where they respond at all time points, 
excluding any patients who did not respond to all follow-ups. Nonetheless, the 
primary outcome does not rely on repeated measure analyses, and still indicated 
significant differences between groups. Furthermore, where necessary, conservative 
p-values were adopted to ensure relationships between variables were not over-
estimated. Moreover the findings do give an indication of the impact of a one-off 
educational intervention on treatment control, and future studies may replicate the 
study with larger sample sizes to further explore interrelationships between variables, 
with correspondingly greater statistical power. 
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The systematic review (Chapter 2) highlighted the difficulties in blinding the data 
analyst or researcher to which intervention arm the patient was assigned. It is 
possible to blind the analyst to group assignment, but this was only undertaken in 
four of the trials included in the review (McAlister, et al., 2005; Christensen, Magaard, 
Sorensen, Hjortdal, & Hasenkam, 2006; Gadisseur, Kaptein, Breukink-Engbers, van 
Der Meer, & Rosendaal, 2004; Beyth, Quin, & Landefeld, 2000). However, the 
TREAT study integrated a systematic randomisation procedure (see methods 
Section 4.2). Furthermore, the use of randomisation codes ensured that the 
researcher carried out blinded questionnaire scoring, reducing the risk of bias. 
 
The number of patients eligible for the study was 331, thus 29% of those eligible 
were included in the final cohort. Reasons given for non-participation included 
mobility issues, how time-consuming participation would be and the burden of other 
co-morbidities. This leaves a possibility of inclusion bias, as the demographic 
differences between participants and non-participants is well established. Those 
patients taking part in randomised trials are often healthier (Osler & Schroll, 1992), 
more educated (Alkerwi, Sauvageot, Couffignal, Albert, Lair, & Guillaume, 2010) and 
more motivated to change their behaviour (Graham, et al., 2008), than non-
participants. Thus the results of this trial may not generalise to all AF patients, and 
the intervention may have a greater or poorer impact if used as a usual care 
procedure. Based on those trials included in the review, the percentage of eligible 
patients randomised into trials can be as little as 18% (Gadisseur, Kaptein, Breukink-
Engbers, van Der Meer, & Rosendaal, 2004). Therefore, the TREAT study is 
comparable, if not more representative, than some other trialled interventions with 
this group.  
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The development of the TREAT intervention included piloting the materials with 
‘expert’ patient groups, the integration of current clinical guidelines, guidance from 
expert cardiologists and the use of theoretical models (see intervention development 
Chapter 3). The MRC framework for interventions recommends additional theoretical 
modelling to determine whether the components of the intervention are relevant to 
the patient group (MRC, 2000). Whilst we took into consideration the findings from 
previous studies (McCabe, Barnason, & Houfek, 2011; Steed, Newman, & Hardman, 
1999), neither of these studies examined illness perceptions as a predictor of 
treatment adherence. Therefore, whilst the development stage did not include a 
formal pilot study to trial which intervention components were most successful; the 
trial findings do allow for future development of the materials, focussing specifically 
on the key beliefs and perceptions that significantly predict TTR.  
 
In order to determine the effectiveness of an intervention, we rely on the validity and 
reliability of the measurement tools. Recently, the validity of the Brief-IPQ has been 
called into question. Originally this questionnaire was included as an alternative to 
the IPQ-Revised, in order to reduce patient fatigue. However, reviews of the 
questionnaire have challenged the level of criterion validity (i.e. the extent to which 
questionnaire items test what they are supposed to be testing) (van Oort, Schroder, 
& French, 2011). The validation paper of the IPQ-B suggests that it is developed by 
forming one question which summarised the items on each subscale of the IPQ-
Revised. The authors of the critique paper suggest that construct validity is flawed, 
as one questionnaire item cannot assess all aspects of a construct (van Oort, 
Schroder, & French, 2011). Patients appear to have problems in completing the 
questionnaire, particularly personal control, identity, illness coherence, emotional 
representation and causal attribution items. Items relating to cause and control were 
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often misinterpreted and the identity item caused the most difficulty (van Oort, 
Schroder, & French, 2011).  
 
Similarly in the TREAT study it is clear that the identity item could give misleading 
results. The question focussed on symptoms ‘How much do you experience 
symptoms from your illness?’, and patients with AF vary in their presentation of 
symptoms, and have responded differently to the identity question in a previous study 
(Steed & Newman, 1999). Thus the questionnaire may lack construct validity in not 
assessing the entirety of the identity component. The results from the ‘think aloud 
study’ also suggest that patients do not answer the questionnaire for one illness 
specifically (van Oort, Schroder, & French, 2011). This could be problematic, as the 
TREAT cohort has a range of co-morbidities, including diabetes, heart failure, and 
hypertension. Thus our results may not give an accurate or ‘complete’ evaluation of 
the impact of the intervention on patients’ AF-specific illness perceptions. 
 
6.3 Clinical implications 
 
Patient beliefs about their health can influence their decision to accept, decline, or 
comply with anticoagulant therapy, particularly warfarin. Several barriers to oral 
anticoagulation therapy can be related to patients’ beliefs, including fear of the 
increased bleeding risks with warfarin, and the inherent difficulties associated with 
warfarin such as drug-, diet-, and alcohol-interactions, as well as lifestyle changes 
because of regular monitoring and dose adjustments. The results of the TREAT 
study suggest that by informing patients about their illness and targeting their beliefs 
about their medication, we can improve their understanding and subsequently 
improve patient adherence. The TREAT intervention differs from usual care by 
including ‘patient focussed’ educational materials, for example, using a DVD with 
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‘expert patient’ narratives, and including patients themselves in the development 
process. The intervention also provides a variety of different media to appeal to all 
learning styles and reinforce the key messages. By using the findings of the TREAT 
study we can begin to understand factors that may improve patients levels of 
anticoagulation control (see Figure 6.1). The study findings suggest that sustained 
knowledge, beliefs surrounding treatment necessity and harm and patients concerns 
about their AF can all play a role. The TREAT intervention can have an affect on 
these perceptions. For example, where patients have concerns about their AF or 
their treatment these may be alleviated, reducing the risk of intentional non-
adherence. 
 
Figure 6.1: TREAT model of factors influencing INR control. 
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Some self-management trials have demonstrated that interventions with atrial 
fibrillation (AF) patients can increase time spent within the therapeutic INR range 
(Khan, Kamali, Kesteven, Avery, & Wynne, 2004; Gadisseur, Kaptein, Breukink-
Engbers, van Der Meer, & Rosendaal, 2004; Christensen, Magaard, Sorensen, 
Hjortdal, & Hasenkam, 2006), thus potentially decreasing the prevalence of adverse 
thromboembolic and haemorrhagic events (Wan, et al., 2008). Whilst self-
management improves anticoagulation control, this may not be a feasible option for 
the majority of the patients requiring anticoagulation, due to the training required 
(Fitzmaurice & Machin, 2001). In addition, the associated costs of self-monitoring 
may prevent wide-scale uptake (Fitzmaurice & Machin, 2001), particularly with the 
arrival of new oral anticoagulants which do not require monitoring (Lip, et al., 2011; 
Wrigley, Lip, & Shantsila, 2010).  
 
Whilst novel OAC provides an alternative treatment, without the burden of INR 
monitoring and lifestyle changes; there is likely to be further resistance to prescribing 
them due to cost compared to warfarin.  In addition, patient preferences for OAC 
treatment are also important (Lane & Lip, 2007; Nadar, Begum, Kaur, Sandhu, & Lip, 
2003) in facilitating a shared decision-making process; and many patients may 
choose warfarin, or be unable to take the new OACs.  Clinicians are often reluctant to 
prescribe warfarin (due to lack of knowledge surrounding OAC and inexperience 
prescribing it to patients) and the intervention may help to alleviate some of these 
fears, increase uptake and adherence, and translate into fewer adverse outcomes. 
Thus a one-off intensive intervention package provides a cost-effective alternative in 
improving INR control, and this intervention could be adapted for use with novel 
anticoagulant drugs. 
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While there are usual care practices in place which provide educational materials for 
newly referred patients, these procedures vary substantially between hospitals and 
are often generic, not specifically considering the illness and reason for OAC 
prescription. It is evident that there needs to be a greater focus on disease-specific 
patient education for high risk treatments, so that patients understand the link 
between their treatment and the risks associated with their condition.  
 
6.4 Future directions 
 
In AF, warfarin has been the mainstay oral anticoagulant for the past 50 years; 
however novel oral anticoagulants are in development and have been tested in 
Phase III clinical trials. For example, the recent results of the Randomized 
Evaluation of Long- Term Anticoagulation Therapy (RE-LY) study suggest 
dabigatran is non-inferior to warfarin in reducing the risk of stroke, with fewer 
bleeding complications (Connolly, et al., 2009). In addition, novel OAC do not 
require regular blood tests (i.e., no INR monitoring) and do not appear to have 
drug-, food- and alcohol- restrictions, as seen with warfarin. 
 
However, there is a lack of evidence on patients’ perceptions of novel oral 
anticoagulants and the impact of patients’ beliefs about novel oral anticoagulants 
on uptake and adherence. Further, the availability of novel oral anticoagulants will 
shift the pattern of initiating anticoagulants from secondary to primary care.  
Therefore, it is pertinent to understand how physicians perceive novel 
anticoagulants, how they make decisions about whether or not to prescribe 
antithrombotic therapy, the choice of appropriate anticoagulant therapy, and 
whether or not there are important differences between general practitioners and 
cardiologists in these factors affecting anticoagulant treatment decisions. 
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In the future the TREAT intervention materials will also need to be developed, aiming 
to [1] adapt the intervention for use with a range of OAC including the new 
anticoagulants, [2] to ensure that the intervention is widely available in a number of 
hospitals and GP practices across the country, and [3] to provide the existing and 
updated educational materials to patient organisations for inclusion within their 
patient materials (physical) and on-line.  
To disseminate the intervention so that it is widely available for use in both research 
and clinical practice, it is possible to develop a website allowing specific focus on the 
psychological and practical barriers to adhering to anticoagulant therapy and lifestyle 
recommendations that have been highlighted in numerous studies (Coelho-Dantas, 
Thompson, Manson, Tracy, & Upshur, 2004; Hylek, Evans-Molina, Shea, Henault, & 
Regan, 2007; Fuller, Dudley, & Blacktop, 2004). Filmed patient narratives could also 
be available from the original TREAT intervention, alongside filmed expert-responses 
to some of the key patient concerns (i.e. missed dose, side effects and psychological 
side effects). This will aim to increase awareness of patient barriers and act as a 
social comparison tool for patients who are concerned about their treatment or 
condition. Our research group have existing links with charities, patient organisations 
and professional bodies that already provide educational materials to AF patients 
(e.g. Atrial Fibrillation Association (AFA); Anticoagulation Europe (ACE); StopAFib) 
and it may be possible to collaborate with these groups to improve the educational 
resources for patients. 
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6.5 Conclusion 
 
The TREAT intervention provides a simple one-off behavioural session, which could 
be delivered by any health care practitioner (with appropriate training), and 
significantly improves adherence to warfarin as evidenced by greater TTR. Improving 
understanding about a disease and its treatment allows patients to make informed 
decisions about the management of their condition and treatment and can make a 
significant difference to adherence outcomes. The intervention’s ability to improve 
adherence is reliant on providing adequate information surrounding risks so that 
patients can ‘trade-off’ the risks and benefits of their new medication. It further 
highlights the importance of AF patients’ perceived necessity of medication and 
concerns or barriers about taking warfarin, which in turn will influence adherence, 
TTR, and subsequently clinical outcomes. By integrating theory-driven behavioural 
change techniques into usual care practices, and improving our methods of 
communication we may endeavour to improve patients’ health outcomes in both the 
short- and long-term. 
 
Table 6.1: Key findings from the TREAT study 
Key findings 
 Disease specific education can significantly improve INR control, even where 
TTR is relatively well controlled within usual care. 
 Those patients with sustained knowledge over time, lower illness concern, 
and decreased perception of treatment harm are more likely to adhere to 
OAC medication. 
 Patients with AF commencing OAC are at increased risk of psychological 
morbidity and clinical guidance should reflect that by improving screening and 
intervention provision. 
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 Patient Information Sheet 
 
Part 1 
 
Study title 
TRial of an Educational intervention on patient’s knowledge of Atrial fibrillation and 
anticoagulant therapy, INR control, and outcome of Treatment with warfarin (TREAT) 
 
Dear Patient 
 
We would like to invite you to take part in a research study.  Before you decide it is 
important for you to understand why the research is being done and what it will involve.  
Please take time to read the following information carefully and discuss it with others if 
you wish.  Part 1 tells you the purpose of this study and what will happen to you if you 
take part. Part 2 gives you more detailed information about the conduct of the study.  
Ask us if there is anything that is not clear or if you would like more information.  Take 
time to decide whether or not you wish to take part.  
 
What is the purpose of the study? 
The purpose of this study is to examine whether giving patients like you, with atrial 
fibrillation (an irregular heart rhythm) more detailed information about your condition, the 
need for treatment with a blood-thinning medication called warfarin and the risks and 
benefits of taking warfarin, will help to improve how well-controlled your warfarin 
treatment is, compared to patients receiving usual care.  In addition, this study will also 
assess whether extra education improves your knowledge about atrial fibrillation and if it 
changes your beliefs about atrial fibrillation and how it is treated.  The study will also 
assess what impact your treatment has on your everyday quality of life and emotional 
well-being. Our previous studies and those of others have shown that knowledge about 
atrial fibrillation among patients with this condition is often poor and many patients do 
not understand the risks and benefits of warfarin treatment.  Our previous study showed 
that after a short educational session, patients with atrial fibrillation were more aware of 
their target INR level (a measure of how thin or thick your blood is when taking warfarin), 
the things which may affect their INR, and the risks and benefits of taking warfarin. 
 
Why have I been invited? 
You have been asked to take part in this research study because you have atrial 
fibrillation (an irregular heart rhythm).  This means that your heart does not beat in a 
regular rhythm, some or all of the time.  As your doctor will have explained to you, 
having atrial fibrillation can increase your risk of having stroke (a blood clot in your 
brain).  Other conditions, such as having high blood pressure, diabetes, heart failure, 
having had a previous stroke or mini stroke (transient ischaemic attack) and being 75 
years of age or older, can increase your risk of having a stroke further.  Your doctor has 
offered you treatment with a blood-thinning medication called warfarin, to decrease your 
risk of a blood clot forming and reduce your risk of having a stroke.  We are asking all 
patients with atrial fibrillation who have agreed to start taking warfarin if they will take 
part in this study. 
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Do I have to take part? 
It is up to you to decide whether or not to take part in the study.  We will describe the 
study and go through this information sheet, which we will then give to you.  We will then 
ask you to sign a consent form to show that you have agreed to take part.  If you decide 
to take part, you are still free to change your mind at any time and stop taking part in the 
study, and you do not have to give a reason.  A decision to withdraw at any time or a 
decision not to take part will not affect the standard of care you receive. 
 
What will happen to me if I take part? 
If you agree to take part in this study you will be asked to attend the ASCOT centre if 
attending City Hospital anti-coagulation clinic/ SMRU if attending Sandwell Hospital 
anticoagulation clinic/Good Hope Hospital [delete as applicable] before your first anti-
coagulation clinic appointment to sign the consent form.  We are trying to find out 
whether giving people more information about atrial fibrillation and its treatment can 
improve INR control and increase patients’ knowledge compared to standard care.  We 
put people into different groups and give each group a different treatment.  The results 
are compared to see if one is better than the other.  To try to make sure the groups are 
the same to start with, each patient is put into a group by chance (randomly).  There are 
two groups in this study: usual care or the educational intervention.  You have an equal 
chance of being allocated to either group. 
 
After you have signed the consent form, you will be asked to complete seven 
questionnaires.  These questionnaires ask about how you feel about taking warfarin and 
about having atrial fibrillation, how much you know about atrial fibrillation and the risks 
and benefits of taking warfarin, your experiences of taking warfarin and the impact your 
atrial fibrillation has on your life.  You can either complete the questionnaires with the 
researcher or by yourself at home. If you decide to complete them at home you will be 
given a stamped addressed envelope in which to return then to the hospital. 
 
You will be asked to complete six of these questionnaires on four further occasions: 1, 2, 
6 and 12 months after starting to take warfarin.  The questionnaires will be sent to your 
home address, with a pre-paid envelope in which to return the completed questionnaires 
to the hospital.  Four weeks after you start taking warfarin one of the study researchers 
will contact you via telephone to as you about the financial costs you have incurred by 
travelling to the hospital. This will take 5 minutes and consist of 7 questions. 
 
If you are put into the usual care group, you will receive the standard Yellow Book 
given to all patients who start taking warfarin, which explains the need for taking 
warfarin. 
 
If you are put into the education intervention group, you will also be asked to attend 
the ASCOT centre at City Hospital for a one hour group education session.  During 
this time, a doctor will go through a slide presentation and talk through all the 
information you need to know about regarding atrial fibrillation and warfarin 
treatment.  You will be given the opportunity to ask questions and the doctor will 
answer your questions.  After this session you will be given an information booklet 
containing all the information presented for you to keep and take home with you to 
read. 
 
Regardless of which group you are put into, you will attend the anticoagulation clinic to 
have your first INR check, approximately seven days after starting to take warfarin.  The 
International Normalised Ratio (INR) is a measure of how thin or thick your blood is 
when taking warfarin.  The target level for your INR is between 2.0 and 3.0.  At your first 
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visit, the dosing officer will go through the standard information contained in the 
Anticoagulation Yellow Book regarding the use of warfarin.  You will attend the 
anticoagulation clinic for all INR tests and the results of each test will be written into you 
Anticoagulant Yellow Book.  You will be followed up as part of the TREAT study for 12 
months for the date you start taking warfarin.  However, it is important to note that 
warfarin is a life-long medication to thin the blood and reduce the risk of stroke in 
patients with atrial fibrillation, and you will continue to take warfarin after the trial has 
finished, unless you decide that you do not wish to take warfarin any longer. 
 
Expenses and payments 
You will have your travel expenses (bus fare, fuel allowance and parking) reimbursed for 
the visit to the hospital when written informed consent is obtained and the first set of 
questionnaires are completed.  If you are put into the education group you will also 
receive travel expenses (bus fare, fuel allowance and parking) for the visit to the hospital 
for the group education session. 
 
What are the alternatives for diagnosis or treatment? 
Currently, warfarin is the best blood-thinning medication for people like you who are at 
moderate- to high-risk of suffering a stroke.  If during the course of this study other 
medications to thin the blood become available that are as good as or better than 
warfarin, at reducing stroke risk, then you will be informed about them and offered the 
alternative therapy. 
 
What are the possible disadvantages and risks of taking part? 
There are no disadvantages or risks to you in taking part in this study.  This study is 
comparing the effect of extra education on atrial fibrillation patients’ INR control and 
knowledge and beliefs about taking warfarin. 
 
What are the side effects of any treatment received when taking part? 
There are no side effects of the educational intervention. 
 
What are the possible benefits of taking part? 
We cannot promise that the study will help you but the information we get from this 
study may help to improve the treatment of people with atrial fibrillation in the future.  If 
you receive the extra education you may benefit from increasing your understanding of 
this condition and the medication used to treat it. 
 
What happens when the research study stops? 
We will follow-up you up for the first 12 months after you start to take warfarin.  At the 
end of the study, you will continue to take warfarin, as this is a life-long medication to 
thin the blood and reduce your risk of having a stroke, and you will continue to have your 
INR monitored at the anticoagulant clinic. 
 
What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any possible 
harm you might suffer will be addressed.  The detailed information on this is given in 
Part 2. 
 
Will my taking part in the study be kept confidential? 
Yes.  We will follow ethical and legal practice and all information about you will be 
handled in confidence.  The details are included in Part 2. 
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If the information in Part 1 has interested you and you are considering participation, 
please read the additional information in Part 2 before making any decision. 
 
 
Part 2 
 
What if new information becomes available? 
If new blood-thinning medications become available during the course of this study that 
you doctor feels may be of benefit to you compared to taking warfarin, then your doctor 
will tell you and discuss whether you should continue in the study.  If you decide to carry 
on, your research doctor will make arrangements for your care to continue.  If you 
decide to continue in the study, your doctor may ask you to sign an updated consent 
form. 
 
Alternatively, your research doctor might decide that you should withdraw from the 
study.  He/she will explain the reasons and arrange for your care to continue.  If the 
study is stopped for any other reason, we will tell you and arrange your continuing care. 
 
What will happen if I don’t want to carry on with the study? 
You can withdraw from the study at any point but we would like to keep in contact with 
you to follow-up your progress.  If you decide not to continue taking warfarin you will be 
withdrawn from the study and your reasons for stopping warfarin will be recorded. 
 
What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to speak to one of 
the researchers who will do their best to answer your questions (contact Prof Lip 0121-
507-5080/5678).  If you remain unhappy and wish to complain formally, you can do this 
through the NHS Complaints Procedure.  Details can be obtained from the hospital 
Complaints and Litigation Department on 0121-507-4346. 
 
In the event that something does go wrong and you are harmed during the research and 
this is due to someone’s negligence than you may have grounds for a legal action for 
compensation against Sandwell and West Birmingham Hospitals NHS Trust/Good Hope 
Hospital [delete as applicable] but you may have to pay your legal costs.  The normal 
National Health Service complaints mechanisms will still be available to you. 
 
Will my taking part in this study be kept confidential? 
If you join the study, some parts of your medical records and the data collected for the 
study will be looked at by authorised persons from the company sponsoring the study 
and by authorised employees of the NHS Trust.  They may also be looked at by 
representatives of regulatory authorities and by people authorised to check that the 
study is being carried out correctly.  We all have a duty of confidentiality to you as a 
research participant and we will do our best to meet this duty. 
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Involvement of the General Practitioner/Family doctor (GP) 
Your GP will be informed about your participation in this research study if you agree to 
this on the consent form. 
 
What will happen to the information I give? 
All information that is collected about you during the course of the research will be kept 
strictly confidential.  The questionnaires will not contain your name; instead you will be 
given a unique code known only to the Principal Investigator and the researchers.  The 
completed questionnaires will be kept in a secure location within the hospital and data 
stored on computers will be anonymised (using your unique code) and the computers 
will be password protected.  Only the researchers will have access to this data. 
 
What will happen to the results of the research study? 
At the end of the study, we hope to publish the results.  You will not be identified in any 
report or publication.  If you wish, we will send you a summary of our findings. 
 
Who is organising and funding the research? 
This research is being organised by the University Department of Medicine, City 
Hospital.  The study is being funded by Bayer Healthcare Pharmaceuticals to cover the 
running costs of the study.  No payments will be made to members of staff involved in 
this study. 
 
Who has reviewed the study? 
All research in the NHS is looked at by an independent group of people, called a 
Research Ethics Committee, to protect your safety, rights, well-being, and dignity.  This 
study has been reviewed and given favourable opinion by Black Country Research 
Ethics Committee. 
 
Further information and contact details 
If you have any questions about the study, please call the person listed below.  They will 
answer your questions or give you advice. 
Principal Investigator: Danielle Smith  0121-507-5053 
 
If you have any concerns about this study, please call Balvinder Baines (R&D 
department on 0121-507-4946). 
 
Thank you for taking the time to read this Patient Information Sheet and considering 
whether to take part in the study. 
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Consent form 
 
Patient Identification Number: 
 
CONSENT FORM 
Title of Project: TRial of an Educational intervention on patient’s knowledge of Atrial 
fibrillation and anticoagulant therapy, INR control, and outcome of Treatment with warfarin 
(TREAT) 
 
Name of Researchers: Danielle Smith, Dr DA Lane, Professor GYH Lip 
     
1. I confirm that I have read and understand the information sheet dated 
24/08/2009, Version 5 for the above study. I have had the opportunity to 
consider the information, ask questions, and have had these answered 
satisfactorily. 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical 
care or legal rights being affected. 
3. I understand that relevant sections of my medical notes and data collected dur
the study may be looked at by individuals from QED, from regulatory authorities or
from the NHS Trust, where it is relevant to my taking part in this research. I give my
permission for these individuals to have access to my records. 
4. I agree to my GP being informed of my participation in this study. 
 
 
5. 
 
I agree to take part in the above study. 
 
 
 
Name of Patient     Date    Signature 
 
 
Name of Person taking consent   Date    Signature 
 
 
Name of person taking consent (if different  Date    Signature 
from researcher) 
Please initial the box 
                                               
  
280 
 
 
 
 
 
 
 
 
Appendix 2 
                                               
  
281 
 
 
 Baseline demographics 
 
A: PATIENT DEMOGRAPHICS 
1. Date of Birth:      
 
2. Age:  years 
 
 
3. Sex:           M      F 
 
4. Height: 
       .    cm 
 
5. Weight:          .    kg BMI:  
 
6. Education level [please indicate [x] appropriate level] 
 
Secondary school 
 
College 
 
University 
 
Post-graduate/ Other professional qualification 
 
7. Post-code 
 
 
8. Current occupation 
 
_______________________________________________________ 
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9. Previous occupation (if different from that specified in q8) 
 
_______________________________________________________ 
 
10. What is your ethnic group? 
 
A. White         British             Irish         Any other white background 
 
 
B. Mixed        White and black Caribbean   White and Black African       Any 
other  
 
 
C. Asian or Asian British         Indian      Pakistani           Bangladeshi          Other 
Asian 
 
 
D. Black or Black British         Caribbean        African            Other Black 
 
 
E. Chinese                
 
F. Other (please specify) 
 
_________________________________________________ 
 
B: AF HISTORY 
1. Specify type of AF?    Persistent Paroxysmal Permanent  
 
2. Date of AF diagnosis:  
                day      month       year 
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3. Current antithrombotic treatment for AF 
 Aspirin  None    Other    (specify) ________________ 
 
4. Has the patient ever taken Warfarin Previously? 
 Yes  No 
 
If yes, please give details 
 
_____________________________________________________________ 
 
5. Previous stroke?      Yes         No 
 
6. Previous TIA?   Yes       No 
 
7. Previous systemic embolism?     Yes         No 
 
8. Valvular heart disease?   Yes         No 
9. ECG tested:  YES  NO 
10. Date of ECG: 
 Day Month Year 
11. ECG result: 
a) Rhythm: Atrial Fibrillation        Atrial Flutter               Sinus 
  Atrial paced         Ventricular paced 
Other  (specify):___________________ 
b) Ventricular rate:     bpm 
c) Was left ventricular hypertrophy present on ECG?  YES  NO 
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C: BLOOD PRESSURE 
 
1. Average Bp         /          mmHg 
 
 
2. Average Heart Rate   bpm 
 
 
 
D: LEFT VENTRICULAR FUNCTION 
 
1. Has Ventricular Function been assessed in the past year?     YES NO 
 
 
1a) Date of assessment: 
           day           month      year 
1b) LV Ejection Fraction:    % OR        ≤40%       > 40%   
OR         Unknown 
 
2. How was VF assessed? 
 
Echocardiogram  MUGA  TOE  Other      
(please specify below) 
________________________ 
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E: SUBSTANCE USE 
 
1. a) Is the patient currently using tobacco?  YES (please specify below)          
NO        
b) Has the patient previously used tobacco regularly? 
     YES (please specify below)     NO 
c) Type of tobacco use: 
 
cigarettes pipes/ cigars       chewing tobacco other  
(specify): ___________ 
 
d)      per day (cigarettes) 
 
 
e) Age started    Age stopped (if relevant) 
 
 
2. Current weekly alcohol consumption:          (units) 
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F: INCLUSION CRITERIA 
 
1. AF confirmed on ECG? Yes  No 
 
2. Stroke risk factors (please indicate [x] all that apply) 
 
Congestive Heart Failure 
 
Aged ≥ 75yrs 
 
Hypertension 
 
Diabetes mellitus 
 
Previous stroke 
 
Previous TIA 
 
Previous systemic embolism 
 
Peripheral vascular disease 
 
Female gender 
 
3. NICE guidelines stroke risk         Low          Moderate  High 
 
4. CHADS2 Score             (0-6) 
 
Are all the Inclusion Criteria met?  YES  NO 
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G: EXCLUSION CRITERIA 
 
1. Does the patient require Warfarin for any indication other than AF? 
Yes  No 
 
Are any of the Exclusion Criteria met?  YES  NO 
 
No  Patient is eligible 
Yes  Patient is ineligible 
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Concomitant medication 
BA
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NO
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M
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A: ANTITHROMBOTIC THERAPY    
    
1. ASA    
2. AGGRENOX    
3. TICLOPIDINE    
4. PARENTERAL ANTICOAGULANT    
5. CLOPIDOGREL    
6. DIPYRIDAMOLE    
7. VITAMIN K ANTAGONIST    
    
B: ANTIHYPERTENSIVE FALIURE    
    
1. ARB    
2. SPIRONOLACTONE    
3. ALPHA BLOCKER OR OTHER VASODILATOR    
4. DILTIAZEM    
5. BETA BLOCKER    
6. ACE INHIBITOR    
7. OTHER DIURETIC    
8. VERAPAMIL    
9. OTHER CCB    
10. DIGOXIN    
    
C: ANTIARRHYTHIMIC DRUGS    
    
1. SOTALOL    
2. FLECANIDE    
3. DRONEDARONE    
4. AMIODARONE    
5. OTHER ANTIARRHYTMIC    
6. PROPAFENONE    
7. PROCANAMIDE    
8. MEXILENTINE    
9. QUINIDINE    
    
D: METABOLIC AND ANTI-INFLAMMATORY    
    
1. STATIN    
2. COX II INHIBITOR    
3. INSULIN    
4. NON-STATIN LIPID LOWERING DRUG    
5. OTHER NSAID    
6. ORAL HYPOGLYCEMIC    
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F: OTHER DRUGS    
    
1. VITAMINS    
2. PROTON PUMP INHIBITORS    
3. HERBAL REMEDIES    
4. H2 BLOCKERS    
5. ANTIBIOTICS    
OTHER 1    
Specify_______________________________________    
OTHER 2    
Specify_______________________________________    
OTHER 3    
Specify_______________________________________    
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IPQ-B 
 
For the following questions, please circle the number that best corresponds to your views: 
How much does your illness affect your life? 
0  1  2  3  4  5  6  7  8  9  10 
no affect         severely 
at all          affects my life 
How long do you think your illness will continue? 
0  1  2  3  4  5  6  7  8  9  10 
a very          forever 
short time 
How much control do you feel you have over your illness? 
0  1  2  3  4  5  6  7  8  9  10 
Absolutely        extreme amount 
no control         of control 
 
How much do you think your treatment can help your illness? 
0  1  2  3  4  5  6  7  8  9  10 
not at all         extremely 
helpful 
How much do you experience symptoms from your illness? 
0  1  2  3  4  5  6  7  8  9  10 
no symptoms         many severe 
at all          symptoms 
 
 
How concerned are you about your illness? 
0  1  2  3  4  5  6  7  8  9  10 
not at all         extremely 
concerned         concerned 
 
How well do you feel you understand your illness? 
0  1  2  3  4  5  6  7  8  9  10 
don't understand        understand 
at all          very clearly 
 
How much does your illness affect you emotionally? (e.g. does it make you angry, scared, 
upset or depressed? 
0  1  2  3  4  5  6  7  8  9  10 
not at all         extremely 
affected         affected 
emotionally         emotionally 
 
 
Please list in rank-order the three most important factors that you believe caused your 
illness. The most important causes for me:- 
 
1. __________________________________ 
 
2. __________________________________ 
 
3. __________________________________ 
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Knowledge questionnaire 
 
1. What is the name of your heart condition? 
 
__________________________________________________________________ 
 
2. How long have you been diagnosed with having atrial fibrillation? 
 
__________________________________________________________________ 
 
3. What is atrial fibrillation? 
 
__________________________________________________________________ 
 
4. What are the symptoms of atrial fibrillation (or what were your symptoms?) 
 
__________________________________________________________________ 
 
5. What can cause atrial fibrillation? (What caused you to have atrial fibrillation?) 
 
__________________________________________________________________ 
 
6. Do you perceive atrial fibrillation as a serious condition? 
 
         Very serious                   Serious           Not very serious 
 
 
7. What types of problems can atrial fibrillation cause? 
 
__________________________________________________________________ 
 
8. What anticoagulant therapy are you taking? 
 
__________________________________________________________________ 
 
9. Why you are taking warfarin? 
 
__________________________________________________________________ 
 
10. What are the side effects of taking warfarin? 
 
__________________________________________________________________ 
 
11. What are the benefits of taking warfarin? 
 
__________________________________________________________________ 
 
12. How do you perceive the risk of taking warfarin? 
 
__________________________________________________________________ 
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13. What is your target INR? 
 
__________________________________________________________________ 
 
14. What factors may affect your INR levels? 
 
 
__________________________________________________________________ 
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BMQ 
 
We are interested in your beliefs about the medicines which YOU TAKE SPECIFICALLY 
FOR YOUR ATRIAL FIBRILLATION. Read each of the following statements and then circle 
the appropriate number to the right of the statement to indicate your belief. 
 
 Strongly 
disagree 
Disagree Uncertain Agree Strongly 
agree 
1. My health, at present, depends 
on my medicines 
1 2 3 4 5 
2. Having to take medicine 
worries me 
1 2 3 4 5 
3. My medicines control my heart 
rate 
1 2 3 4 5 
4. Without my medicines I would 
be very ill 
1 2 3 4 5 
5. I sometimes worry about the 
long-term effects of my medicines 
1 2 3 4 5 
6. My medicines are a mystery to 
me 
1 2 3 4 5 
7. My medicines disrupt my life 1 2 3 4 5 
8. I sometimes worry about 
becoming too dependent on my 
medicines 
1 2 3 4 5 
9. My health in the future will 
depend on my medicines 
1 2 3 4 5 
10. My medicines prevent my 
heart from beating too fast 
1 2 3 4 5 
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We are also interested in your beliefs about medicines IN GENERAL. There are no ‘right’ or 
‘wrong’ answers, so choose the most accurate answer for YOU - not what you think ‘most 
people’ would say. Read each of the following statements and then circle the appropriate 
number to the right of the statement to indicate your belief. 
 
 Strongly 
disagree 
Disagree Uncertain Agree Strongly 
agree 
1. Most medicines are 
additive 
1 2 3 4 5 
2. People who take medicines 
should stop their treatment for 
a while every now and again 
1 2 3 4 5 
3. Medicines do more harm 
than good 
1 2 3 4 5 
4. All medicines are poisons 1 2 3 4 5 
5. Natural remedies are safer 
than medicines 
1 2 3 4 5 
6. Doctors place too much 
trust on medicines 
1 2 3 4 5 
7. If doctors had more time 
with patients they would 
prescribe fewer medicines 
1 2 3 4 5 
8. Doctors use too many 
medicines 
1 2 3 4 5 
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AF-QoL-18
 
The following phrases refer to your feelings or thoughts about your arrhythmia (Atrial 
Fibrillation).  Your answers will allow us to know more about how you have been feeling and 
how your illness has interfered with your regular activities in the last 30 days.    
Below each phrase you will find a possible answer.  Please read each phrase thoroughly.  
After reading each phrase, make an X next to the option which best describes what you think 
is happening to you.  There are NO correct or incorrect answers.  We are only interested in 
knowing about the consequences of your arrhythmia (Atrial Fibrillation).   
 
 
Due to my atrial fibrillation……… 
To
ta
lly
 
Di
sa
gr
e
e
 
Su
ffi
cie
n
tly
 
Di
sa
gr
e
e
 
Ne
ith
e
r 
Ag
re
e
 
No
r 
Di
sa
gr
e
e
 
Su
ffi
cie
n
tly
 
Ag
re
e
 
To
ta
lly
 
 
Ag
re
e
 
1 What affects me the most is the helplessness I feel 
during a crisis 
     
2 I am afraid that my disease complicates things      
3 I am afraid of pain or suffering from a heart attack      
4 I am afraid of having a sudden or unexpected 
tachycardia 
     
5 I feel depressed when I find that I get tired      
6 I feel depressed when I think that my disease will last 
forever 
     
7 I have negative thoughts about my future      
8 I get more tired than usual when I perform physical 
exercise 
     
9 I get tired during a brisk walk      
10 I felt more vitality before I was diagnosed with the 
disease 
     
11 I have stopped performing physical exercise      
12 My disease has impaired my quality of life      
13 I feel affected by the impossibility of carrying out 
certain activities, “I want to but my body cannot” 
     
14 Sexual relationships are less frequent than before I 
was diagnosed with the disease 
     
15 I get tired when I walk for thirty minutes and I have to 
rest 
     
16 Changes have occurred in my sexual activity due to 
the medications I take 
     
17 I am afraid that my heart is “triggered” during sexual 
intercourse 
     
18 I find it difficult to get out of the house and carry out 
any activity 
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Hospital Anxiety and Depression Scale 
 
 
1.  I feel tense or ‘wound up’:  
Most of the time…………………… 
A lot of the time .…………….……. 
Time to time, Occasionally ...….….. 
Not at all……………………………  
 
3.  I still enjoy the things I used to enjoy: 
Definitely as much………………… 
Not quite so much…………….…… 
Only a little………………………... 
Hardly at all……………………….. 
 
5.  I get a sort of frightened feeling as if something awful 
is about to happen: 
Very definitely and quite badly……. 
Yes, but not too badly…………..…  
A little, but it doesn’t worry me……  
Not at all……………………………  
 
 
 
7.  I can laugh and see the funny side of things: 
As much as I always could…………  
Not quite so much now…………….. 
Definitely not so much now………..  
Not at all…………………………… 
 
9.  Worrying thoughts go through my mind: 
A great deal of the time…………….  
A lot of the time………………...….  
From time to time but not too often.. 
Only occasionally…………………..  
 
11.  I feel cheerful: 
Not at all……………………………  
Not often…………………………… 
Sometimes………………………….  
Most of the time…………...……….  
 
 
 
 
  
  
  
  
 
  
  
  
  
 
  
  
  
  
 
  
  
  
  
 
  
  
  
  
 
  
  
  
  
 
Please read each item below and place a tick in the box opposite the reply which comes close to how you 
have been feeling in the last week.  Don’t take too long over your replies: your immediate reaction will 
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13.  I can sit at ease and feel relaxed: 
Definitely…..……………………….  
Usually………….…….……………. 
Not often……….…………………...  
Not at all…………………………… 
2.  I feel as if I am slowed down: 
Nearly all the time……………….…. 
Very often……………………….…..  
Sometimes………………………….. 
Not at all…………………………….  
 
4.  I get a sort of frightened feeling like ‘butterflies’ in 
the stomach: 
Not at all………………….…………  
Occasionally…………….………….. 
Quite often………………………….. 
Very often…………………………...  
 
6.  I have lost interest in my appearance: 
Definitely………………………….…  
I don’t take so much care as I should.. 
I may not take quite as much care…...  
I take just as much care as ever……... 
 
8.  I feel restless as if I have to be on the move: 
Very much indeed…………………...  
Quite a lot…………………………… 
Not very much……………………….  
Not at all……………………………..  
 
10.  I look forward with enjoyment to things: 
As much as I ever did……………….  
Rather less than I used to……………  
Definitely less than I used to………..  
Hardly at all…………………………  
 
12.  I get sudden feelings of panic: 
Very often indeed…………………...  
Quite often………………………….. 
Not very often……………….…...….  
Not at all…………………………….  
 
14.  I can enjoy a good book or radio or TV 
programme: 
Often………………………………... 
Sometimes……………………..…..... 
Not often…………………………….  
Very seldom…………………
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Adverse 
event 
Date 
 
dd/mm/yy 
Event Status 
 
1=resolved 
2=unresolved 
Intensity 
 
1=mild (symptom 
awareness, easily 
tolerated) 
2=moderate 
(discomfort, 
tolerable) 
3=Severe 
(incapacitating) 
4=Not assessable/ 
unknown 
Outcome 
 
1=recovered 
2=not yet 
recovered 
3=sequelae 
4=fatal 
5=unknown 
Action Taken 
 
1=none 
2=observation only 
3=out-patient 
medical 
management 
4=Hospitalised-
medical 
management or 
observation 
5=Hospitalised-
surgical intervention 
6=other 
Action Taken with 
Study Med 
 
1=continued 
2=permanent 
discontinuation 
3=temporary 
discontinuation-No 
restart 
4=temporary 
discontinuation-
Restart 
5=N/A, patient 
previously 
permanently 
discontinued 
Event 
Serious 
 
1=yes 
2=no 
Causal 
relationship to 
study drug 
 
1=yes 
2=no 
1.  
 
        
2.  
 
        
3.  
 
        
4.  
 
        
5.  
 
        
6. 
 
        
7. 
 
        
8. 
 
        
9. 
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Stroke report 
 
PART A. Stroke details 
 
1. Date of onset of event     (dd/mm/yy) 
 
 
 
2. Was the patient hospitalised for this event       Yes          No   
 
3. Criteria for diagnosis of a stroke (must be YES to at least one) 
 
a) Rapid onset of focal neurological deficit lasting ≥ 24 hours  Yes 
 No 
 
NOTE: If stroke resulted in death please complete Death Report CRF (?) in addition 
to this stroke report. 
 
4. Symptoms and signs (Mark [x] all symptoms present for at least 24 hours) 
         
 
i. Weakness/ paralysis (mark all that apply)          arm      face      lower 
extremity 
 
ii. Numbness/ sensory loss (mark all that apply)          arm      face                                 
lower extremity 
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iii. Change in condition      iv. Aphasia         v. Hemianopia   vi. Sensory  
 
        vii. Change in levels of consciousness   viii. Cerebeller signs 
 
        ix. Other _________________________(please specify) 
 
5. This event has been evaluated by (Mark [x] all that apply) 
 
    MRI   Autopsy   CT     Vascular imaging   
 
6. Final diagnosis (Mark [x] only one) 
 
a) Ischemic stroke   Secondary haemorrhagic transformation 
          Y     N 
b) Haemorrhagic stroke  
 
b) Stroke of uncertain classification 
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Death report 
 
PART A. Stroke details 
 
1. Date of death            (dd/mm/yy)  2. Time : 
 
3. Death Witnessed:   Yes      No 
 
4. Cause of death (Indicate vascular or Non-vascular): 
 
a) VASCULAR (Mark (x) one only) 
 
    
i) Sudden/arrhythmic death (mark [x] all that apply) 
  
  Documented asystole 
 
  Documented VF 
 
  Recent MI 
 
   Other, Specify______________________________ 
 
 
        ii) Pump failure death (mark [x] all that apply) 
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  CHF/ Cardiac Shock 
 
  Cardiac tamponade 
 
  Recent MI 
 
   Other, Specify______________________________ 
 
 
          iii) Stroke (Complete STROKE Report CRF_)  Report # 
    
  
          iv) Pulmonary Embolus 
 
 
          v) Peripheral Embolus 
 
          vi) Aortic Dissection/ Rupture 
 
 
          vii) Haemorrhage    
 
 
          viii) Unknown cause 
 
  
         ix) Other (specify):___________________________ 
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b) NON-VASCULAR (Specify): 
 
 
Infection 
 
  Cancer 
 
  Trauma 
 
  Respiratory Failure 
 
   Other, Specify______________________________ 
 
5. Summary of details of death (provide a brief summary of events leading up to 
patient death) 
 
___________________________________________________________________ 
 
___________________________________________________________________ 
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Appendix 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(For intervention DVD and Booklet please request loose 
materials) 
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Warfarin Worksheet 
 
 
SECTION A: Assess your personal risk of stroke 
 
One way to work out your risk of stroke is to use the acronym CHADS2. The 
CHADS2 gives 1 point to each of the risk factors mentioned above except for stroke 
which gets 2 points. The higher the total number of points, the higher the risk of 
stroke. 
 
If a question below does not apply to you, write 0 in the ‘your score’ column 
 
 
Questions Points Your Score 
Are you 75 years or older? 
 
Do you have high blood pressure? 
 
Do you have diabetes? 
 
Do you have heart failure or have you had heart 
failure in the past? 
 
Have you suffered a stroke (even a mild 
stroke)? 
1 
 
1 
 
1 
 
1 
 
 
2 
  
Total 
– 
  
 
 
Recommendations depending on your total 
• If a score of 0 or 1 is recorded, patients are usually advised to take aspirin 
(75-300 mg daily). 
• If a score of 2 or more is recorded, patients are usually advised to take 
warfarin (INR 2.0-3.0). 
 
 
SECTION B: Your personal warfarin plan 
 
 
What is your target INR?  _____ . _____ 
 
 
Lifestyle changes: 
 
 
Target daily alcohol intake  _______ units 
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Your usual alcoholic drinks 
 
1. _____________________  units _______ 
 
2. _____________________  units _______ 
 
3. _____________________  units _______ 
 
SECTION C: Medication concerns 
 
When prescribed a new life-long treatment such as warfarin, patients often come 
across problems and concerns which can prevent them from taking their medication 
and successfully reducing their risk of stroke. These can be psychological concerns 
for example; worrying about side effects and the burden of the medication or practical 
concerns for example; how you will remember to take the medication, what to so if 
you miss a dose etc. 
 
In the space below list some of your key concerns about taking warfarin: 
 
 
 
 
_____________________________________________________ 
 
 
_____________________________________________________ 
 
 
_____________________________________________________ 
 
 
_____________________________________________________ 
 
 
_____________________________________________________ 
 
 
_____________________________________________________ 
 
 
_____________________________________________________ 
 
 
_____________________________________________________ 
 
You should always discuss these concerns with a doctor or other health care 
professional. You can raise them in the group session or if you would prefer to talk 
privately about your concerns you can contact one of the investigators at a later date. 
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Appendix 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
309 
 
 
 
The Cochrane Library 
#1 MeSH descriptor patient education as topic this term only 
#2 MeSH descriptor attitude to health explode all trees 
#3 MeSH descriptor patient participation this term only 
#4 MeSH descriptor behavior therapy this term only 
#5 MeSH descriptor cognitive therapy this term only 
#6 MeSH descriptor counseling explode all trees 
#7 MeSH descriptor motivation this term only 
#8 MeSH descriptor goals this term only 
#9 MeSH descriptor Biofeedback (Psychology) this term only 
#10 MeSH descriptor decision support techniques this term only 
#11 MeSH descriptor Communications Media explode all trees 
#12 education in All Text 
#13 (training in All Text or train in All Text) 
#14 (teaching in All Text or teach in All Text) 
#15 (behaviour* in All Text or behavior* in All Text) 
#16 "patient knowledge" in All Text 
#17 counsel* in All Text 
#18 (cognitiv* in All Text near/3 therapy in All Text) 
#19 (cognitiv* in All Text near/3 intervention* in All Text) 
#20 motivation* in All Text 
#21 contingency next management in All Text 
#22 (biofeedback in All Text or bio-feedback in All Text) 
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#23 (goal in All Text or goals in All Text) 
#24 (decision* in All Text near/3 aid* in All Text) 
#25 pamphlet* in All Text 
#26 booklet* in All Text 
#27 video* in All Text 
#28 decision next aid* in All Text 
#29 "patient participation" in All Text 
#30 (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10) 
#31 (#11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20) 
#32 (#21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29) 
#33 (#30 or #31 or #32) 
#34 MeSH descriptor warfarin this term only 
#35 MeSH descriptor Coumarins explode all trees 
#36 MeSH descriptor anticoagulants this term only 
#37 MeSH descriptor vitamin k explode all trees with qualifiers: AI 
#38 oral next anticoagula* in All Text 
#39 Oral next anti-coagula* in All Text 
#40 ("vitamin K" in All Text and (antagonist* in All Text or inhibitor* in All Text) ) 
#41 "antivitamin K" in All Text 
#42 "anti-vitamin K" in All Text 
#43 warfarin in All Text 
#44 acenocoumarol in All Text 
#45 sintrom in All Text 
#46 sinthrome in All Text 
#47 jantoven in All Text 
#48 marevan in All Text 
#49 coumadin* in All Text 
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#50 waran in All Text 
#51 phenprocoumon in All Text 
#52 nicoumalone in All Text 
#53 VKA in All Text 
#54 coumarin* in All Text 
#55 dicoumarol in All Text 
#56 dicumarol in All Text 
#57 (#34 or #35 or #36 or #37 or #38 or #39 or #40 or #41 or #42 or #43) 
#58 (#44 or #45 or #46 or #47 or #48 or #49 or #50 or #51 or #52 or #53 or #54 or #55 or 
#56) 
#59 (#57 or #58) 
#60 (#33 and #59) 
MEDLINE on Ovid 
1. Warfarin/ 
2. acenocoumarol/ 
3. Coumarins/ 
4. Phenindione/ 
5. Dicumarol/ 
6. Anticoagulants/ 
7. oral anticoagula$.tw. 
8. exp Vitamin K/ai [Antagonists & Inhibitors] 
9. warfarin.tw. 
10. acenocoumarol.tw. 
11. sintrom.tw. 
12. sinthrome.tw. 
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13. jantoven.tw. 
14. marevan.tw. 
15. coumadin$.tw. 
16. waran.tw. 
17. Phenprocoumon/ 
18. nicoumalone.tw. 
19. (vitamin k adj3 antagonist$).tw. 
20. vitamin k inhibitor$.tw. 
21. oral anticoagula$.tw. 
22. oral anti-coagula$.tw. 
23. vka.tw. 
24. antivitamin k.tw. 
25. anti-vitamin k.tw. 
26. or/1-25 
27. Patient Education as Topic/ 
28. exp Attitude to Health/ 
29. Patient Participation/ 
30. ((educat$ or train$ or teach$) adj3 (program$ or intervention$)).tw. 
31. (patient$ adj3 (train$ or teach$ or educat$ or inform$)).tw. 
32. patient knowledge.tw. 
33. Behavior Therapy/ 
34. Cognitive Therapy/ 
35. exp counseling/ 
36. (behavi$ adj3 (therap$ or manage$ or modif$ or chang$ or intervention$)).tw. 
37. (cogniti$ adj3 (therap$ or intervention$)).tw. 
38. counsel$.tw. 
39. Motivation/ 
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40. motivational interview$.tw. 
41. contingency management.tw. 
42. biofeedback.tw. 
43. bio-feedback.tw. 
44. goals/ 
45. (goal$ adj3 set$).tw. 
46. decision support techniques/ 
47. decision$ aid$.tw. 
48. exp communications media/ 
49. pamphlet$.tw. 
50. booklet$.tw. 
51. video$.tw. 
52. or/27-51 
53. 26 and 52 
54. randomized controlled trial.pt. 
55. controlled clinical trial.pt. 
56. randomized.ab. 
57. placebo.ab. 
58. clinical trials as topic.sh. 
59. randomly.ab. 
60. trial.ti. 
61. 54 or 55 or 56 or 57 or 58 or 59 or 60 
62. exp animals/ not humans.sh. 
63. 61 not 62 
64. 53 and 63 
EMBASE OVID 
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RCT filter as recommended in the Cochrane Handbook (Lefebvre C, Manheimer E, Glanville 
J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook 
for Systematic Reviews of Interventions Version 5.0.2 (updated September 2009). The 
Cochrane Collaboration, 2009. Available from www.cochrane-handbook.org.) applied. 
  
1. phenindione/ 
2. antivitamin K/ 
3. exp coumarin anticoagulant/ 
4. anticoagulant agent/ 
5. warfarin.tw. 
6. acenocoumarol.tw. 
7. sintrom.tw. 
8. sinthrome.tw. 
9. jantoven.tw. 
10. marevan.tw. 
11. coumadin$.tw. 
12. waran.tw. 
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13. nicoumalone.tw. 
14. (vitamin k adj3 antagonist$).tw. 
15. vitamin k inhibitor$.tw. 
16. oral anticoagula$.tw. 
17. oral anti-coagula$.tw. 
18. vka*.tw. 
19. antivitamin k.tw. 
20. anti-vitamin k.tw. 
21. coumarin$.tw. 
22. vitamin K group/po [Oral Drug Administration] 
23. or/1-22 
24. patient education/ 
25. attitude to health/ 
26. patient participation/ 
27. ((educat$ or train$ or teach$) adj3 (program$ or intervention$)).tw. 
28. (patient$ adj3 (train$ or teach$ or educat$ or inform$)).tw. 
29. patient knowledge.tw. 
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30. behavior therapy/ 
31. cognitive therapy/ 
32. exp counseling/ 
33. (behavi$ adj3 (therap$ or manage$ or modif$ or chang$ or intervention$)).tw. 
34. (cogniti$ adj3 (therap$ or intervention$)).tw. 
35. counsel$.tw. 
36. motivation/ 
37. motivational interview$.tw. 
38. contingency management.tw. 
39. biofeedback.tw. 
40. bio-feedback.tw. 
41. (goal$ adj3 set$).tw. 
42. decision support system/ 
43. decision$ aid$.tw. 
44. (decision$ adj3 support).tw. 
45. mass medium/ 
46. pamphlet$.tw. 
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47. booklet$.tw. 
48. video$.tw. 
49. or/24-48 
50. random$.tw. 
51. factorial$.tw. 
52. crossover$.tw. 
53. cross over$.tw. 
54. cross-over$.tw. 
55. placebo$.tw. 
56. (doubl$ adj blind$).tw. 
57. (singl$ adj blind$).tw. 
58. assign$.tw. 
59. allocat$.tw. 
60. volunteer$.tw. 
61. crossover procedure/ 
62. double blind procedure/ 
63. randomized controlled trial/ 
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64. single blind procedure/ 
65. or/50-64 
66. (animal/ or nonhuman/) not human/ 
67. 65 not 66 
68. 23 and 49 and 67 
  
PsycINFO 
  
1. anticoagulant drugs/ 
2. warfarin.tw. 
3. acenocoumarol.tw. 
4. coumadin$.tw. 
5. waran.tw. 
6. nicoumalone.tw. 
7. (vitamin k adj3 antagonist$).tw. 
8. oral anticoagula$.tw. 
9. vka*.tw. 
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10. coumarin$.tw. 
11. or/1-10 
12. client education/ 
13. client participation/ 
14. behavior therapy/ 
15. cognitive therapy/ 
16. exp counseling/ 
17. motivation/ 
18. exp goals/ 
19. biofeedback/ 
20. decision making/ 
21. exp communications media/ 
22. ((educat$ or train$ or teach$) adj3 (program$ or intervention$)).tw. 
23. (patient$ adj3 (train$ or teach$ or educat$ or inform$)).tw. 
24. patient knowledge.tw. 
25. health knowledge/ 
26. (behavi$ adj3 (therap$ or manage$ or modif$ or chang$ or intervention$)).tw. 
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27. (cogniti$ adj3 (therap$ or intervention$)).tw. 
28. health attitudes/ 
29. counsel$.tw. 
30. motivational interview$.tw. 
31. contingency management.tw. 
32. biofeedback.tw. 
33. bio-feedback.tw. 
34. (goal$ adj3 set$).tw. 
35. decision$ aid$.tw. 
36. (decision$ adj3 support).tw. 
37. pamphlet$.tw. 
38. booklet$.tw. 
39. video$.tw. 
40. or/12-39 
41. 11 and 40 
42. random$.tw. 
43. factorial$.tw. 
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44. crossover$.tw. 
45. cross-over$.tw. 
46. placebo$.tw. 
47. (doubl$ adj blind$).tw. 
48. (singl$ adj blind$).tw. 
49. assign$.tw. 
50. allocat$.tw. 
51. volunteer$.tw. 
52. control*.tw. 
53. "2000".md. 
54. or/42-53 
55. 41 and 54 
  
CINAHL 
  
S76 S57 and S75   
S75 S58 or S59 or S60 or S61 or S62 or S63 or S64 or S65 or S66 or S67 or S68 or S69 or 
S70 or S71 or S72 or S73 or S74   
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S74 TX cross-over*   
S73 TX crossover*   
S72 TX volunteer*   
S71 (MH "Crossover Design")   
S70 TX allocat*   
S69 TX control*   
S68 TX assign*   
S67 TX placebo*   
S66 (MH "Placebos")   
S65 TX random*   
S64 TX (doubl* N1 mask*)   
S63 TX (singl* N1 mask*)   
S62 TX (doubl* N1 blind*)   
S61 TX (singl* N1 blind*)   
S60 TX (clinic* N1 trial?)   
S59 PT clinical trial   
S58 (MH "Clinical Trials+")   
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S57 S17 and S56   
S56 S18 or S19 or S20 or S21 or S22 or S23 or S24 or S25 or S26 or S27 or S28 or S29 or 
S30 or S31 or S32 or S33 or S34 or S35 or S36 or S37 or S38 or S39 or S40 or S41 or S42 or 
S43 or S44 or S45 or S46 or S47 or S48 or S49 or S50 or S51 or S52 or S53 or S54 or S55   
S55 (TI video*) or (AB video*)   
S54 (TI booklet*) or (AB booklet*)   
S53 (TI pamphlet*) or (AB pamphlet*)   
S52 (MH "Communications Media+")   
S51 (TI decision* N3 support) or (AB decision* N3 support)   
S50 (TI "decision* aid*") or (AB "decision* aid*")   
S49 (MH "Decision Support Techniques+")   
S48 (TI goal* N3 set*) or (AB goal* N3 set*)   
S47 (TI bio-feedback) or (AB bio-feedback)   
S46 (TI biofeedback) or (AB biofeedback)   
S45 (TI "contingency management") or (AB "contingency management")   
S44 (TI "motivational interview*") or (AB "motivational interview*")   
S43 (MH "Motivation+")   
S42 (TI counsel*) or (AB counsel*)   
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S41 (TI cogniti* N3 intervention*) or (AB cogniti* N3 intervention*)   
S40 (TI cogniti* N3 therap*) or (AB cogniti* N3 therap*)   
S39 (TI behavi* N3 intervention*) or (AB behavi* N3 intervention*)   
S38 (TI behavi* N3 chang*) or (AB behavi* N3 chang*)   
S37 (TI behavi* N3 modif*) or (AB behavi* N3 modif*)   
S36 (TI behavi* N3 manage*) or (AB behavi* N3 manage*)   
S35 (TI behavi* N3 therap*) or (AB behavi* N3 therap*)   
S34 (MH "Counseling+")   
S33 (MH "Cognitive Therapy")   
S32 (MH "Behavior Therapy")   
S31 (TI "patient knowledge") or (AB "patient knowledge")   
S30 (TI patient* N3 inform*) or (AB patient* N3 inform*)   
S29 (TI patient* N3 educat*) or (AB patient* N3 educat*)   
S28 (TI patient* N3 teach*) or (AB patient* N3 teach*)   
S27 (TI patient* N3 train*) or (AB patient* N3 train*)   
S26 (TI teach* N3 intervention*) or (AB teach* N3 intervention*)   
S25 (TI teach* N3 program*) or (AB teach* N3 program*)   
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S24 (TI train* N3 intervention*) or (AB train* N3 intervention*)   
S23 (TI train* N3 program*) or (AB train* N3 program*)   
S22 (TI educat* N3 intervention*) or (AB educat* N3 intervention*)   
S21 (TI educat* N3 program*) or (AB educat* N3 program*)   
S20 (MH "Consumer Participation")   
S19 (MH "Attitude to Health")   
S18 (MH "Patient Education")   
S17 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11 or S12 or S13 or S14 or 
S15 or S16   
S16 (TI dicumarol) or (AB dicumarol)   
S15 (TI dicoumarol) or (AB dicoumarol)   
S14 (TI coumarin*) or (AB coumarin*)   
S13 (TI VKA*) or (AB VKA*)   
S12 (TI phenprocoumon) or (AB phenprocoumon)   
S11 (TI coumadin*) or (AB coumadin*)   
S10 (TI sintrom) or (AB sintrom)   
S9 (TI acenocoumarol) or (AB acenocoumarol)   
S8 (TI warfarin) or (AB warfarin)   
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S7 (TI "antivitamin K") or (AB "antivitamin K")   
S6 (TI "vitamin K" N2 inhibitor*) or (AB "vitamin K" N2 inhibitor*)   
S5 (TI "vitamin K" N2 antagonist*) or (AB "vitamin K" N2 antagonist*)   
S4 (TI oral N2 anti-coagula*) or (AB oral N2 anti-coagula*)   
S3 (TI oral N2 anticoagula*) or (AB oral N2 anticoagula*)   
S2 (MH "Warfarin")   
S1 (MH "Anticoagulants")   
 
 
 
 
